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ABSTRACT
5-Nitrosothiols (RSNO) are an important class of NO-donor drugs. They have been used 
clinically and occur naturally where they may have a role in several biological and 
physiological processes in the human body. The medical importance of S-nitrosothiols has 
been highlighted recently by several reports which describe the clinical use of GSNO (13) 
to inhibit platelet aggregation during coronary angioplasty and also to treat a form of pre­
eclampsia , a high blood pressure condition suffered by some pregnant women.
We set out to extend the range of compounds of this type by synthesising a novel series of 
biologically active ^-nitrosothiols (1-13) and to look for a correlation between structure, 
chemical stability, and physiological activity. The situation has been complicated by the 
recent discovery that the main route for the release of NO from ^-nitrosothiols is a copper- 
catalysed process. A detailed kinetic study of copper ions, and thiols on the stability of the 
compounds we synthesised has shown that the dominant pathway for the decomposition of 
5-nitrosothiols in most circumstances is one catalysed by Cu+ ions. We suggest that Cu+ 
ions are formed by the reaction of Cu^+ ions with thiol, present in the 5-nitrosothiols as an 
impurity. The implications of this discovery for an understanding of the biological action of 
S-nitrosothiols is suggested.
All the new S'-nitrosated dipeptides (2-12) examined show less susceptibility to copper (I)- 
catalysed release of NO than SNAP (1) but are more reactive than GSNO (13). We found 
that S-nitrosated dipeptides are potent vasodilators and suitable inhibitors of platelet 
aggregation but are chemically very stable in the absence of copper ions. All thirteen 
compounds combine the favoured property of chemical stability with a high level of 
biological activity.
X V lll
We found that copper(I)-chelation induced reduction of the biological activity of S- 
nitrosothiols in smooth muscle relaxation. The results show that responses to both SNAP 
and GSNO are reversibly inhibited by neocuproine. We conclude that relaxation of 
vasodilator smooth muscle by SNAP and GSNO is caused in part by NO released into 
solution via a Cu+-dependent catalytic reaction, and provide evidence that endogenous Cu+ 
ions may also contribute to the maintenance of vasodilator 'store' in vivo by catalysing the 
decomposition of naturally-occurring ^-nitrosothiols. A particularly interesting finding 
recently by Gordge et al. (1995) shows that the inhibition of platelet aggregation activity 
shown by GSNO is much reduced in the presence of neocuproine and the closely related 
bathocuproine, both specific Cu+-chelating agent. However, it was shown very recently 
(Schrammel et al., 1996) that copper ions inhibit basal and NO-stimulated recombinant 
soluble guanylate cyclase activity and that Cu+ is more effective than Cu^+ in this regard.
L-Ascorbic acid (vitamin C) could play a role in the in vivo release of NO from naturally 
occurring and exogenous 5-nitrosothiols and so play a part in smooth muscle relaxation 
and in inhibition of platelet aggregation.
All thirteen compounds examined show the ability to release NO in vitro. The inhibitory 
effect of Hb, a recognised NO scavenger, was investigated. In smooth muscle, responses 
to intermediate doses of ^-nitrosothiols were significantly inhibited by Hb, though not 
abolished entirely. In platelet, we found that the inhibitory activity of these 5-nitrosothiols 
was reversed by haemoglobin, indicating the involvement of NO in the process.
We found that the solution stability of the ^'-nitrosothiols did not correlate with relaxation 
of vascular smooth muscle or inhibition of platelet aggregation, again suggesting that the 
tissue specificity is a function of the R- group.
We conclude that the biological activity of 5-nitrosothiols depends upon the release of NO 
in a process catalysed by Cu(I), and that the decomposition may occur inside or outside the 
cell, depending upon the structure of RSNO.
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NO-DONOR DRUGS USED IN THIS RESEARCH
The following list of the NO-donor drugs used in this research is given for ease of 
reference.
I. 6"-nitroso-N-acetyl-D,L-p,p-dimethylcysteine (SNAP; 1):
SNO
A OH
O (SNAP; 1)
II. 5-nitrosO“AAacetyl-D,L-p,|3-dimethylcysteinylglycine methyl ester (2):
SNO
/
o
(2 )
III. 5-nitroso-A-acetyl-D,L-|3,p-dimethylcysteinyl-L-alanine methyl ester (3):
SNO
O I O
HA N \ o /
O
(3)
IV. S-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-valine methyl ester (4):
A
XXI
V. S-nitroso-iV-acetyl-D,L-p,[3-dimethylcysteinyl-L-leucine methyl ester (5):
SNOO   I  OAA/V\i/X
(5)
VI. S-nitroso-V-acetyl-D,L-13,|3“dimethylcysteinyl-L-phenylalanine methyl ester (6):
SNO
OA o X
(6)
VII. 5'-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-isoleucine methyl ester (7):
SNO
O I  QA7vvxX
o
(7)
VIII. 5-nitroso-iV-acetyl-D,L-[î,p-dimethylcysteinyl-L-methiomne methyl ester (8);
SNO
xxii
IX. S-nitroso-iV-acetyl-D,L-p,p-dimethylcysteinyl-L-Ve-CBZ“L-lysine methyl ester (9):
SNO
0 I 0
/
O
O
H
O
(9)
X. 5'-nitroso-V-acetyl-D,L-p,p-dimethylcystemyl-L-proline methyl ester (10):
SNO
OA N— r /
(1 0 )
XI. S-nitroso-M-acetyl-D,L-p,|3-dimethylcysteinyl-L-aspartic acid dimethyl ester (11):
SNO
A
) =
o
o
/
(1 1 )
xxm
XII. 5-nitroso-A^-acetyl-D,L-|3,p-dimethylcysteinyl-L-glutamic acid dimethyl ester (12):
SNO
(12)
XIII. 5-nitroso-L-glutathione (GSNO; 13):
SNO
OHHO
NH
(GSNO; 13)
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L IO\^ ODUCyTl09l
In tfiis câapter xve iviCCBriefCy discuss tfte foCIozving suBjects: S-nitrosotfUoCs as OdP-donor drugs, tfu 
BiofogicaC activity of S-nitrosotfiiols, T.ndotfteCium-(Derived!^ùi?(gtion factor (‘BD ff), pBysiological 
function of nitric 07(ide (9\{p), and die purpose of the present ïVorfç.
iü\ii!HPü)ucyno9i
fwenty-sv^years ago, it was chimed that (Vasu, 1967): "from an industrialpoint o f view, nitric 07(ide 
is prohaèCy the most important 07(ide o f nitrogen". Sifter that, nitric oTçide was hrgeCy ignored and 
simply considered as a tojçk mohcuCe, one o f a numher o f environmentaCpoCCutants.
^However, during recent years, certain discoveries have shozvn that 9 ^  is invoCved in several important 
SiohgicaC events. Its BioCogicaC roies are so eTçtensive that in 1992 it Became the mokcuie o f the year 
(Culotta and 9(pshhnd, 1992): "a starthngCy simple molecule unites neuroscience, physiology, 
immunology, and revises scientists' understanding o f how ced communicate".
9dP seems to Be implicated in a vHde range o f Biological processes: neurotransmission (Qarthwaite, 
1991); immune regulation (thUBBs, 1991; M arietta et a!, 1988; Stuehr et a l, 1989; Moncada et a l,
1991); smooth muscle rela?(ation (Ignarro, 1989a&B; Moncada et a l, 1986a&B); and platelet 
inhiBition (Pizuma et a l, 1986; furlong et a l, 1987; fgdomsiçi et al, 1987a,B,c&d). Several reviews 
on the Biology o f ÜdO have recently Been puBlished ((Butler and Williams, 1993; feldman et a l, 1993; 
JQiowles and Moncada, 1992; 9^than, 1992; Stander, 1992a,B,c,d&e; Qalh, 1993).
fh is contriBution attempts to Bring together the following aspects o f S-nitrosothiol chemistry: (a) 
Synthesis, chemical stability, and physiological activity (vasodihtor activity and inhiBition o fph telet 
aggregation). (B) fractions o f S-nitrosothiols with particular emphasis on two recently discovered 
decomposition paihways in aqueous solution hading to nitric o?(ide formation, the firs t Brought about 
By catalytic quantities o f metal ions most notably the second involving L-ascorbic acid (vitamin
C). (c) (Detection of9>(P rehasefrom the S-nitrosothiols.
1.1. S-Nitrosothiols as NO-Donor Drugs
5-Nitrosothiols (RSNO) are the sulphur analogues of the alkyl nitrites RONO. They are 
not as well-known as the alkyl nitrites, mainly because many of them are unstable in the 
pure state at room temperature (Williams, 1988).
^-Nitrosothiols have come to prominence in recent years as part of the nitric oxide story, 
since they are believed to decompose non-enzymatically to give nitric oxide, and could, 
in principle, be used therapeutically as NO-producing drugs. They might replace the 
much-used glyceryl trinitrate, which is subject to a tolerance problem in some patients 
(Butler, 1995). Additionally, 5^-nitrosothiols have been detected in vivo and many believe 
that they play a part in the mechanisms of some well-documented physiological processes 
which have been attributed to nitric oxide (Stamler and Loscalzo, 1991). Indeed, there 
have been suggestions that 5-nitrosocysteine, rather than nitric oxide itself, constitute the 
so-called Endothelium Derived Relaxing Factor (EDRF), but this is not the current 
majority view (Myers et al., 1990; Rubanyi et al., 1991a&b). Because of these 
possibilities much more attention has been paid to the chemistry (and pharmacology) of 
5-nitrosothiols in recent years. Studies have concentrated on their synthesis, reactions 
which lead to nitric oxide formation and reactions whereby the NO group can be 
tranferred to other thiols.
1 .1 .1 . Synthesis of S-Nitrosothiols
^-Nitrosothiols are red or green compounds which can be easily obtained during 
treatment of thiols with a variety of nitrosating agents (Gae and Shinhama, 1983; 
Williams, 1985). The most common synthetic reactions are:
(a) Thiol and any electrophilic nitrosating agent XNO (NOCl, RONO, N204^ NO2, 
N2O3, HNO2 which can act as a reagent capable of delivering 'W0+ " as shown in 
the following equation:
RSH + XNO --------- ► RSNO + X" + H+
The most commonly used reagent is an aqueous solution of nitrous acid generated from 
sodium nitrite and a mineral acid and the nitrosothiol is separated by filtration or by 
solvent extraction.
(b)Thiol and alkyl nitrites in aqueous acid or alkaline solution and also in a number of 
non-aqueous solvents such as acetone and chloroform:
RSH  ^butyl nitrite ^  RgNQ
The nitrosation by alkyl nitrites in water may occur by two mechanisms depending on the 
pH (Fontecave and Pierre, 1994):
(a) acidic medium:
RONO + H+  ► R'OH + N0+
RSH + N0+  ► RSNO + H+
(b) basic medium:
RSH + OH' --------------- RS' + HgO
RS" + RONO --------------- ► RSNO + R'O'
The reaction is the sulphur analogue of the reaction whereby alkyl nitrites are generated 
from alcohols and a source of "NO+". One difference between the two reactions is that 
whilst alkyl nitrite formation is a significantly reversible process (the reaction driven to 
completion by the removal of the alkyl nitrite by distillation), the reaction of thiols is 
essentially irreversible which makes separation of the product easier. The difference can 
readily be explained in terms of the difference in nucleophilicities and basicities of the 
sulphur and oxygen atoms in these systems.
5-Nitrosothiols are usually quite unstable in water at physiological pH. They appear to 
release NO spontaneously without redox or photochemical activation, even though light 
greatly accelerates the reaction. Moreover, the decomposition is strongly catalyzed by 
Cu^+ or Fe3+, even as contaminants of aqueous buffered solutions, and is thus inhibited 
by chelators (McAninly et al., 1993). The reaction proceeds through homolytic cleavage 
of the S-N bond generating a thiyl radical and NO:
RSNO -► RS + NO
2 RS ----► RSSR
These NO generators are also very interesting since it is possible to get a wide range of 
rates of production of NO by simple chemical modification of the R group of S- 
nitrosothiols (RSNO; Mathews and Kerr, 1993). The highest stabilities are obtained with 
tertiary S-nitrosothiols (Williams, 1988).
S-Nitroso-A-acety 1-D,L-penicillamine (SNAP) is indefinitely stable as a powder, allowing 
determination of its crystal structure by X-ray diffraction (Field et at., 1978):
SNO
O
OH
S-nltroso-A/-acetyl-D,L-penicillamine (SNAP)
SNAP is slow generator of NO in water at pH =7.0, and can be used as a vasodilator. S- 
Nitrosothiols are also good inhibitors of ribonucleotide reductase and all cell growth. It 
has been recently shown that nitrosation of cysteine in proteins may occur during 
exposure to NO (Stamler et al., 1992a,b,c,d&e; McDonald et a i, 1993; Girard et al.,
1993). However, the reaction can not be a simple one between NO and cysteine. The 
stability of such protein-bound nitrosothiols is remarkable, especially considering the
extreme lability of the free 5-nitrosocysteine. Whether this process is involved in the 
regulation of vascular tone or in cytotoxicity remains to be established. Moreover, 
endogenous 5-nitroso-L-glutathione has been found to be present at nano- to micromolar 
concentrations in the human airways (Gaston et ai, 1993).
While alkyl nitrites are essentially NO+ donors and thus useful nitrosating agents towards 
nucleophiles, in water S-nitrosothiols may behave as either NO or NO"  ^donors. This will 
depend on the substrate and the medium, but also in the stability of the S-nitrosothiols. 
One may suggest that unstable S-nitrosothiols will be NO donors while stable ones will 
be NO+ donors, converting alcohols, thiols and secondary amines into alkylnitrites, 
disulphides, and nitrosoamines, respectively (Fontecave and Pierre, 1994). Nitrosation of 
proteins by S-nitrosothiols is likely to occur, as suggested in the cases of the NMDA 
receptor (Lipton et a i, 1993) and ribonucleotide reductase:
R'OHRSNO
RSNO
pH =7.4  
R'SH
pH =7.4
R'ONO + RSH 
R'SNO + RSH
RSNO R'gNHpH =7.4
R'SSR + NO
R'gNNO + RSH
On the other hand, the nitrosation of phenols by nitrosothiol {e.g. SNAP) involves a 
radical mechanism (Oh and Williams, 1991):
RSNO RS + NO
OH + RS O
o = °  * NO ^  ON OH
1 .1 .2 . The Chemical Stability of 5-Nitrosothiols
In general 5-nitrosothioIs are not as stable in the pure state as are the alkyl nitrites. A 
number however have been successfully purified and characterised; some have been 
known for a number of years (Rheinboldt, 1959). These include the ^-nitrosothiols 
derived from ^-butyl thiol and triphenyl methyl thiol:
■SNO
S-nitroso-f-butane thiol
/ T \ SNO
S-nltrosotrlphenyimethane thiol
More recently it has been shown that the 5-nitrosothiols from iV-acetyl-D,L-penicillamine 
(Field et aL, 1978) and L-glutathione (Hai't, 1985) can be isolated and kept as solids at 
room temperature indefinitely:
SNO
S-nitroso- L-glutathione (GSNO)
A detailed X-ray crystal structre determination has been carried out for the former (Field 
et a/., 1978). Similarly some 5-nitrosothiols from proteins containing the -SH group are 
quite stable (Stamler et a i, 1992a,b,c,d&e) as is S'-nitrosocysteine within a polypeptide 
chain (Myers et al., 1990) (even though 5-nitrosocysteine itself is quite unstable) and also 
the di-nitroso derivative of a penicillamine dipeptide (Moynihan and Roberts, 1994). A 
range of 5-nitrosothiols based on cysteamine and its derivatives has recently been 
described (Roy et at., 1994). Most of the successful syntheses and isolation of stable 
products were carried out with nitrous acid or f-butyl nitrite. Quite often attempted 
syntheses have resulted in decomposition at the last moment with the evolution of brown 
fumes of nitrogen dioxide (Williams, 1988).
1 .1 .3 . The Physical Properties of S-Nitrosothiols
The stable 5-nitrosothiols are green or red solids or liquids. Generally tertiaiy structures 
(such as SNAP) are green and primery ones (such as GSNO) pink or red (Field et at., 
1978; Hart, 1985). There are characteristic infrared frequencies at 1480-1530 cm“  ^ (N=0 
stretch) and 600-730 cm'^ (C-S stretch). In the uv-visible region there are two absorption 
bands in the 330-350 nm and 550-600 nm regions. The former has the larger extinction 
coefficient (typically 10^ dm^mol'^cm"!) and is the one usually used to monitor the 
disappearance of 5-nitrosothiols in quantitative studies, Both and nmr 
spectroscopy have been used to characterise 5-nitrosothiols. The shift due to both a  
protons and a  carbons on 5-nitrosothiols is quite diagnostic (Roy et al., 1994)
1 .1 .4 . The Decomposition of S-Nitrosothiols
5-Nitrosothiols can decompose to yield the corresponding disulphide and nitric oxide as 
in the following equation:
2 RSNO ----------------------- RSSR + NO
by different pathways:
(a) Photochemical decomposition
S'-Nitrosothiols readily decompose photochemically to give disulphide and nitric oxide 
(Barrett et aL, 1965).
(b) Thermal decomposition
Also, 5-nitrosothiols readily decompose thermally to give disulphide and nitric oxide (the 
same products obtained photochemically; Field et al, 1978; Rheinbolt and Mott, 1932).
(c) Copper ions catalysed the decomposition of S-nitrosothiols:
In solution at room temperature in the absence of light, decomposition also occurs and the 
reaction has been much studied in recent years, because of the intense interest the 
development of NO-releasing compounds. The quantitative results reported in the 
literature are however extremely erratic, and there are major difference in the rate form 
(le. in the kinetic order of reactions) and in the reactivities (e.g. as measured in half- 
lives) between the measurements made on the same or similar compounds in different 
laboratories. Consequently, until 1993 when the importance of the presence of catalytic 
quantities of Cu^+ was realised (McAninly et a l, 1993), not even a qualitative 
mechanistic picture was available for these reactions. The current position will be 
discussed in the next chapter (Results & Discussion; Dicks et al, 1996).
(d) Nitroso group is transferred to another molecule
There are a number of literature reports referring to transfer to amines and thiols 
(McAninly et a l, 1993). In principle such a reaction could occur directly, where the S- 
nitrosothiols act as carriers of NO+ as do alkyl nitrites, or indirectly by initial NO loss, 
which is then oxidised to a higher oxidation state of nitrogen which will allow nitrosation 
of amines etc. to occur. If this oxidation is not possible (e.g. if the reaction is carried out
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anaerobically) then reaction will not occur, as nitric oxide itself will not act as a 
nitrosating agent.
The NO group exchange between a 5-nitrosothiols and a thiol has been demonstrared 
(Park, 1988), although under certain circumstances the 5-nitrosothiols will also 
decompose leading to mixtures of disulphides. It has been shown (Barnett et a l, 1994) 
that the reaction actually involves the attack of the thiolate anion, since the pH-rate 
profile follows the thiol ionisation. Reaction occurs quite generally (the following 
equation) for a wide range of R and R' structures:
RSNO + R'S" RS' + R'SNO
R'SH RSH
The reaction rate is much faster than that of the decomposition of RSNO and occurs quite 
readily at the physiological pH, depending on the pKa of the thiol. Rate (Barnett et al,
1994) and equilibrium (Meyer et a l, 1994) constants have been reported.
(e) L-Ascorbic acid
We very recently discovered that addition of L-ascorbic acid (Vitamin C) increases the 
rate of 5-nitrosothiols decomposition. Thus, L-ascorbic acid could play a role in the in 
vivo release of NO from naturally occuring 5*-nitrosothiols (Dasgupta et al., 1996). The 
role of L-ascorbic acid in the breakdown of 6"-nitrosothiols will be discussed in the next 
chapter (Results & Discussion).
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(f) Enzymatic decomposition
5-Nitroso-L~glutathione (GSNO) decomposes to give NO and other products. In vivo the 
first step is enzymatic cleavage of the glutamyl-cysteinyl peptide bond by the enzyme y- 
glutamyl transpeptidase (y-GT; Askew et a l, 1994). The resulting 5-nitrosothiol, S- 
nitrosocysteinylglycine, would be expected to be more susceptible to release of NO by 
metal (copper) ion catalysis.
The proposed mechanism of action of y-glutamyl transpeptidase is show in Scheme 1.1.
(g) Reaction with other metals
The discovery of copper catalysis of S-nitrosothiol decomposition was made during a 
systematic investigation of the effect of metals. Addition of EDTA greatly reduced the 
rate of decomposition but the rate increased when copper salts were added at 
concentrations greater than that of EDTA. Thus copper ion catalysis came to light. The 
exact nature of the catalytic copper will be described in next chapter (Results and 
Discussion). No catalysis by added Zn^+, Ca^+, Mg^+, Ni^+, Co^" ,^ Mn^+, Cr^+ or Fe^"  ^
was detected. Williams et a l found also catalysis by Fe^+ generated by reduction of Fe^+ 
under anaerobic conditions, but this reaction is still under investigation.
12
SNO
HO OH
NH
Y-glutamyltranspeptidase
SNO
glutamate + OH
OH + 2 NOHO NH
Scheme 1. 1: The proposed mechanism of action of y-glutamyl transpeptidase (adaptedfrom Askew, 1994).
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1.1. 5. The Purity of S-Nitrosothiols
The fact that 5-nitrosothiol are less stable than the corresponding oxygen analogues, such 
as alkyl nitrites, made them difficult to isolate and purify. Only a few however have been 
isolated and characterised. A possible reason why pure 5-nitrosothiols are so difficult to 
isolate in the pure solid state could be due to spontaneous decomposition (Park, 1988). It 
has been proposed, although no evidence was presented, that they decompose by second 
order kinetics and therefore evaporation of the solvent would lead to increase 
concentration and more chance of rapid decomposition to their disulphide (Park, 1988). 
Also, it is expected that there would be thiol present even in the pure 5-nitrosothiol 
(McAninly ef a/., 1993).
1 .1 .6 . S-Nitrosothiols in vivo
5-Nitrosothiols have been detected and quantified in vivo. Most occur naturally in human 
plasma as the 5-nitroso albumin (Stamler et a l, 1992a,b,c,d&e). Further, 5-nitroso-L- 
glutathione (GSNO) has been measured at micromolar concentrations in human bronchial 
fluid (Gaston et a l, 1993). A number of 5-nitrosothiols including GSNO have been 
shown to possess vasodilator activity (Mellion et a l, 1983) and also have the ability to 
inhibit platelet aggregation (Ignarro et a l, 1981a&b). They are also implicated in a 
number of other biological processes. An earlier suggestion (Myers et a l, 1990) that the 
EDRF is not free nitric oxide but a 5-nitrosocysteine is now not a view which is widely 
held, but 5-nitrosothiols may well play a role in nitric oxide storage within the body, 
given the ready pathway for NO group transfer to thiolate ion. Already 5-nitrosothiols, 
specifically GSNO are being used therapeutically (a) to inhibit platelet aggregation after 
coronary angioplasty (Langford et al, 1994) (b) to treat a form of pre-eclampsia in 
pregnant women (Beider et a l, 1995). Its activity is believed to be associated with its 
ability to inhibit platelet aggregation at dose levels which do not lower blood pressure, in 
contrast to the other available NO donors.
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1.2. The Biological Activity of 5-Nitrosothiols
The first demonstration that these compounds aie biologically active was the description 
of the antibacterial effects of 5-nitrosocysteine (CysNO; Incze et a l, 1974). More 
recently, attention has focused on the effects of 5-nitrosothiols on vascular smooth 
muscle. 5-Nitrosothiols such as 5-nitroso-N-acetylpenicillamine (SNAP), CysNO, 5- 
nitroso-N-acetylcysteine (NACysNO) and 5-nitrososocaptopril (SNOCAP) have been 
shown to be potent smooth muscle relaxations in a variety of vascular smooth muscle 
prepaiations (Ignarro et a l, 1989a&b; Henry et a l, 1989,Cooke et a l, 1989), and 5- 
nitrosoglutathione (GSNO), CysNO, 5-nitrosohomocysteine (HCysNO), NACysNO, 
SNAP and SNOCAP have been shown to relax tracheal smooth muscle (Jansen et a l,
1992). Smooth muscle relaxation is believed to be mediated by elevated cGMP levels, 
and the ability to stimulate soluble guanylate cyclase (GC) has been described for several 
5-nitrosothiols, including SNAP, NACysNO, SNOCAP, 5-nitrosomercaptoethylamine, 5- 
nitroso-3-mercaptopropanoic acid and 5-nitroso-p-D-thioglucose (Ignarro et a l, 
1981a&b; Mellion et a l, 1983; Loscalzo et a l, 1989). Inhibition of platelet aggregation 
by 5-nitrosothiols has been described for several compounds, including SNAP, CysNO, 
NACysNO, SNOCAP and 5-nitrosothioglucose (Mellion et a l, 1983; Loscalzo et a l, 
1989; Mendelsohn et a l, 1990).
In addition to their pharmacological properties, 5-nitrosothiols may be important 
physiologically. 5-Nitrosothiols have been suggested to be the active metabolites 
responsible for the smooth muscle relaxing activity of nitroglycerine and related 
nitrovasodilators (Ignarro ef a/.,1981a&b). According to this proposal, 5-nitrosothiols 
such as CysNO are formed from endogenous thiols in vivo during metabolism of 
nitrovasodilators. Similarly , the antithrombotic activity of the nitrovasodilators has been 
proposed to be due to the formation of 5-nitrosothiols in platelets (Stamler and Loscalzo, 
1991). Recently, the biological activities of two potent endogenous vasodilators, the
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bovine retractor penis inhibitory factor (Kerr et a l, 1992) and endothelium-derived 
relaxing factor (EDRF, Myers et al, 1990; Rubanyi et a l, 1991a&b) have been suggested 
to be due to 5-nitrosothiols. A number of groups have provided evidence that EDRF is 
identical to nitric oxide (NO) (Furchgott, 1988; Palamer e ta l, 1987; Ignarro e ta l,  1987), 
whereas other dispute that claim (Shikano et a l, 1987; Vedernikov et a l, 1988; Myers et 
al, 1990; Sata et a l, 1990: Rosenblum, 1992). If EDRF is not nitric oxide, it is probably 
a closely related compound such as a 5-nitrosothiols (Myers et a l, 1990; Rubanyi et a l, 
1990). Protein 5-nitrosothiols, predominantly the 5-nitroso derivative of albumin, have 
been found in human plasma and may represent storage forms of nitric oxide (Stamler et 
al, 1992a,b,c,d&e).
The fact that NO, a decomposition product of 5-nitrosothiols, can directly relax vasculai' 
smooth muscle (Gruetter et a l, 1979), inhibit platelet aggregation (Mellion et a l, 1983) 
and stimulate soluble GC (Arnold et a l,  1977) has led to the suggestion that the 
biological activities of 5-nitrosothiols are a direct consequence of decomposition and NO 
production. All of the known 5-nitrosothiols are unstable in solution, and although the 
decompostion of most of them has not been characterized in detail, it probably occurs by 
homolytic cleavage of the S-N bond, resulting in the production of NO and the 
corresponding disulphide (Williams, 1983). Alternatively, NO could be produced via a 
one-electron reduction of 5-nitrosothiols (Rubanyi e ta l,  1991a&b). Feelisch and Noack 
(1991) compared the stability and the biological activity of various 5-nitrosothiols and 
concluded that stimulation of soluble GC is mediated by NO released upon 
decomposition. The ability of CysNO to stimulate soluble GC has likewise been 
attributed to NO (Graven and DeRubertis, 1983). On the other hand, other researchers, 
including Kowaluk and Fung (1990a&b), Rubanyi et a l (1991a&b) and Myers et al 
(1990), provide evidence that the smooth muscle relaxing actively of 5-nitrosothiols is 
not due to spontaneous libration.
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The trouble with all previous studies of the in vitro release of NO from 5-nitrosothiols 
which do not take into account the effect of copper ions from adventitious copper present 
in the buffer and thiol contaminating 5-nitrosothiols need reinterpretation. This will be 
discussed in the next chapter (Results & Discussion).
Some synthetic and naturally occurring 5-nitrosothiols are shown in Scheme 1. 2.
1.3. Endothelium-Derived Relaxation Factor (EDRF)
Early suggestion that EDRF might be a product of the arachidonic acid lipoxygenase 
(Singer and Peach, 1983; Forstermann and Neufang, 1984) or of the cytochrome P-450 
enzyme (Pinto et a i, 1985; Macdonald et al., 1986) or was a compound with a carbonyl 
group near its active site (Griffith et at., 1984) did not lead to the identification of its 
chemical structure. Based on the similarities in the pharmacological behaviour of EDRF 
and NO generated from acidified NO2 "’ Furchgott suggested in 1986 that EDRF may be 
NO (Furchgott, 1988). At the same time, Ignarro et al. also speculated that it may be NO 
or a closely related species (Ignarro et al, 1988).
The first evidence for the formation of NO by mammalian cells came from experiments 
in which EDRF released from vascular endothelial cells was identified as NO by 
chemical means. NO may be measured directly as the chemiluminescent product of its 
reaction with ozone (Downes et al., 1976). It was shown using this method that the 
concentrations of bradykinin that induced the release of EDRF from procine aortic 
endothelial cells in culture also caused a concentration-dependent release of NO. 
Moreover, the amount of NO released by the cells were sufficient to account for the 
relaxation of vascular strips (Palmer et al., 1987). Furthermore, the levels of NO released 
by these cells also accounted for the inhibition of platelet aggregation and adhesion 
induced by EDRF (Radomski et al., 1987a,b,c&d). A key element in all of these studies 
was the correlation the amounts of NO measured by bioassay and those detected by 
chemiluminescence.
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SNO SNO
OH OH
S-nitroso-A/-acetyl-L“Cysteine
NACysNO
S-nitroso-L-cysteine
CysNO
SNO
SNO
OH
HO
S-nitrosocaptopril
SNOCAP
S-nitrosohomocysteine
HCysNO
SNOSNO
/ O H
NH
S-nitroso-mercaptoethylamine S-nitroso~3-mercaptopropanoic acid
CHpOH
SNO
OH
HO I
OH
S-nitroso-p,D-thioglucose
Scheme 1 .2: Some synthetic and naturally occurring 5-nitrosothiols.
A detailed comparison of the biological actions of EDRF and NO on vascular strips 
(Palmer et a l, 1987; Hutchinson et a l, 1987) and on platelets (Radomski et a l ,  
1987a,b,c&d) also shovyed that the two compounds were indistinguishable (Moncada et 
a l, 1988). Both EDRF and NO caused a relaxation of the vascular strips that declined at 
the same rate during passage down the bioassay cascade (Palmer et a l,  1987). 
Furthermore, the rate of the decay during transit in polypropylene tubes was slower but 
similar for both compounds, indicating that they have identical chemical stability even 
under these artificial conditions. Both EDRF and NO also inhibited platelet aggregation 
(Radomski et a l, 1987a,b,c&d), induced the disaggregation of aggregated platelets 
(Radomski et a l, 1987a,b,c&d), and inhibited adhesion (Radomski et a l, 1987a,b,c&d). 
Moreover, their biological half-lives as inhibitors of platelet aggregation were similar 
(Radomski e ta l, 1987a,b,c&d).
The actions of EDRF and NO on vascular strips and on platelet were similarly potentiated 
by SOD (superoxide dismutase) and cytochrome c and inhibited by Fe^ "*" and some redox 
compounds (Palmer et a l, 1987; Hutchinson et a l, 1987; Radomski et a l, 1987a,b,c&d). 
Furthermore, the potency of redox compounds as inhibitors of EDRF-induced and NO- 
induced vascular relaxation was attenuated by SOD (superoxide dismutase) to a similar 
extent. In addition, the inhibitory action of Hb on EDRF can be explained by the fact that 
this substance binds avidly to NO (Hermann, 1965; Gibson and Roughton, 1957; Martin 
et a l, 1986). Finally, both EDRF and NO act on vasculai' smooth muscle (Kukovetz et 
al, 1979; Rapoport and Murad, 1983a,b&c) and platelets (Mellion et a l, 1981) through 
the stimulation of soluble guanylate cyclase and elevation of cyclic GMP.
NO release from vascular endothelial cells from the other species and from a number of 
vascular preparations, in amounts sufficent to account for the biological actions of EDRF, 
has also been demonstrated. It was also shown, using a chemical assay based on the 
diazotization of sulphamic acid and subsequent coupling with A-( 1 -naphthyl)-ethylene 
diamine, that NO or a labile nitroso species was released from perfused bovine
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pulmonary arteiy. Furthermore, perfusion of segments of pulmonary artery or 
pulmonary vein with ACh, caused relaxant responses and elevation of vascular cyclic 
GMP level in the bioassay tissues that could be matched by NO (Ignarro et al., 1987). 
Similar, results were obtained in prefused rabbit aorta stimulated with ACh, and 
substance P (Khan and Furchgott, 1987; Chen et at., 1989). Later, the use of a 
spectrophotometric assay, based on the reaction between NO and Hb, also demonstrated 
the release of NO from vascular endothelial cells in culture (Kelm et al., 1988a&b). 
Furthermore, the release of NO from isolated perfused rabbit (Amezcua et al., 1988) or 
guinea pig (Kelm and Schrader, 1988b) hearts has been shown to account for the 
vasodilator actions of ACh and bradykinin in these preparation. All of this evidence 
strongly supported the proposal that EDRF is NO.
1 .3 .1 . Generation of NO
In general, nitric oxide can be generated in vivo by two main pathways. Firstly, from 
enzymatic sources; secondly , from chemical sources. Here we will briefly review the two 
main pathways.
1. 3 .1 .1 . Enzymatic Sources
In mammalian cells, NO is synthesized by NO synthases, which catalyze the oxidation of 
L-arginine by dioxygen. There are two types of NO synthases that have been recently 
described in great detail in several excellent reviews (Feldman et al., 1993; Marietta, 
1993). One group (macrophages, hepatocytes, tumor cells) is made of inducible NO 
synthases, the other (cerebellar, endothelial cell, platelets) of constitutive enzymes. In the 
latter, the enzyme activity is dependent on Ca^+ and calmodulin.
These enzymes have strong homologies with both cytochrome P450 reductase and 
cytochrome P450 with FMN, FAD and haem as prosthetic groups. Moreover, they 
require tetrahydrobiopterin and NADPH as cofactors. A simplified reaction scheme is 
shown in Scheme 1.3.
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Og, NADPH
Fe(V)=0 Fe(lll)
N OHNH
+ NONADPH 
NO synthase
0.5 NADPH 
NO synthase
GOp-GOp-
Scheme 1. 3: The proposed NO synthase reaction (adapted from Knowles and Moncada, 1994; Marietta, 1993).
The haem moiety serves to carry out a reductive activation of O2 , leading to a high-valent 
ferryl complex which transfers its oxygen atom to L-arginine. The resulting N~ 
hydroxyarginine (NOHA) is further oxidized to NO and citrulline. The source of oxygen 
in both NO and citrulline is molecular oxygen. The nitrogen atom of NO is the guanidino 
nitrogen atom of aiginine. Several arginine derivatives (A-methylarginine) are powerful 
inhibitiors of NO synthases.
Other haemoproteins have recently been found to generate NO from A-hydroxyarginine. 
With cytochrome P450 from rat liver microsomes, the oxidation can be performed with
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NADPH and O2 as well as with H2 O2  or hydroperoxides (Boucher et el, 1992a&b). On 
the other hand, horseradish peroxidase, hemoglobin and catalase could also catalyze the 
oxidative cleavage of a C-N bond of NOHA by H2 O2  or alkyl hydroperoxides (Boucher 
e ta l, 1992a&b).
The reaction has been further extended to a large family of molecules, the aromatic 
amidoximes (Andronik et al, 1992):
In all these reactions, the oxidizing conditions rapidly convert NO into NO2 " or other 
nitrogen oxides.
Some compounds related to arginine are effective inhibitors of NO-synthase and their use 
has proved invaluable in many investigations on the biology of NO.
The structure of L-arginine and of the L-arginine analogues most frequently used as 
inhibitors of NO synthases are displayed in Scheme 1. 4 (adapted from Knowles et a l, 
1994; Butler and Williams, 1993).
NO-synthase in endothelial cells is a constitutive enzyme. This means it is present all the 
time and responds rapidly to activation. On the other hand, the enzyme in the 
macrophages is inducible, that is, it is not present until the macrophages have been 
activated by a cytokine. There is a delay of some hours between activation and the 
appearance of nitrite and nitrate, indicative of macrophage activity. The differerance 
between the two can be understood in terms of their different physiological roles. NO is 
cytotoxic only when large quantities are produced and this explains why NO used to 
activate guanylate cyclase in muscle cells has no adverse effects. Macrophage activity 
must, necessarily, be long-lasting to rid the body of infection but, in order to respond to 
the rapidly changing needs of the body, the effect of NO in muscle cells must be short­
term (Butler and Williams, 1993).
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Scheme
used as inhibitors of NO synthases. 1. 4: The structure of L-arginine and of the L-arginine analogues most frequentlyS
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1. 3.1.2. Chemical Sources
Nitric oxide can be generated from several chemical sources, such as organic nitrates, 
iron-nitrosyl complexes, sydnonimines, C-nitroso compounds, secondary amine/NO 
complex ions and 5-nitrosothiols. All these sources act as NO-donor drugs in direct and 
indirect ways. Here we will discuses each source briefly to provide simple background 
information about these drugs.
(a) Organic Nitrates
Nitroglycerin has been used as a vasodilator (a substance which enlarges blood vessels) 
for the treatment of angina pectoris. Its vasodilatory effects are releated to its 
metabolization to NO within the artery.
RONO2 + R'SH     ROH + R'SNOg
2  R'SNOa ------------► 2 .8 —  hL
O O
R
2  NO + S - S ^
R' O
However, the release of NO from organic nitrates is not spontaneous and requires 
activation through enzymatic pathways, that have not been unambiguously identified. 
Thiols might be involved in such an activation (Fontecave and Pierre, 1994).
(b) Iron-Nitrosyl Complexes
Sodium nitroprusside (SNP) has also been used as a vasodilator. However, SNP does not 
spontanously liberate NO in vitro. It requires either reductive (for example, with a thiol)
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or light activation. This is very often insufficiently appreciated in experiments using SNP 
as a source of NO (Butler, 1994; unpublished observation).
hv[Fe(CN)5(N0)f-
[Fe(CN)5(NO)f-
pH = 7.4 
R'SH
pH = 7.4
NO + [Fe(CN)s HgOf 
R'SNO + [Fe(CN)5H20f-
1/2 R'SSR' + NO
SNP is actually more a source of nitrosonium NO+, and thus behaves as a nitrosating 
electrophilic species. It has been shown to convert amines into nitrosamines, ketones into 
oximes but 5-nitrosation has not been unambiguously detected.
(c) Sydnonimines
These molecules are heterocyclic compounds derived from morpholine. The liberation of 
NO requires both alkaline pH and the presence of oxygen:
Q N
CN
Q N----
CN
Q N
+ NO
NO
O2
Oc
y ^ C N
Q N-----hi
^ N O
Superoxide is generated at the same time and may combine with NO to generate 
peroxynitrite (Fontecave and Pierre, 1994).
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(d) C-Nitroso Compounds
Upon exposure to light, C-nitroso compounds may undergo a homolytic cleavage of the 
C-NO bond and generate NO (Chamulitrat et a l, 1993):
NO hv NO
f-BuNO
O'
(e) Secondary Amine/NO Complex Ions
Compounds of formula R2N[N(0)N0] (so called amine NONOate) (Maragos et al, 
1991; Hrabie eta l, 1993) have the following interesting properties:
(a) They stabilize NO during storage in a solid form.
(b) They are highly soluble in water.
(c) They can release NO at rates that can be reliably adjusted over a wide range with 
judicious choice of the carrier nucleophile R2 NH.
(d) They release of NO is spontaneous and does not require redox or light activation.
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Examples:
HcN
<
<N N\
y N = 0
O'
diethylamlne NONOate
N =  0
N— N
spermine NONOate
^ N  N  ^  2 NO + ^ N -----H
O'
These compounds have both vasorelaxant and antiproliferative (inhibition of DNA 
synthesis in tumor cells) activities (Maragos et al., 1993).
(f) S-Nitrosothiols
5-Nitrosothiols are an important class of NO-donor drugs. They decompose by several 
pathways giving NO and the corresponding disulphide (Section 1.1).
1.4. Physiological Functions of Nitric Oxide
Nitric oxide or EDRF seems to be implicated in a wide range of biological processes 
(Moncada etal., 1991):
(a) Production of nitric oxide acts as a transduction mechanism for the activation of 
soluble guanylate cyclase (in many cells and tissuse).
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(b) Nitric oxide is an effector molecule in immunological reactions.
In this research we have studied the biological activity of a range of 5-nitrosothiols in 
smooth muscle relaxation, and inhibition of platelet aggregation.
1 .4 .1 . Activation of Guanylate Cyclase
Guanylate cyclase, the enzyme responsible for vascular muscle relaxation, is found in 
most cells and throughout the animal kingdom. It is exist in two forms: a soluble enzyme 
inside the cell and membrane-associated (particulate). The relative amount of each within 
the cell varies with the cell type and its physiological state.
Normally purified soluble guanylate cyclase can be activated in vitro by NO-donating 
compounds. It has been shown to be the target enzyme for NO (whether endothelium 
derived or from an exogenous source). However, NO has its main site of action on the 
cytoplasmic isoenzyme (Waldman and Murad, 1987). The presence of multiple 
isoenzyme forms of guanylate cyclase has made the determination of the exact 
constitution of soluble guanylate cyclase difficult, but it is thought to be a heterodimer 
with Mr 82,000 and 70,000 subunits (Waldman and Murad 1987). In bovine lung the 
enzyme contains haem and perhaps copper and when purified, enzyme extracts exhibit 3 
absorption maxima at 433, 550 and 565 nm which are shifted on exposure to either CO or 
NO (Gerzer et al., 1981). Although NO-donor drugs activate soluable guanylate cyclase 
(Katsuki et a l, 1977a,b&c), haem-deficient guanylate cyclase showed modest or little 
activation by these agents (Ignarro et al., 1982a&b). The involvement of the haem group 
in the stimulation of the enzyme was clarified by the inhibitory effect of adding ferro 
metallo-proteins (but not ferric forms) such as haemoglobin or myoglobin, to highly 
purified extracts of the enzyme. Application of NO-donor drugs to the purified enzyme in 
the presence of Fe^^ metallo-proteins was no longer capable of activating cyclic 
guanosine monophosphate (cGMP) production (Mittal et al, 1978; Murad et al, 1978).
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This was thought to be due to the efficient scavenging ability of NO by the Fe+2 metallo- 
proteins:
HN
OH
OH
cGMP
It was found that oxidising agents such as hydrogen peroxide, methylene blue, superoxide 
and ferrocyanide inhibited the activity of the enzyme, whilst reducing agents (ascorbate, 
cysteine, glutathione, dithiothreitol) promoted the activation of the enzyme by NO-donor 
drugs (Braughler, 1983; Graven etal., 1978). The inhibitory effect of oxidising agents is 
likely to be due to a number of reasons; NO may be converted to higher oxides of 
nitrogen (NO2 ) before it reaches the active site of the enzyme; the iron of the recipient 
haem group at the active site may be oxidised to its ferric form; or, an as yet unexplained 
'overoxidation' of key regulatory thiol groups can cause irreversible loss of both basal and 
nitro-activated cGMP production by the enzyme (Waldman and Murad, 1987). 
Consequently, reducing agents may potentiate activation by preventing these oxidations.
Partial purification of hepatic soluable guanylate cyclase results in loss of responsiveness 
to NO-donor drugs, as well as to nitric oxide (Craven et a l, 1978). Responses were 
partially restored by the addition of free haematin, haemoglobin and other haemoproteins, 
but the activity was potentiated by the addition of reducing agents into the incubations, 
which facilitate the generation of nitrosyl haem by maintaining the haem iron in the 
ferrous form (Katsuki et al.„ 1977a,b&c; Craven et a l, 1978). Preformed nitrosyl- 
haemoglobin was found to be 10-fold more effective in activating guanylate cylase than
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certain nitrovasodilators (Craven et a l, 1978). Activation of partially purified guanylate 
cyclase by preformed nitrosyl-haemoglobin was not potentiated by reducing agents, 
supporting the suggestion that reducing agents affect the conversion of the parent 
nitrovasodilator to nitrosyl-haem complexes (Craven et al., 1978). These data imply that 
activation of guanylate cyclase by nitrovasodilators occurs through reductant-dependent 
formation of nitrosyl-haem prophyrin complexes.
Thiols such as cysteine, glutatione, and dithiothreitol are capable of releasing NO from a 
range of nitrovasodilators, although intermediates in the process, such as 5-nitrosothiol 
derivatives, have been found to be 100-fold more effective than certain nitrovasodilators 
in activating guanylate cyclase (Ignarro etal., 1980a,b&c). As thiol groups can undergo 
oxidation/reduction reactions and thiol disulphide conversions have been demonstrated to 
regulate protein structure and function, it is reasonable to suggest that they may also be 
involved in the regulation of guanylate cyclase. Early studies using alkylating agents 
which modify free thiol groups (eg. ethacrynic acid) were shown to alter basal and nitro- 
activated cGMP production (Katsuki et al., 1977a,b&c). Similarly, mixed disulphide 
formation on addition of cysteine or cystamine also inhibited enzyme activity (Ignarro et 
al., 1981a&b; Waldman et al., 1983). Studies with P^S] cystamine resulted in 
incorporation of the radioactive label into the enzyme along a time course which 
paralleled inhibition of the enzyme. This effect was reversed by dithiothreitl which 
reforms the thiols (Brandwein et al., 1981). It has been proposed that guanylate cyclase 
possesses multiple thiol sites, one of which is responsible for regulation of basal cGMP 
production and another for regulation of nitro-activated cGMP production (Braughler et 
a i, 1983). At least one, but probably two, thiol groups aie located at or near the catalytic 
site of the enzyme, as preincubation with the activating agent (nitrovasodilators) or 
excess substrate (Mg^+-GTP) protected the enzyme against inactivation (Ignarro et a l, 
1981a&b).
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Although the mechanism by which the nitrosyl-haem complex activates guanylate 
cyclase remains unknown, a model has been presented which could explain this 
phenomenon (Figure 1.1).
HAEM GROUP
GUANYLATE CYCLASE
Figure 1.1: A simplified diagram showing the out-of-plane movement of the porphyrin iron centre of guanylate cyclase when activated by NO.
Conformational change in an enzyme is widely belived to be a regulatory phenomenon in 
regulating its action as envisioned by Koshland in his induced-fit model of enzyme
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action (Stryer, 1988). If these changes occur at, or near, the active site the conformational 
change may influence function. Based on the findings that protoporphyrin IX gave the 
same activation effect as NO-haem, and that haem inhibits, not activates, the enzyme, 
Ignarro proposed that a haem structural change is caused by NO binding (Ignarro et a l, 
1982a&b). He suggested that once bound the haem-NO complex elicits an out-of-plane 
movement of the central iron to produce a haem core size similar to that of a free 
porphyrin (Ignarro, 1992).
Traylor et al. (1993) support this theory with work on model haem systems. Based on the 
finding that NO binds preferentially to the haem lacking a proximal ligand, they proposed 
that when NO binds haem, there is a tendency to expel the basic ligand on the proximal 
side of the haem. This mechanism liberates a free base to catalyse the hydrolysis of the 
phosphate diester bond of guanosine triphosphate (GTP). This theory was tested using 
NO to release 1 -methylimidazole from a 5-coordinated model haem. This promoted 
hydrolysis of p-nitrophenolate in the aqueous medium used. However there are important 
aspects of the proposed mechanism which remain to be explained. It is not known 
whether haem is present in the ferric form in the native enzyme, because reductants such 
as dithiothreitol are used during enzyme purification. Furthermore, the strong binding of 
NO to ferrous haem and possible dissociation of haem from proteins due to this binding 
would tend to severely limit the number of turnovers of the enzyme and make for a very 
inefficient biocatalyst.
1. 4. 2. Endothelium-Dependent and Independent Smooth Muscle 
Relaxation
The production of cGMP from activation of guanylate cyclase was shown to correspond 
to a relaxation of certain smooth muscles and this activation was markedly enhanced by 
free radicals such as NO and hydroxyl radical (Murad et a l, 1979).
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Murad and his colleagues proposed that many potent vasodilators, such as sodium 
nitroprusside (SNP), organic nitrates and inorganic nitrites, activated guanylate cyclase 
indirectly via NO, which may be released as a reaction product (Murad et a l, 1979). 
Speculation that EDRF would stimulate an increase in intracellular cGMP in arterial 
smooth muscle cells was confirmed by experiments carried out by Rapoport and Murad 
(1983a,b&c) and Furchgott and Jothianandan (1983) on the rat and rabbit aorta. 
Stimulation of the tissues with intact endothelium produced elevated levels of cGMP in 
the smooth muscle which was not present if the endothelium had been removed. This led 
to speculation that EDRF was a free radical. It has since been shown that the production 
of EDRF from NO synthase requires intracellular calcium to inititate its release (Palmer 
et al.y 1988). This calcium appears to be released from intracellular stores as there is no 
evidence of calcium channels cells (Zheng et a i ,  1994). Endothelium dependent 
vasodilators such as ACh stimulate membrane-bound muscarinic receptors on endothelial 
cells initiating the release of calcium. This is required by the constitutive NO synthase for 
NO production, and leads to stimulation of guanylate cyclase in arterial smooth muscle in 
a similar way to nitrovasodilators.
Rapoport and co-workers (1983a,b&c) have shown that increase in cGMP in rat aorta due 
to this process is accompained by a change in the pattern of phosphorylated proteins. This 
finding was particularly interesting as this change of pattern of phosphorylated proteins 
was identical to that previously found after exposure to the endothelium independent 
vasodilator SNP fuelling the hypothesis that the EDRF and the activating agent released 
by the nitrovasodilators (NO) were the same. They suggested that this processes was 
mediated through cyclic GMP production. In addition, the entry of calcium into the 
smooth muscle cells, which is necessary for contraction, diminished. Figure 1. 2 
summarises the endothelium-dependent and endothelium-independent mechanisms of 
vascular smooth muscle relaxtion which bring about vasodilation.
Recently work by Megson, (1993) and Venturini et al, (1993) has shown that vascular 
smooth muscle cells contain a finite store of a photosensitive molecule(s) which is
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capable of releasing NO when irradiated with visible or UV light. This store can be 
exhausted rapidly by exposing vessels to laser light but subsequently regenerates in the 
dark with an absolute dependence upon endothelium-derived NO (Megson, 1993). The 
repriming of the store is prevented by L-NMMA or haemoglobin and accelerated by 
donor drugs. Venturini et al. proposed that the 'store' is a 5-nitrosothiol, a nitrosoprotein 
or an iron-sulphur nitrosyl complex. The work of Megson provides evidence that the 
'store' is, in fact, an 5-nitrosothiol or nitrosoprotein, since it is known that ethaciynic acid, 
a thiol alkylating agent, also prevents repriming of the 'store'.
1 .4 .3 . Inhibition of Platelet Aggregation
The discovery of a role for NO in platelet function occurred in 1981, when it was found 
that NO and other nitrovasodilators inhibited ADP-induced platelet aggregation by a 
cGMP-dependent mechanism (Mellion et al., 1981). It was not until 1986 that a link was 
identified between the actions of NO on platelet aggregation and those of EDRF on 
vascular smooth muscle (Azuma et al, 1986). It was shown by these and other workers 
that EDRF itself was capable of inhibiting platelet aggregation in vitro (Furlong et 
al. 1987; Radomski et al., 1987a,b,c&d) and in vivo. Radomski et al. showed that NO and 
prostacyclin were both capable of enhancing the disaggregating effects of the other on 
platelets ( Radomski et al., 1987a,b,c&d), although the effects of prostacyclin are 
mediated by cAMP (Radomski et al., 1987a,b,c&d), and that both have cytoprotective 
properties (Radomski et al., 1988). The cytoprotective effects of NO are now thought to 
be due to its reacting with the potentially harmful oxygen free radicals (O2" in particulai) 
(Rubanyi et a l, 1991a&b). It has also been reported that NO inhibited platelet adhesion 
to collagen, endothelial cell matrix and cultured endothelial cell monolayers by a cGMP- 
dependent mechanism (Radomski et at., 1987a,b,c&d). This, however, is in contrast to 
prostacyclin, which only has a weak, cAMP-mediated inhibitory effect on platelet 
adhesion (Higgs et al, 1987c) and does not synergise with NO in this case.
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It has been shown that nitrovasodilators which release NO spontaneously (3-morpholino- 
sydnonomine) are capable of inhibiting platelet aggregation by a cGMP-dependent 
mechanism. However, some organic nitrates (e.g. GTN) which can elicit vasodilation in 
vascular smooth muscle are not able to inhibit platelet aggregation (Gerzer et a/., 1988). 
The inference is that platelets lack the necessary enzymes for biodégradation, leading to 
release of NO.
It is now known that NO is generated in platelet and that it acts as a negative feedback 
system to modulate aggregation (Radomski et a l, 1990 a,b). Generation of platelet- 
derived NO is NADPH-dependent, inhibited by LNMMA and dependent on free 
intracellular Ca^+. Addition of L-arginine to the medium does not alter basal NO 
production, but enhances the increase in NO production when aggregation is initiated 
using collagen, or ADP or arachidonic acid. The inference from this is that nitric oxide 
synthase exists in platelets and is stimulated to produce NO synthesis from L-arginine 
once aggregation is initiated (due to an increase in intracellulai" Ca^+i Ware et a l, 1986). 
The increase in intracellular NO has been shown to be accompanied by an increase in 
cGMP but not cAMP. The mechanism by which cGMP inhibits aggregation is not fully 
understood, but it may involve sequestration of free intraplatelet Ca^+ (Busse et a l, 
1987).
NO, therefore, may play an important antithrombotic role in vivo by inhibiting both 
platelet aggregation and adhesion to vessel walls, particularly as its actions are enhanced 
by the synergistic effect of prostacyclin.
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1. 5. Purpose of the Present Work
The aims of this research are:
I. The design and synthesis of a new series of biologically active S-nitrosothiols as NO- 
donor drugs with the following properties:
(a) Stable drugs.
(b) Solid or liquid but preferably solid because it will be easier to handle.
(c) Lipophilic drugs in order to increase the ability of these drugs to enter the cell.
(e) With high purity, but we know from literature sources that this will be difficult to 
achieve due to contamination by thiol and the corresponding disulphide, and the lack of a 
suitable method of purification due to the nature of S-nitrosothiols.
(e) More stable than SNAP but less stable than GSNO.
(f)They can release NO in vivo,
(f) They do not release NO during storage.
II. The kinetics and the mechanism of decomposition of 5-nitrosothiols catalysed by 
copper ions in vitro has not been thoroughly investigated. One aim of this study is to 
explore the decomposition of SNAP, the new 5^-nitrosothiols, and GSNO in pH = 7.4 in 
the hope that this will shed light on the mode of action of the copper ions.
III. The role of copper(I) ions in the breakdown of 5'-nitrosothiols in vivo is as yet 
unexplored. Here we investigate the effect of the specific copper(I) chelator, neocuproine 
(NCu), on vasodilator responses to bolus injections of SNAP or GSNO in the isolated rat 
tail artery.
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IV. Study the chemical stability of the 5-nitrosothiols.
V. Study the pharmacological and physiological properties of the ^-nitrosothiols by:
(i) smooth muscle relaxation.
(ii) inhibition of platelet aggregation.
VI. Correlate the structure, chemical stability and biological activity of the S- 
nitrosothiols.
VII. The role of L-ascorbic acid (Vitamin C) in the breakdown of S'-nitrosothiols in vivo is 
as yet unexplored. Here we investigate the effect of L-ascorbic acid on the decomposition 
of GSNO in vitro and ex vivo at pH = 7.4 in the hope that this will shed light on the mode 
of action of the L-ascorbic acid.
VIII. Detecting of NO by using the sensor lOS-NO to show that 5-nitrosothiols are NO- 
donor drugs.
IX. From this study we hope to answer the following question:
Do 5'-nitrosothiols decompose before or after entering the cell?
X. Also we hope to learn something about the tissue selectivity of the drugs. Which can 
act as good drugs to reduce blood pressure but do not affect the platelet, or vice versa?
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IL DISCUSSlOOi
In this chapter, we report the synthesis of (a) an S-nitrosated amino-acid; (6) a series of new S- 
nitrosated dipeptides; and (c) an S-nitrosated tripeptide. Lhey were prepared in order to study and 
œrrelate structure, pharmacological and physioCogicaC activity (vasodilator activity and inhiSitwn 
of platelet aggregation), and chemicaC staSiCity . Moreover, the mechanism of hreahfown of S- 
nitrosothioCs in vitro and in vivo is notfuCCy understood and a study of this matter is reported, to 
address idie questions governing their actual roCe in the human Body, the reason for them Being 
recycled in the Body, and to determine if  die decomposition is an e;(p- or endo-ceüular event. Sifter 
thus elucidating ffie rote of S-nitrosothioCs as 9^-donor drugs attempts wiCC Be made to design and 
synthesise a tissue selective 9(jp-donor drug for further study. Hhen, detection of 9{p By three 
methods to show that S-nitrosothioCs are 9dP~donor drugs.
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SLA(P DISCUSSI09i
2. 1. The Design and Synthesis of A New Series of Biologically 
Active S-Nitrosothiols as NO-Donor Drugs
The aim of the work described in Section 2.1 was the design and synthesis of a number of 
dipeptides where one amino acid contains an -SH group. These compounds were readily 
converted into the corresponding 5-nitrosothiols. A number of other syntheses are also 
described.
Although the role of nitric oxide (NO) in effecting the relaxation of vascular smooth 
muscle, and thus controlling blood pressure (Butler and Williams, 1993), is firmly 
established, the part played by ^-nitrosothiols is far less clear. ^-Nitrosocysteine (SNC), 
rather than NO, was proposed (Myers et ah, 1990) as the true endothelium derived 
relaxation factor (EDRF) but a recent study (Feelisch et a l, 1994), in which the properties 
of the EDRF were compared with those of SNC and NO, has shown that this is most 
unlikely. On the other hand, S-nitrosothiols do occur naturally in the body (Stamler et al, 
1992a,b,c,d&e) but so far no role has been ascribed to them, although it has been 
suggested that they provide a pool of nitric oxide for use in metabolic processes.
Exogenous 5-nitrosothiols are potent vasodilators. 5-Nitroso-V-acetylpenicillamine 
(SNAP) and 5-nitrosocaptopril (SNOCAP), inter alia, effect relaxation of endothelial 
smooth muscle (Ignarro et a l, 1981a&b). Also, S-nitrosoglutathione (GSNO), has been 
shown to relax bronchial smooth muscle (Gaston et a l, 1994). ^-Nitrosothiols are not 
particularly stable compounds and breakdown thermally, photochemically (Williams, 1988)
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and in a metal ion catalysed process (McAninly et al., 1993; Dicks et al., 1996), to give a 
disulphide and nitric oxide.
It is possible that 5'-nitrosothiols are vasodilators because they release nitric oxide while in 
solution before reaching the muscle cells and are merely convenient compounds for the 
delivery of nitric oxide. However, Kowaluk and Fung (1990a&b) claim that for a number 
of 5-nitrosothiols no correlation exists between vasodilator effects and spontaneous 
liberation of nitric oxide. They conclude that NO production from ^-nitrosothiols may be 
catalysed by an external vascular membrane. Mathews and Kerr examined eight S- 
nitrosothiols and found that there was no correlation between solution stability and 
biological activity. The shortcomings of these two studies aie that the changes in chemical 
structure between 5-nitrosothiols are rather great and the role of metal ions in NO release 
was not considered. Metal ions can bring about NO release from 5-nitrosothiols even if the 
metals are present as complexed ions (Dicks et al., 1996). However, the two studies 
mentioned above established the general principle that the vasodilator action of S- 
nitrosothiols is dependent upon structure in a way that does not reflect the ease of NO 
release.
Moynihan and Roberts (1994) have shown that the nitrosated dipeptide, 5-nitroso-A- 
acetyl-p,p-dimethylcysteinyl-,S-nitroso-V-acetyl-(I,p“dimethylcysteine is an effective 
vasodilator only 10 times less potent than glyceiyl trinitrate.
In view of the importance of 5-nitrosothiols, peptides containing an -SH group and the 
complex problems associated with their synthesis, V -cy clo h ex y l-V -2 -[A - 
morpholino]ethylcarbodiimide metho-p-toluenesulphonate was used to form the peptide 
bond (Bodanszky and Bodanszky, 1984; Sheehan and Hess, 1955; Sheehan et a l, 1956; 
Bondanszky and Ondetti, 1966; and Sheehan and Hlauka, 1956) and r-butyl nitrite was 
used for nitrosation of the thiol group (Doyle et a l, 1983).
5-Nitrosothiols are very easily generated in solution from thiols by electrophilic nitrosation. 
The current literature surrounding the use of 5'-nitrosothiols has involved the authors
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generating them in situ because of the difficulties in isolation. Many 5-nitrosothiols are too 
unstable in their pure form to be isolated and this has contributed to the lack of knowledge 
of their chemistry relative to that of alkyl nitrites until compaiatively recently. Those with 
primary alkyl groups are unstable. The presence of r-alkyl groups confers some stability 
(Williams, 1988).
We set out to extend the range of the 5-nitrosothiols in order to leain more about them. We 
knew from the literature that they are unstable for several reasons and we will discuss those 
later in this chapter. The main problem with these drugs is the lack of a suitable procedure 
for their purification due to their nature. They are usually contaminated by small amounts of 
the corresponding thiols (McAninly et al., 1993) and, in some cases, by the corresponding 
disulphides (Park, 1988).
From previous work, we knew that the ^-nitrosated amino acid SNAP is quite stable (Field 
et a l, 1978). We thought that if we built up a series of S-nitrosated dipeptides they may be 
more stable than SNAP and less stable than the S-nitrosated tripeptide GSNO; (Hart, 
1985), and that was one aim of our work.
We followed a systematic design for the series by keeping the parent unit for all of them 
fixed and changing only one part of the drug in order to make it more lipophilic. We 
thought it might be of value to prepare a series of S-nitrosated dipeptides in which one 
component is kept constant as S-nitroso-A-acetyl-D,L-p,p-dimethylcysteine and the other is 
varied to give changes in structure without altering the immediate chemical vicinity of the 
-SNO group. In this section we report the synthesis of this series of compounds and 
compare their chemical stability, in the presence and absence of copper ions, with that of 
SNAP and GSNO. Full details of the way in which copper ions bring about NO release 
from 5"-niti'osothiols are given in the later sections.
In the present work we describe the preparation and the characterisation of new S- 
nitrosothiols. We have studied their stabilities in aqueous solutions and shown that they 
spontaneously generate nitric oxide at physiological pH in the presence of copper ions.
43
The compounds described here might be convenient and useful as drugs for spontaneous 
generation of nitric oxide in biological systems, at rates that can be finely tuned and 
controlled over a wide range.
2. 1. 1. Design and Synthesis of a Number of Dipeptides Where 
One Amino Acid Contains an -SH Group
The basic reaction involved here is the linking of an amino group in one unit with the 
carboxyl group of another forming an amide (or peptide) (Jones, 1991).
The -SH containing amino acid used in these studies was N-acetyl-D,L-p,p- 
dimethylcysteine (jV-acetyl-D,L-penicillamine) and this remained unchanged. The other 
amino acid was an ester to make the product more lipophilic and to simplify the coupling 
procedures. The general formula of product is as follows:
SH
We thought that the structure of the R group of the dipeptide would play a significant role 
in determining the biological activity and the chemical stability of the corresponding S- 
nitrosothiol. Once this dependence has been delineated, it should be possible to predict the 
drug action of other nitrosated dipeptides.
Carbodiimides have been the most important reagent for activating carboxy groups in 
peptide synthesis ever since Sheehan and Hess reported their results in 1955 (Sheehan and 
Hess, 1955).
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There are two types of carbodiimide: (a) water insoluble carbodiimides; and (b) water 
soluble carbodiimides (Mackie et al, 1992).
The advantages of the carbodiimide method are (see Scheme 2.2):
(i) good yields in a short reaction time, and
(ii) low racémisation when Z = (CH3 )3 COCO or PhCH20C0.
Disadvantages include the following (see Scheme 2. 2):
(i) racémisation if Z is an amino acid residue,
(ii) contamination of the product with the carbodiimide (water insoluble carbodiimide) 
which is difficult to remove, and
(iii) reaction of activated ester with the V-protected amino acid to give an anhydride which 
may be difficult to separate from the peptide.
This difficulty can be circumvented by the application of water soluble carbodiimides since 
they give rise to water soluble urea derivatives.
With the use of V-cyclohexyl-iV'-2-[V-morpholino]ethylcarbodiimide metho-p- 
toluenesulphonate (water soluble carbodiimide), V-acetyl-D,L-|3,p-dimethylcysteine was 
coupled with glycine methyl ester hydrochloride, L-alanine methyl ester hydrochloride, L- 
valine methyl ester hydrochloride, L-leucine methyl ester hydrochloride, L-phenylalanine 
methyl ester hydrochloride, L-isoleucine methyl ester hydrochloride, L-methionine methyl 
ester hydrochloride, Vg-CBZ-L-lysine methyl ester hydrochloride, L-proline methyl ester 
hydrochloride, L-aspartic acid dimethyl ester or L-glutamic acid dimethyl ester in one step. 
The solvent used was purified methylene chloride at room temperature (Scheme 2. 1).
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2. CH2CI23. RT
SH
Scheme 2.1; The coupling reaction between protected amino acid and amino acid ester to form the corresponding dipeptide.
We found it was not necessary to protect the thiol group due presumably to the steric effect 
of the two p-methyl groups. Since the coupling reagent and its reaction product are both 
neutral, the synthesis can take place in the presence of acid- and base- sensitive groups in 
the reactants. The structure of the coupling reagent is:
N = C : N
O S
O
A/-cyclohexyl-A/-2-[A/-morpholino]ethylcarbodiimide metho-p- 
toluenesulphonate
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Activation of the carboxyl group occurs through its addition to the N=C double bond in the 
carbodiimide. The mechanism of the reaction is shown in Scheme 2. 2 .
The other product of the coupling reaction is a urea derivative which is insoluble in most 
organic solvents and is readily removed from the reaction mixtures by filtration. Unreacted 
carbodiimide was extracted with water (Bodamszky, 1993):
/  \ + /  
w -
NY
o —
o
N-cyclohexyl-A/-2“[A/-morpholino]ethylurea metho-p-toluenesulphonate
The desired dipeptides were formed in moderate yields (~ 25%).
I. //-acetyl-D,L-p,|3-dimethylcysteinylglycine methyl ester:
SH
II. //-acetyl-D,L-p,p-dimethylcysteinyl-L-alanine methyl ester;
SH
O
O/
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ni. //-acetyl-D,L-p,p-dimethylcysteinyl-L-valine methyl ester:
SH
o /
o / \
IV. iV-acetyl-D,L-p,p-dimethylcysteinyl-L-leucine methyl ester:
SHO   I  O
X
V. V-acetyl-D,L-p,p-dimethylcysteinyl-L-phenylalanine methyl ester:
SH
OA o /
VI. V-acetyl-D,L-p,p-dimethylcysteinyl-L-isoleucine methyl ester:
SH
AÿA"\Ao/
O
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Scheme 2. 2: The mechanism of peptide bond formation using a coupling agent.
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VII. V-acetyl-D,L-jI,p-dimethylcysteinyl-L-methionine methyl ester:
SH
Yin. iV-acetyl-D,L-p,p-dimethylcysteinyl-L-A'e-CBZ-L-lysine methyl ester;
SH
NH
IX. V-acetyl-D,L“p,p-dimethylcysteinyl-L-proline methyl ester:
SH
X. V-acetyl-D,L-j3,p-dimethylcysteinyl-L-aspartic acid dimethyl ester:
SH
XI. AT-acetyl-D,L-p,13-dimethylcysteinyl-L-glutamic acid dimethyl ester:
SH
The dipeptides were characterised by a variety of criteria, including elemental analysis, IR, 
iH-, DEPT 90“ and DEPT 135“-NMR spectroscopy. Accurate mass determinations of 
the molecular ion peaks were obtained only by the use of high resolution FAB-MS but not 
by other techniques. Data are displayed in the Experimental Section (next chapter).
2. 1.2.  Synthesis of S-N itrosothiols from the Corresponding  
Dipeptides
S-Nitrosothiols are now recognised as an important class of nitric oxide (NO) donor drugs 
as they decompose to give NO and the corresponding disulphide only:
RSNO 1/2R SSR  + NO
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If the RS- moiety is a thiol-containing amino acid, S-nitrosothioIs should have therapeutic 
potential as the disulphide produced on NO release should have no harmful side effects.
The major requirements for a good NO generator are the following: first, the compound has 
to be easy to prepare in a stable and pure form, preferably as a solid; second, it has to 
release NO in aqueous solution, preferably without the need for redox activation; third, it 
has to generate NO quantitatively at a predictable rate; and fourth, the by-products should 
be nontoxic. Such compounds are rare.
5-Nitrosothiols are prepared by nitrosation of thiols and no purification procedure is 
possible because of the ease of decomposition. S-Nitrosothiols have been previously 
prepared by several methods, including reaction of thiols with nitrous acid under acidic 
conditions, and with dinitrogen tetroxide in carbon tetrachloride or ether (Williams, 1988). 
The nitrous acid method has limited applicability, and the use of dinitrogen tetroxide is 
complicated by the requirement for controlled stoichiometry and low reaction temperatures 
(Williams, 1988). Use of f-butyl nitrite was expected to be advantageous for the synthesis 
of a broad range of 5-nitrosothiols without the restrictions normally encountered with the 
use of dinitrogen tetroxide (Doyle et al., 1983). f-Butyl nitrite has the requisite chemical 
and physical properties of a useful synthetic reagent. It has a relatively low boiling point, 
and the corresponding alcohol can be easily removed from higher boiling or water- 
insoluble products (Doyle et at., 1983). Doyle et al. report that .S-nitrosothiois were 
conveniently formed by rapid nitrosyl exchange reactions with f-butyl nitrite (Doyle et al., 
1983). In our work, f-butyl nitrite was used to form 5-nitrosothiols from the 
corresponding dipeptides according to the following Scheme (Scheme 2. 3):
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1. f-butyl nitrite
2. CH2CI23. -78 “C
SNO
o  R
Scheme 2. 3; The nitrosation reaction of the dipeptides to the corresponding ^-nitrosated dipeptides.
The dipeptides were converted into the corresponding 5-nitrosothiols (2-12) in high yields 
(more than 80%) by this procedure described in detail in the Experimental Section to give 
solids or sticky solid (Butler et a l, 1996). Compound 1, 2, 4, 7, 10, 11, and 13 were 
obtained in a pure state but the others (3, 5, 6, 8, 9, and 12) were contaminated by 
small amounts of the unreacted thiol and/or by small amounts of the disulphide formed 
during nitrosation (see element analysis; Experimental Section).
For comparison purposes we also prepared 5-nitrosated /V-acetyl-D,L-(3,(l-dimethylcysteine 
(SNAP) and glutathione (GSNO).
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(a) S-Nitrosated Amino-acid
5-Nitroso-N-acetyl-D,L-p,p-dimethylcysteine (SNAP; 1) was synthesised, characterised 
and its X-ray crystal structure obtained by Field et a l in 1978. In the crystalline state, it is 
the most stable 5-nitrosothiol known to date, although in solution it decomposes to release 
NO and form its disulphide. It has been shown to be a potent relaxation agent for vascular 
smooth muscle and consequently a fast acting vasodilator (Ignarro et a l, 1981a&b). Along 
with other 5-nitrosothiols, it possesses anticoagulant properties, as it inhibits the 
aggregation of blood platelets and their adhesion to the sub-endothelium (Radomski et a l, 
1992). In this work SNAP was synthesised as described by Doyle et a l  in 1983:
SNO
OH
(SNAP; 1)
(b) 5-Nitrosated Dipeptides
The following 5-nitrosated dipeptides were prepared by reaction of the thiol with r-butyl 
nitrite:
I, 5-nitroso-A-acetyl-D,L-p,p-dimethylcysteinylglycine methyl ester (2):
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II. S-nitroso-iV-acetyl-D,L-p,p-dimethylcysteinyl-L-alanine methyl ester (3):
III. 5~nitroso-A^-acetyl-D,L-p,p-dimethylcysteinyl-L-valine methyl ester (4):
IV. 5-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-leucine methyl ester (5):
SNO 
O  I  O
/
X
(5)
V. 5'-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-phenylalanine methyl ester (6):
SNO 
OA
O
(6)
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VI. 5^-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L“isoleucine methyl ester (7):
Vn. 5'-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-methionine methyl ester (8):
SNO
O/
/
(8 )
VIII. i'-nitroso-V-acetyl-DjL-Pjp-dimethylcysteinyl-L-Ve-CBZ-L-lysine methyl ester (9):
SNO
o
o
o NH
O
(9)
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IX. 5-nitroso-A^-acetyl“D,L-3,p-dimethylcysteinyl-L-proline methyl ester (10):
SNO
(10)
X. 5-nitroso-A^-acetyl-D,L-p,p-dimethylcysteinyl-L-aspartic acid dimethyl ester (11);
SNO
XI. 5'-nitroso-A/ -^acetyl-D,L-(I,p“dimethylcysteinyl-L-glutamic acid dimethyl ester (12):
SNO
(12 )
(c) s-Nitrosated Tripeptide
5-Nitroso-L-glutathione (GSNO; 13) was first synthesised and characterised in 1985 by 
Hart using a modification of a method designed by Saville (1958). GSNO is a derivative of 
the tripeptide L-glutathione (L-y-glutamyl-L-cysteinylglycine), which is found in numerous 
cellular systems and is considered an essential constituent of all living cells. L-Glutathione 
is generally the most abundant intracellular non-protein thiol (Meister and Anderson, 
1983), with a concentration approaching 2-3 mM in erythrocytes. Consequently, the 
discovery of EDRF and the suggestion that it is an S-nitrosothiol, together with evidence 
that the physiological half-life of NO can be stabilised by thiols (Ignarro et a l, 1980a,b&c; 
Stamler et al., 1992a,b,c,d&e; Feelisch et at., 1994), raises the possibility that S~ 
nitrosoglutathione could be the most important ^-nitrosothiol synthesised in vivo and 
involved in physiological processes.
Since 1985, GSNO has been synthesised by other researchers using different methods 
(Park and Means, 1989; Clancy and Abramson, 1992).
GSNO has been shown to be a hypotensive drug as effective as sodium nitroprusside 
(Means and Park, US patent 1990) and a potent inhibitor of platelet aggregation (Radomski 
et a l, 1992). Along with SNAP, it is one of the few stable 5-nitrosothiols in the crystalline 
state, and GSNO kept at 4 °C or below is stable over a number of months (Park and 
Means, 1989; Butler et a l, 1996). In this work GSNO was prepared as described in the 
literature by Hart in 1985.
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SNO
NHg
(GSNO; 13)
5-Nitrosothiols 1, 2, 4, 7,11, and 13 were obtained as stable green solids in the pure 
form. 5-Nitrosothiols 3, 5, 6, and 12 were also green solids and were obtained together 
with a small amount of the starting material (the corresponding thiols) and/or the 
corresponding disulphide. ^-Nitrosothiol 10 was obtained as a green sticky solid in the 
pure form. ^-Nitrosothiols 8 and 9 were obtained as green sticky solids, and were 
contaminated with a small amount of the starting material (the coixesponding thiols) and/or 
the corresponding disulphide.
Dipeptides and their derivatives are sometimes difficult to characterise by elemental analysis 
as small amounts of the disulphide or thiol are present and we were unable to remove these 
impurities. In most instances FAB-MS was used to obtain a molecular ion peak and this 
gave the required characterisation, which was confirmed by a close examination of the I^C- 
NMR spectrum to ensure that it contained no additional, unassigned peaks.
In order to see how 5-nitrosothiols might bind to metal ions, which is the main factor 
affecting their stability and perhaps their biological activity, a representation of the three- 
dimensional structure was produced using the computer programme Chem 3D and is 
shown in Figure 2. 1.
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mS-nitrosated amino acid (SNAP; 1) S-nitrosated dipeptides ( 2-12)
S-nitrosated tripeptide (GSNO; 13)
Figure 2.1: The three-dimensional nature of SNAP (1), 5-nitrosated dipeptides (2-12), and GSNO (13).
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2. 1. 3. Characterisation of S-N itrosothiols
The presence of the -SNO group in a molecule can be readily determined from both infrared 
and UV-visible spectroscopy.
The broad and strong IR band at 1480-1530 cm“l has been assigned to the stretching 
vibration of the N=0 bond of the 5-nitrosothiol. N=0 vibrations of tertiary 5-nitrosothiols 
have been found at frequencies lower than those of primary ^-nitrosothiols. A second 
absorption band at 600-730 cm"^ is characteristic of the vibration of the C-S bond (see 
Figure 2. 2).
%T »-
a-
it-
INO INm UN NO
cm
Figure 2. 2: Infrared Fourier Transform spectrum of compound 2.
The UV-visible spectra of the 5-nitrosothiols display two bands at aiound 330-340 nm and 
550-600 nm, which are responsible for their red or green colour in solution. These bands 
are shifted to lower energies by substitution at the a  carbon atom. Tertiary 5-nitrosothiols 
are usually green compounds, whereas primary and secondary 5'-nitrosothiols aie red (see 
Figure 2. 3).
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Figure 2. 3: UV-visible spectrum of compound 2 (5 x 10“^  mol dm~3).
From the literature sources, only few a ^-nitrosothiols have been previously characterised 
by or l^c-NMR spectroscopy. Both methods allowed a very convenient and reliable 
proof for nitrosation of thiol compounds. While thiols and disulphides had very similar 
NMR spectra, the a  protons in the ^'-nitrosothiols were strongly shifted downfield (about 
Ippm) (Roy et a l, 1994). The P protons were also affected by the ^-nitrosation, to an 
extent that was dependent on the substitution at the a  carbon. Almost no shift was 
observed for the primary 5-nitrosothiols, about 0.1 ppm for the secondary 5-nitrosothiols 
and about 0.5-0.8 ppm for the tertiary 5-nitrosothiols (Roy et al, 1994).
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The l^C-NMR spectra were also changed by nitrosation of thiols. Resonances of a  carbon 
atoms were shifted downfield, with stronger shifts observed for tertiary ^-nitrosothiols and 
resonances of p-carbon atoms were shifted upfield. The l^C-NMR chemical shifts for 5- 
nitrosothiols were in general found to be intermediate between those of the corresponding 
thiols and those of the disulphide (Roy et at., 1994).
As the A-acetyl-D,L“p,p-dimethylcysteine used was a racemic mixture the products were 
formed as a mixture of two diastereomers: e.g. V-acetyl-D-p,p-dimethylcysteinyl-L-amino 
acid methyl ester, and V*-acetyl-L-p,(3-dimethylcysteinyl-L-amino acid methyl ester. Due to 
this the compounds have complicated ^H-NMR spectra in most cases, but we were able to 
identify the -SH, CH3 CONH, and the proton of the peptide bond (-CONH-) which 
indicate that we have the correct dipeptide. After the nitrosation of the dipeptides, there are 
still two diastereomers: 5-nitroso-V-acetyl-D-p,p-dimethylcysteinyl-L-amino acid methyl 
ester, and •S-nitroso-A-acetyl-L-p,p-dimethylcysteinyl-L-amino acid methyl ester, and it was 
possible to identify the CH3 CONH- and -CONH- signals and the disappearance of -SH 
which indicates that nitrosation has occurred. Some decomposition occurred while the 
spectra were being run.
In l^C-NMR for both the thiols and the S-nitrosothiols there are two lines for each carbon 
due to the presence of the two diastereomers and usually DEPT 90“ and DEPT 135" 
enabled ÇH3 -, -CH2 -, and -CH- to be distinguished.
In the case of compound 2 the two isomers formed are enantiomers rather than 
diastereomers. Accordingly only one set of lines is seen in the l^C-NMR and the proton 
spectrum is also simpler.
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Figure 2. 4: ^H-NMR spectrum of compound 2.
Figure 2. 5: l^C-NMR spectrum of compound 2.
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Figure 2.6: DEPT 90°-NMR spectrum of compound 2.
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Figure 2. 7: DEPT 135°-NMR spectrum of compound 2.
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Figure 2. 8: FAB-MS spectrum of compound 2.
Compound 2 is pure but the others are contaminated by small amounts of the 
corresponding thiol and/or disulphide. This may be due to steric hindrance by the R group 
in the other compounds interfering with the nitrosation reaction.
Microanalysis of the green solid or green sticky solid obtained from some 5-nitrosothiols 
showed that some disulphide had formed in its isolation as indicated by the high caihon and 
low nitrogen values (see elemental analyses; Experimental).
Samples of ^ -nitrosothiols were characterised by a vaiiety of criteria, including elemental 
analysis, IR (e.g. Figure 2. 2), UV-visible (e.g. Figure 2. 3), ^H-(e.g. Figure 2. 4), l^C- 
(e.g. Figure 2. 5), DEPT 90° (e.g. Figure 2. 6), and DEPT 135°-NMR spectroscopy (e.g. 
Figure 2.1). Accurate mass determinations of the molecular ion peaks were obtained only 
by the use of high resolution FAB-MS but not by other techniques (e.g. Figure 2. 8). Data 
are displayed in the Experimental Section (next chapter).
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A chemical and physiological comparison of the action of (a) 5-nitrosated amino acid 
(SNAP; 1) (b) 5-nitrosated dipeptides (2-12) and (c) S'-nitrosated tripeptide (GSNO; 13) 
is the subject of a large proportion of this thesis. Data have been compiled which give an 
insight into why these three types of 5-nitrosothiols (1-13) act differently and how S~ 
nitrosothiols might be developed in the future to improve their pharmacokinetic profiles.
2. 2. Mechanistic Study of the Decomposition of S-N itrosothiols
5-Nitrosothiols are endothelium-independent vasodilators which are susceptible to 
decomposition by a number of mechanisms. The rates of decomposition of y-nitrosothiols 
in vitro have been shown to be influenced by;
1. Metal ions,
II. Transnitrosation (NO transfer from ^-nitrosothiols to other thiols),
III. Enzymatic decomposition of ^ -nitrosothiols,
IV. Photochemical decomposition, and
V. Thermal decomposition.
The extent to which each of these different mechanisms causes decomposition of S- 
nitrosothiols in vivo is difficult to ascertain quantitatively. In this thesis we are concerned, 
almost exclusively, with the effect of metal ions, and mention only briefly the other four 
mechanisms.
2. 2. 1. M etal Ions Catalysed Release of NO from S - 
N itrosothiols
5-Nitrosothiols are decomposed by metal ions to the corresponding disulphide and nitric 
oxide. A survey of commonly occurring-metals showed that copper is the most effective 
catalyst. It enhanced the rate of decomposition even at concentrations as low as 10"  ^mol 
dm"3.
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2. 2. 1. 1. The Role of Copper Ions in the in vitro and in vivo
Release of NO from S-Nitrosothiols
The work (Section 2. 2. 1, 1) was carried out in close collaboration with a group at the 
University of Durham (Prof. D. L. H. Williams, A. P. Dicks and H. R. Swift). Some of 
the results reported are from the Durham group as they are key observations in the 
elucidation of this rather complex mechanism. The computer simulations were carried out 
by Dr B. G. Cox of Zeneca Fine Chemicals Manufacturing Organisation in Huddersfield, 
to whom we extend grateful thanks.
Decomposition of 5-nitrosothiols in aqueous solution at pH 7.4 is brought about by copper 
ions, either present as an impurity or specifically added. The primary products are nitric 
oxide and the disulphide.
2. 2. 1. 1. 1. The First Report of the Role of Copper Ions in the 
Release of NO from 5-N itrosothiols
At first quantitative rate measurements of RSNO decomposition reactions in aqueous 
solution yielded erratic results, with reported half-lives of reaction varying considerably 
using the same substrate, usually SNAP. Further, the rate-form reported varied widely, 
zero-, first-, second- and various intermediate orders having been reported at some stage. 
This picture was resolved when it was realised that reaction occurred by a Cu^+-catalysed 
reaction pathway (Figures 2. 9, 2. 10, and 2. 11), and that for some reactants there can be 
enough Cu^+ in the distilled water/buffer components used, to bring about reaction. The 
[Cu^+] varied from source to source and often daily within the same source which goes 
some way to explaining the erratic nature of the reported results.
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Figure 2. 9: Absorbance time plots for the decomposition of SNAP (1) (5 x 10"^ mol 
dm-3) (a) [Cu2+] 2.7 x 10'6 (square) (b) [Cu2+] 5.4 x 10-6 (diamond) (c) [Cu2+] 8.1 x 
IQ-6 (circle) (d) [Cu2+] 10.8 x 10-6 (triangle) (e) [Cu2+] 13.5 x 10-6 mol dm-3 (segment 
square) at pH = 7.4, 340 nm and 30 “C.
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Figure 2. 10: Absorbance time plots for the decomposition of SNAP (1) (5 x 10“4 mol 
dm-3) (a) no added Cu^+ (b) [Cu2+] 1 x 10"5 (c) [Cu2+] 2 x 10"5 (d) [Cu2+] 3 x 10“5 mol 
dm-3 at pH = 7.4, 340 nm and 30 "C.
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Figure 2.11: Plots of 1 + log (At - Aoo / Aq - Aoo) versus time for the decomposition of 
SNAP (1) (a) when [Cu2+] = [ EDTA ] (b) when 1/2 [Cu2+] = [EDTA] (c) when 1/3 
[Cu2+] = [ EDTA ] at pH = 7.4, 340 nm and 30 “C (r = 1.0, 0.996, and 0.995 respectively).
When Cu^+ is removed by complexation with EDTA, virtually no reaction takes place 
(Scheme 2. 4). There was no catalysis for a range of other metal ions investigated, 
including Zn^+, Ca^+, Mg2+, Ni2+, Co2+, Mn2+, Cr3+, and Fe3+.
In the earlier work Askew et a l reported (1995a&b) that for many RSNO compounds over 
a given [Cu2+] range (which vaiied with the substrate), the following equation:
Rate = k[RSNO][Cu2+]
applied, often with a small autocatalytic component, which was ignored. The copper is 
fully regenerated and so is truly catalytic.
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Structure 2. 1: The proposed six-membered ring intermediate formed when copper binds to an amine group of the ^-nitrosothiols.
N =  0
Structure 2. 2: The proposed six-membered ring intermediate formed when copper binds to a carboxylate group of the 5'-nitrosothiols.
These two binding sites are shown as the nitroso-nitrogen atom in each case and either an 
amine or carboxylate group. In the absence of either of these features reaction was very 
slow indeed.
Although a qualitative structure-reactivity pattern was established it was clear that a full 
mechanistic picture of this reaction had not been described, since outside a given [Cu^+J 
(which differed for different substrates) other kinetic patterns emerged. In particular, at low 
[Cu2+] there was an increasing tendency for autocatalysis to be observed and at high 
[Cu^+] there was a move towards a zero-order dependence upon [RSNO] and also upon 
[Cu2+].
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These rate forms together with a whole range of intermediate situations cleaiiy led to quite 
a complex set of data. A further unusual feature occurred in the reaction of A-acetyl-^"- 
nitrosocysteine in that there was a very long induction period (many hours) before reaction 
set in, with approximately a first-order dépendance. This thesis describes in more detail the 
more unusual kinetics and proposes a mechanism which is consistent with all of the 
experimental results.
2. 2. 1. 1. 2. Experimental Observations Which Indicate that the 
True Catalyst is not Cu^+
The complex kinetic behaviour of 5-nitrosothiols during decomposition has four 
characteristics: (a) there is no reaction in the absence of copper, (b) in the presence of 
moderate amounts of copper the reaction may be zero or first order, dependent upon the 
nature of RSNO, (c) at low copper concentrations the reaction appear to be autocatalytic, 
and (d) at high copper concentrations the rate becomes independent of the copper 
concentration. How can these effects be explained?
Ealier work in our laboratories (Askew et al, 1995a&b) concentrated upon kinetic analysis 
of rate forms, which gave first order dependencies upon both RSNO and Cu^+, in order to 
establish structure-reactivity factors. We now report the results of a more systematic kinetic 
study in which other rate forms appeared. In all cases we followed the decrease in 
absorbance at ca. 340 nm due to the RSNO reactant, usually at an initial concentration of 
around 5x10"^ mol dm“3. We have been able to observe four limiting absorbance-time 
patterns: (a) first order reaction with an induction period, (b) first order reaction with no 
induction period, (c) zero order reaction with induction period, (d) zero order reaction with 
no induction period.
In addition we observed many forms which could be regarded as intermediate between any 
two of the four limiting forms. Example of each aie given in Figures 2. 12, 2. 13, 2. 14, 2. 
15, and 2. 16.
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Figure 2. 12: Absorbance-time plot for the reaction of 5 '-n itroso-2-A ,A - 
dimethylaminoethanethiol (5 x 10"  ^mol dm“^ ) in the presence of added Cu^ "  ^(1 x 10"  ^mol
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Figure 2.13: Absorbance-time plots for the reaction of SNAP (1 x 10“^  mol dm-3) the 
presence of Cu^+(1 x 10"  ^mol dm"3) and varying concentrations of added A-acetyl-D,L- 
penicillamine (NAP) (a) 4 x 10"6 mol dm"3 NAP (b) 6 x lQ-6 mol dm"3 NAP (c) 8 x 10"6 
mol dm"3 NAP (d) 1 x 10"  ^mol dm“3 NAP.
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Figure 2. 14: Absorbance-time plots for the reaction of 6^-nitroso-2-A,A- 
dimethylaminoethanethiol (1 x lO"  ^mol dm"^) in the presence of added Cu^+ (a) 5 x 10"  ^
mol dm-3 Cu2+ (b) 7.5 x 10“^  mol dm“3 (c) 1 x 10"  ^mol dm"3 (d) 3 x 10"  ^
mol dm“3 Cu^+ (e) 6 x 10'^ mol dm“3 Cu^+.
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Figure 2. 15: Absorbance-time plots for the reaction of 2 (1 x 10"3 mol dm"3) in the 
presence of added Cu^+ (a) 2.7 x 10"6 mol dm“3 Cu^+, (b) 5.4 x 10“6 mol dm“3 Cu2+, (c) 
8.1 X 10-6 mol dm-3 Cu2+, (d) 1.1 x lQ-5 mol dm"3 Cu2+, and (e) 1.4 x lQ-5 mol dm"3 
Cu2+.
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Figure 2. 16: Absorbance-time plots for the reaction of 5 -n itroso-2-A ,A - 
dimethylaminoethanethiol (2 x 10"  ^mol dm“3) m the presence of added (1 x 10"  ^mol 
dm“3) as a function of added 2-A,A-dimethylaminoethanethiol (a) no added thiol (b) added 
thiol (1 X 10"  ^mol dm-3) (c) added thiol (3 xl 0"  ^mol dm-3).
Figure 2. 12 is an absorbance/time plot for the reaction of 5-nitroso-2-A ,A - 
dimethylaminoethanethiol (SNDMA), at low [Cu^+] with no added thiol, Figure 2. 13 
shows the reaction of SNAP at lxlO"5 mol dm"3 Cu^+ in the presence of various [NAP], 
Figure 2. 14 shows the reaction of 5'-nitroso-2-iV,A-dimethylaminoethanethiol with 
various concentrations of added Cu "^ ,^ Figure 2. 15 shows a similar pattern for the reaction 
of 5-nitroso-A-acetyl-D,L-P,P-dimethylcysteinylglycine methyl ester (2) with different 
[Cu^+], and Figure 2. 16 shows the results for SNDMA at low [Cu^+] varying the 
concentrations of added thiol.
^ S N O  
^ N M e g  
S-nitroso-2-A/,A/-dimethylaminoethanethio! (SNDMA)
The induction period is quite clear in Figures 2. 12, 2. 14, and 2. 15 and is completely 
absent in Figures 2. 13, and 2. 16 at high [RSH]. Equally clear is the first order pattern in 
Figure 2. 12, and 2. 13 and zero order dependence in 2. 14, 2. 15, and 2. 16.
76
2. 2. 1. 1. 3. Explanation of the Experimental Data if Cu+, 
rather than Cu2+, is the True Catalyst
The question then arises: if Cu+ rather than Cu^+ effects catalysis of S-nitrosothiol 
decomposition, why does addition of a Cu^+ salt result in decomposition? S-Nitrosothiols 
are prepared by nitrosation of thiols and no purification procedure is possible because of 
the ease of decomposition. Contamination of the S-nitrosothiol sample by thiol is not only 
possible but probable and this leads immediately to the reduction of the Cu^+ ions present 
in the buffer. The concentration of copper ions required for catalysis is so low that only ca. 
1% contamination of S-nitrosothiol by thiol would be needed for complete conversion to 
Cu+.
However, there is one, initially puzzling, observation which provides further confirmation 
of the formulation and catalytic role of Cu+ ions. The catalytic effect of added copper 
nitrate on the decomposition of 5’-nitrosO“A-acetyl-p,p-dimethylcysteinylglycine methyl 
ester (2) is shown in Figure 2. 15. Although at low concentrations of added copper ions 
the catalytic effect is concentration dependent, at high copper levels the rate becomes 
independent of the amount of copper salt added. The concentration of the catalytic Cu'*' ions 
can never be greater than the concentration of thiol present as an impurity in the S- 
nitrosothiol. When the concentration of added copper ions exceeds the concentration of 
contaminating thiol no further Cu+ ions are formed and no increased catalytic effect is 
produced.
2. 2. 1, 1. 3, 1. Reduction of Cu^+ to Cu+ by Thiol
For this study we use SNAP with the addition of the corresponding thiol, A-acetyl-D,L- 
penicillamine (NAP). Use of a different thiol would complicate the situation by rapid NO 
group transfer from RSNO to R'SH leading to RSNO formation (Barnett et al., 
1995a&b). With [SNAP] 1 x 10"3 mol dm"3, added [Cu^+] 1 x 10"  ^mol dm“3 and [NAP] 
in the range 1 x 10" -^1 x 10"3 mol dm“3, reactions aie kinetically first order. The results aie 
shown more dramatically in Figures 2. 17, 2. 18, and 2. 19.
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As expected at low added NAP there is a very sharp, linear increase in the rate constant 
until [NAP] ~ 1 X 10"  ^ mol dm"^. The reduction of Cu^+ by thiolate is a well-known 
process (Davis et a l, 1983; Scrivens et a l, 1995; Reid, 1958) and has been studied 
mechanistically as the Cu^+ catalysed oxidation of thiols to give disulphide:
2Cu2+ 2RSH 2Cu+ 2H' + RSSR
2 0 -
o
-O
2 5 0 5 0 0
106 [ N A P ]  /  m o l  d m - 3
1 0 0 07 5 0
Figure 2.17: First order rate constants {k) for the reaction of SNAP (1 x 10"^  mol dm"3) as a function of added 7V-acetyl-D,L-penicillamine (NAP).
At higher [NAP] there is initially a sharp drop in k followed by a gradual decrease towards 
zero. We can explain this pattern in terms of the complexing of Cu^+ by NAP, thus 
effectively removing it from solution. These results explain the apparently contradictory 
reports in the literature (Feelisch et a l, 1994) some of which report catalysis of RSNO 
decomposition by added thiols, whilst other find a reduction in rate upon thiol addition. It 
is now clear at low added [RSH] there will be catalysis, as this favours the reduction of 
Cu^+ whereas complexation of Cu^+, probably by the carboxylate group, takes over at 
higher added [RSH] resulting in inhibition of nitric oxide formation. Such copper- 
carboxylates are well-known (Stmcture 2. 3) and some have been isolated and examined 
structurally (Doedens, 1976).
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Structure 2. 3: The general binuclear structure of copper binding to carboxylate groups.
We have previously noted (Askew et ai, 1995a&b) a reduction in reactivity with increasing 
buffer concentration when the buffer contains a carboxylic acid, an effect we attributed to 
competitive complexation with the carboxylic acid.
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Figure 2. 18: Absorbance-time plots for the decomposition of SNAP (1) (5 x lO'^ mol 
dm-3) (a) [NAP] 2.5 x 10-4 and [Cu^+J 2.7 x lQ-6 (b) no added NAP and [Cu2+] 2.7 x 
10-6 (c) no added NAP and [Cu^+] 8.1 x 10-6 (d) [NAP] 2.5 x 10‘4 and [Cu2+] 8.1 x 10“6 
mol dm-3 at pH = 7.4, 340 nm and 30 “C.
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Figure 2,19: Absorbance-time plots for the decomposition of SNAP (1) (5 x 10"^ mol 
dm-3) (a) no added NAP and [Cu2+] 8.1 x 10-6 (b) [NAP] 2.5 x 10-4 and [Cu2+] 8.1 x 
10-6 (c) no added NAP and [Cu2+] 13.5 x 10"6 (d) [NAP] 2.5 x 10“4 and [Cu2+] 13.5 x 
10-6 niol dm-3 at pH = 7.4, 340 nm and 30 °C.
2. 2. 1. 1. 3. 2. Direct Proof that the True Catalyst of the 
Decomposition of S-Nitrosothiols is Cu+ by use of Neocuproine
The unusual kinetic forms found for a number of RSNO species under different conditions 
of [Cu2+], particularly the tendency in some cases towards zero-order behaviour, led us to 
consider the possibility that the effective reagent in these reactions is in fact Cu+ and not 
Cu2+. Zero-order dependence upon [RSNO] might then be interpreted in terms of a rate-
limiting Cu2+------------- > Cu+ reduction. Earlier Askew et al. considered this possibility
and rejected it on the basis that there was no evidance for it from preliminary esr 
experiments with SNAP. In an alternative approach, we have now made use of the specific 
Cu+-chelating agent neocuproine (Smith and McCurdy, 1952; Yoshida et a l, 1994; James 
and Williams, 1961) shown in the complexed form in Scheme 2. 5. In aqueous solution the 
stability constant of Cu+-neocuproine complex is ~ IxlO^^ mol~2dm6. When a Cu 24- 
solution (2x10-6 mol dm-3) was added to one of neocuproine hydrochloride (4x1 Q-6 mol 
dm-3) there was no detectable change in the uv/visible spectrum.
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Cu
Scheme 2. 5; The general binuclear stmcture of Cu+ binding to neocuproine.
However, upon addition of sodium dithionite (a well-known reducing agent for
Cu2+-------------- > Cu+) an immediate yellow colour was noted and an absorbance
maximum at 453 nm was found, as reported in the literature (Smith and McCurdy, 1952; 
James and Williams, 1961) for the spectrum of Cu+-neocuproine complex. We then 
examined the decomposition of SNAP (1 x 10"  ^mol dm"^) at pH 7.4 containing added 
Cu^+ (2 X 10"  ^mol dm"3) in the presence of increasing concentrations of neocuproine in 
the range 4 x 10~5 - IxlO"^ mol dm“3. The resulting absorbance-time plots taken at 340 nm 
(the absorbance maximum for SNAP and 2) are shown in Figures 2. 20, and 2. 21.
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Figure 2. 20: Reaction of SNAP (1 x 10“^  mol dm“3) in the presence of Cu^+ (2 x lO"  ^
mol dm"3) and varying concentrations of neocuproine (a) no added neocuproine (b) 4 x 1 0 “ 
5 mol dm“^  neocuproine (c) 5 x 10"  ^ mol dm“^  neocuproine (d) 6 x 10"  ^ mol dm"^ 
neocuproine (e) 8 x 10“^  mol dm"^ neocuproine (f) 1 x 10“^  mol dm“^  neocuproine (g) 2 x 
10“4 mol dm“^  neocuproine (h) 1 x 10"  ^mol dm"^ neocuproine.
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Figure 2. 21: Absorbance time plots for the decomposition of 2 (5 x lO"'^  mol dm“^ ) (a) 
neocuproine 5 x 10"  ^mol dm"3 (square) (b) no added neocuproine at pH = 7.4, 340 nm and 30 °C (diamond).
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It is immediately clear that the presence of neocuproine reduces the reaction rate 
progressively and at 1 x 10“^  mol dm"^ neocuproine the reaction is completely suppressed. 
The full spectra showed the increasing absorbance at 453 nm as expected for the formation 
of Cu+-neocuproine complex. Similar experiments over a slightly smaller range of [added 
neocuproine] yielded reasonably good first-order plots and the data are given in Figure 2. 
22 showing clearly the inhibiting effect of neocuproine.
2 -
10^ [Neocuproine] / mol dm’^
Figure 2. 22: First order rate constants (Jc) for the reaction of SNAP (1 x 10“^  mol dm"^) 
in the presence of Cu^+ (2 x 10"  ^mol dm“^ ) as a function of [neocuproine].
Clearly Cu+ is being generated and the question arises as to the nature of the reducing 
agent. Previously we have suggested that the reduction could be achieved by thiolate ion 
present from a small quantity of thiol impurity in the 5-nitrosothiol sample. However in 
some experiments we were able to avoid any thiol impurity by carrying out reactions on 
solution samples of RSNO generated from thiols and nitrous acid with the nitrous acid 
present in a slight excess, and reaction still occurs. An alternative suggestion is that thiolate 
is generated by hydrolysis of the ^-nitrosothiols:
RSNO + HoO RS' NOc 2H+
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This is not expected to be a rapid process given earlier studies of the hydrolysis in acid 
solution (Al-Kaabi et al, 1982), but even a few percent reaction could be enough to initiate 
the reduction. When the corresponding thiol is added to the reaction mixtures a rapid 
increase in the rate constant is found.
2. 2. 1. 1. 4. Proposed Mechanism of the Copper Ion Catalysed 
Decomposition of S-N itrosothiols
On the basis of these and earlier results we propose the following outline mechanism 
(Scheme 2. 6):
Cu^+ + RS- ^ ------------   X  Cu+ + RS
Cu+ + RSNO ..............— Y  ► + RS' + NO
2RS- -------------- ► RSSR
Scheme 2. 6: The proposed mechanism of copper ion catalysed decomposition of 5- nitrosothiols.
Cu^+ is reduced by RS" (generated from RSNO or added as RSH) via intermediate X to 
give Cu+ and RS . Intermediate X is probably RSCu+. Reaction then occurs between Cu+ 
and RSNO via intermediate Y releasing Cu^+, RS", and NO. This is essentially the 
mechanism we suggested earlier (McAninly et a i, 1993) as a possibility, but without at that 
time sufficient evidence to support it.
Qualitatively we can account for the induction period by the time required for the generation 
of RS" and Cu+. A first-order dependence occurs if the reaction of RSNO with Cu+ is 
rate-limiting and a zero order dependence occurs (for the more reactive RSNO species) 
when Cu+ formation is rate limiting. The length of the induction period can be reduced by 
the addition of either RSH or Cu2+ which will increase the rate of formation of Cu+.
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Alternatively, if only RSNO and Cu^+ are present initially, the step for the generation of 
Cu+ must be included in the simulation. This results in an absorbance-time profile given in 
Figure 2. 23, with an autocatalytic feature which reproduces that observed experimentally 
in Figure 2. 12.
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Figure 2. 23: Computed absorbance-time plot with no added RSH with rate-limiting 
RSNO reaction with Cu+.
6 0
Time (arbitrary units)
3 0 1 20
Figure 2. 24: Computed absorbance-time plot with added RSH with rate-limiting RSNO 
reaction with Cu+.
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Figure 2. 25: Computed absorbance-time plot with no added RSH with rate-limiting 
Cu+ formation.
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Figure 2. 26: Computed absorbance-time plot with added RSH with rate-limiting Cu"  ^formation.
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(2) Rate-limiting Cu+ formation
Under these circumstances Scheme 2. 6 effectively reduces to the following equations:
RS' + Cu^+ -------------- » 1/2 RSSR + Cu+
RSNO + Cu+ ------— ----- RS- + Cu^++ NO
Scheme 2. 8: The proposed mechanism of copper ion catalysed decomposition of S- 
nitrosothiols in the case of rate-limiting Cu+ formation.
If RSNO, Cu+, and RS" are all present initially then we get a truly zero-order reaction 
(simulation in Figure 2. 26) with RSNO scavenging Cu+ as it is formed and immediately 
regenerating RS" and Cu^+. However, if only RSNO and Cu^+ are present initially, then 
RS" has to be generated as before and this results in an induction period followed by a 
zero-order reaction (Figure 2. 25). Experimental examples of both types of behaviour have 
been observed as in Figure 2. 16 as [RS"] is increased, 2. 14 and 2. 15. Figures 2. 14 and 
2.15 clearly show a saturation effect in Cu^+ at high [Cu^+] which requires that in Cu+ 
formation there is an equilibrium involving intermediate X.
All of these experiments were conducted at pH 7.4 in normal aerated solvent. When 
oxygen was rigorously excluded then we found no significant difference in behaviour for 
any of the limiting rate forms. This implies that any oxidation reaction such as of Cu+ by 
dissolved oxygen is not a significant reaction under these conditions. However, for very 
slowly reacting RSNO compounds, such as A-acetyl-5^-nitrosocysteine (SNAC), we found 
a very long induction period, typically 3 hours, as shown in Figure 2. 27. This result was 
obtained using a rather impure solid sample of SNAC which was known to contain some 
of the thiol and was very difficult to purify. Repetition of this experiment with SNAC 
generated in situ in solution gave no reaction whatsoever over a 16 hour period (Figure 2. 
28), so it is likely that the thiol is playing a part here in Cu+ generation as expected.
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Figure 2. 27: Absorbance-time plot for the reaction of iV-acetyl-5-nitrosocysteine 
(SNAC; crude sample).
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Figure 2. 28: Absorbance-time plots for the reactions of GSNO and A-acetyl-5- nitrosocysteine (SNAC) showing the effect of the presence of oxygen (a) GSNO under aerobic conditions (b) SNAC under aerobic conditions (c) GSNO under anaerobic conditions (d) SNAC under anaerobic conditions.
However, when the same reaction was carried out in the absence of oxygen, reaction 
occurred immediately with no induction period. Exactly the same pattern was found with S-
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nitroso-L-glutathione (GSNO), although in both cases it is not clear why complete reaction 
does not occur. There is, however, a very dramatic effect due to the presence of oxygen 
here, which implies that oxidation of Cu+ by oxygen is a competing reaction with that of 
Cu+ with RSNO.
Cu+ + O2 ----------------► Cu^+ + O2
When the oxygen is removed, decomposition can occur. For both of these substrates 
reaction can be induced by the addition of the corresponding thiol. An induction period 
occurs which is reduced as the concentration of added thiol is increased until we get a good 
first order plot at very high [thiol] (~ 0.15 mol dm"^). In the presence of thiol, the effect of 
increasing the [Cu^+] is also to reduce the induction period and, as before, the removal of 
oxygen also removes the induction period completely. For these slower reacting substrates 
it does seem that re-oxidation of Cu+ by dissolved oxygen is an important pathway in their 
decomposition reactions.
2. 2. 1. 2. Copper Ions in vivo
Copper is present in blood plasma {ca. 1.0 x 10'^ mol dm"^), approximately 5% of which 
is bound to albumin protein and is known to be in rapid equilibrium with copper in tissues 
(Bearn and Kunkel, 1954). Later studies (Neumann and Sass-Kortsak, 1967; Sarkai' and 
Kruck, 1966) established the presence of an equilibrium between this fraction and copper 
bound to amino acids in blood plasma as shown by the set of equilibria:
+ Albumin : " ' ' —  [Cu^  ^ (Albumin)]
[Gu^ '*' (Albumin)] + AA [Cu^  ^(AA)] + Albumin
Cu^+ + AA u:;;:— — I -  [Cu^ + (AA)]
The amino acid complexes are thought to mediate the transport of copper through the 
biological membranes by virtue of their small molecular size.
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Although earlier studies (Sarkar and Kruck, 1966) established histidine as the major ligand 
for Cu in the amino acid fraction, the low concentration of the metal ion and the complex 
equilibria have defied detailed experimental study to date. Instead, computer simulation 
models have been developed (Hallman et aL, 1971; May et aL, 1977a&b) to delineate the 
spéciation in this low molecular weight plasma fraction and have been put to use to 
determine the influence of chelating drugs on the low molecular weight plasma fraction 
equilibria (May et al, 1977a&b).
It is noteworthy that cysteine is present in blood plasma (ca. 23 x 10~^  mol dm"^) (Brigham 
et a/., 1960) and cysteine is known to reduce rapidly Cu2+ according to the stoichiometry:
2Cu^ + + 2CysH 2Cu+ + 2H+ + CysSSCys
However, there is an even larger excess of other amino acids in the low molecular weight 
plasma fraction which, by chelation, could stabilise the Cu^+ state by lowering the 
Cu^+/Cu+ redox potential.
2. 2. 1, 3. Is in vitro Release of NO from S-Nitrosothiols due to 
Copper Ions?
We believe that we have shown that Cu+ is the effective reagent in bringing about 
decomposition of 5-nitrosothiols to yield nitric oxide. Both the experiments with 
neocuproine and all the kinetic evidence support the outline mechanism given in Scheme 2. 
6. Some details remain as yet unresolved, e.g. the detailed mechanism for the breakdown 
of intermediate Y, for which at present we have no experimental evidence.
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These findings could well have implications for the reactions of 5-nitrosothiols in vivo. It 
is known that they have specific biological activity, notably vasodilation (Ignarro et a l, 
1981a&b), the inhibition of platelet aggregation (Radomski et al., 1992), and the inhibition 
of neutrophil functions (Clancey and Abramson, 1992). In the body, copper is present not 
as free Cu^+, but in a bound form with amino acids and proteins. Possibly this is reducible 
to Cu+ by thiolate. Experiments to test this possibility are described in later following 
sections.
The reactivity pattern of GSNO is particularly interesting. In aerobic solution it is 
particularly stable, with only a negligibly small amount of decomposition occurring over 
many hours. However, in the presence of L-glutathione (GSH), decomposition occurs 
much more rapidly, but possibly with an induction period (Figure 2. 29), the length of 
which is dependent on [RSH] and [Cu%+].
(b)
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Figure 2. 29: Effect of added L-glutathione (GSH) on the copper-catalysed 
decomposition of GSNO (5 x 10’5 mol dm"3), [Cu^+j = (a) 1.4 x 10"  ^ and (b) 1.4 x 10“5 
mol dm“3, and [GSH] = 2.5 x 10"  ^mol dm"^.
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Although in the presence of L-cysteine (CysH), decomposition also occurs much more 
rapidly, but possibly with an induction period (Figure 2. 30) the length of which is 
dependent on [CysSH] and [Cu^+J.
g 0 . 4 -
JO
(b)0 . 2
1 2 0 0 08 0 0 04 0 0 0
Time / s
Figure 2. 30; Effect of added L-cysteine (CysH) on the copper-catalysed decomposition 
of GSNO (5 X 10"5 mol dm"3), (a) no added cysteine and (b) added cysteine (12.5 x lO"  ^
mol dm"3).
Further, in the absence of oxygen and without added GSH then reaction occurs quite 
readily without an induction period. Finally, the presence of another oxidising agent (e.g. 
hydrogen peroxide) has the effect of stabilising GSNO, again over a period of many hours. 
In our experiments no perceptible decomposition occurred overnight. Again, the re­
oxidation of Cu+ to Cu^+ does not allow Cu+ to have a catalytic role.
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2. 2. 2. Transnitrosation (NO Transfer from S-Nitrosothiols to 
other Thiols)
When the in vivo release of NO from 5-nitrosothiols is considered, the effect of metal ions 
is supplemented by possible NO transfer to one or more of the numerous sulphydryl 
containing molecules present. Clearly, the process of transnitrosation can also affect the 
nature and stability of S'-nitrosothiols. The sulphydryl groups present in vivo are contained 
in molecules which are either membrane bound, or free, either in the intracellular matrix 
(e.g. cysteine and glutathione) or in the plasma (albumin). These sulphydryl containing 
molecules, together with the tissue-type plasminogen activator and cathepsin B, are 
susceptible to nitrosation and NO transfer from 5'-nitrosothiols under physiological 
conditions (Stamler et al., 1992a,b,c,d&e). NO transfer to these proteins or amino acids, 
and the extent to which it happens, are likely to depend on a number of factors. These 
include the relative pKa's of sulphydryl moieties, the concentration at which they are 
present, and the steric hindrance likely to be caused by the movement of the NO group to 
the acceptor thiol. It has recently been suggested that bioactive NO equivalents in plasma 
are bound predominantly to thiol groups of proteins and that this reservoir has a role in 
modulating vasodilator tone (Stamler et at., 1992a,b,b,c&d).
If transnitrosation occurs from relatively stable S'-nitrosothiols, such as GSNO or SNAP, 
to a thiol such as cysteine, which is a relatively abundant thiol in vivo (Jocelyn, 1972), the 
formation of the unstable 5-nitrosothiols, such as S'-nitrosocysteine, could facilitate the 
release of NO and account in part for the biological action of GSNO.
Addition of cysteine appears to enhance copper catalysis in the decomposition of SNAP. 
Figures 2.31 and 2. 32 show the effect of added cysteine. It is clear that without cysteine
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Figure 2. 33 shows the effect on the decomposition rate of 2. It is clear that without 
cysteine the decomposition rate is very small, but in the presence of cysteine it is rapid. 
Similar results for compounds 3-13 were found.
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Figure 2, 33: Absorbance-time plots for the decomposition of 2 (5 x 10“'^  mol dm“^ ) (a) 
no added cysteine (b) cysteine 12.5 x 10'^ mol dm"3.
Although cysteine addition has a dramatic effect on the release of NO from 5-nitrosothiols, 
it appeal's that copper ions are still required. The results displayed in Figures 2. 34 and 2. 
35 show the effects on the decomposition rate of 2 of adding cysteine, and of adding 
cysteine and 2,9-dimethyl-1,10-phenanthroline (^ = 1.2 x 10"^ and 3.0 x 10"  ^ s"  ^
respectively). Even when 5-nitrosocysteine is formed, its decomposition rate is very slow 
in the absence of copper ions.
From these results we suggest a mechanism whose details are reproduced in Scheme 
2. 9
96
0 . 6 -,
0 .4
(b)
1 2 0 0 09 0 0 06 0 0 0  
Time / s
3 0 0 0
Figure 2. 34; Absorbance-time plots for the decomposition of 2 (5 x 10"'^  mol dm"^) (a) 
Cysteine 12.5 x 10“^  mol dm“^  and 2,9-dimethyl-1,10-phenanthroline 5 x 10"  ^mol dm"^ 
(b) Cysteine 12.5 x lO"  ^mol dm" .^
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Figure 2. 35: Plots of 1 + log (At - Aoo / Aq - Aoo) versus time for the decomposition of 
(a) 2, Cysteine 12.5 x 10"  ^mol dm“^ , and neocuproine 5 x 10“^  mol dm“^  (b) 2 and 
Cysteine 12.5 x 10"  ^mol dm"  ^(r = 0.999, 0.996 respectively).
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Scheme 2. 9: The proposed mechanism of transnitrosation.
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According to this mechanism (Scheme 2. 9), at pH = 7.4, the cysteine (Cys-H) will be 
converted into the corresponding thiolate (Cys“); (a) the thiolate (Cys“) will react with 
to give the corresponding thiyl radical (Cys*), which is converted directly into the 
corresponding disulphide (Cys-Cys), and Cu+; (b) the thiolate (Cys") will react with the S- 
nitrosothiols (RSNO) to give S-nitrosocysteine and the corresponding thiolate (RS“), then 
6"-nitrosocysteine, unstable in the presence of Cu'*', will decompose into cystine and nitric 
oxide.
If step 4 is the rate detemiining step, therefore: 
rate = k4 [RSNO] [Cys"]
Because [RSNO] «  [CysH], therefore, the reaction is pseudo-first order with respect to 
5-nitrosothiols.
rate = kobs [ RSNO]
kobs = ^4 [Cys"]
The rate constants for 5-nitrosothiol decomposition in the presence of added cysteine are 
listed (Table 2. 1). In the absence of cysteine decomposition is very slow for 2-13 but the 
rate of spontaneous decomposition for SNAP is quite high.
Our results indicate that the transnitrosation mechanism could be important in the 
endogenous decomposition of 5-nitrosothiols,
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2. 2. 3. Enzymatic Decomposition of S-Nitrosothiols
GSNO, a derivative of the endogenous peptide glutathione, has been detected in vivo at 
concentrations of approximately 0.25 |iM  in venous plasma and up to 1.2 |liM in arterial 
plasma (Stamler et al., 1992a,b,c,d&e; Meyer et al., 1994). Therefore it is more likely that 
this ^-nitrosothiol could be acted upon enzymatically to produce NO and vasodilation.
Previous work in our laboratories (Askew et al., 1995a&b) has shown that y-glutamyl 
transpeptidase (y-GT) could bring about decomposition of GSNO, by y-glutamyl cleavage 
as a first step. This would form an 5-nitrosothiol which is likely to have greatly reduced 
stability compared with GSNO and which could readily release NO.
We have also shown (Section 2. 2. 1) that in general 5-nitrosothiols do not breakdown to 
release NO except in the presence of Cu"**. Probably GSNO, a naturally occurring S- 
nitrosothiol, undergoes enzymatic metabolism to give 5-nitrosocysteinylglycine and this 
will be decomposed again by Cu"*" catalysis to give the corresponding disulphide and NO. 
In view of the previous results, a modified mechanism of action of y-glutamyl 
transpeptidase is shown in Scheme 2. 10.
Evidence that this mechanism is possible may imply that this enzyme, or a closely related 
enzyme, or a number of other members of this gene family (Morris et a l, 1993), could be 
responsible, in part, for the biological activity of GSNO.
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Y-glutamyltranspeptidase
SNO
glutamate + OH
Cu
OH + 2 NOHO" NH
Scheme 2.10: The modified mechanism of action of y-glutamyl transpeptidase.
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2, 2. 4. The Photochemical Decomposition of S-Nitrosothiols
5^-Nitxosothiols are decomposed photochemically to the corresponding disulphide and nitric 
oxide (Josephy etal., 1984):
hvRSNO 1/2 RSSR + NO
Barrett et al. (1966) reported that the absorption of 365 nm-radiation by 5-nitrosotoluene 
resulted in excitation to the extent of 79 kcal mol"l, which was sufficient to cause fission 
of the S-N bond. The reaction mechanism was formulated as follows (Scheme 2. 11);
RSNO  ► RSNO* RS + NO
RS + RSNO ■*- RSSR + NO
Scheme 2. 11; The proposed mechanism of photochemical decomposition of S- nitrosothiols (Mechanism A).
Josephy et at. (1984) and Mile et al. (1995) suggested another mechanism. The initial step 
in ^-nitrosothiol decomposition is believed to be homolytic cleavage of the S-N bond to 
give NO and an alkyl thiyl radical. In the final step the thiyl radical will react by 
combination with another thiyl radical to give the corresponding disulphide (Scheme 2. 12):
2 RSNO
2 RS
hv 2 RS + 2 NO
RSSR
Scheme 2. 12: The suggested mechanism of photochemical decomposition of S- nitrosothiols (Mechanism B).
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Several studies of spin trapping of thiyl radicals have been reported using 2-methyl-2- 
nitrosopropane (MNP; Wargon and Williams, 1975), (X-pheny 1-N-f-butyInitrone (PEN; 
Graceffa, 1983; Janzen et a l, 1978), and 5,5-dimethyl-3,4-dihydropyrrole-A-oxide 
(DMPO; Josephy et a l, 1984). The DMPO spin adducts gave at least one hundred times 
more intense signals than the MNP or PEN spin adducts, and in many cases the latter spin 
traps did not give detectable signals. Probably, DMPO is more reactive towards RS- than 
are MNP or PEN. DMPO adducts show considerable dependence of hyperfine splitting 
constants on the structure of the thiyl radical (Josephy et al, 1984).
The intermediates in the photochemical decomposition of tertiary 5-nitrosothiol 2 in 
acetonitrile solution were investigated by ESR spectroscopy. When 2 in acetonitrile 
solution was photolysed in the presence of excess DMPO (Scheme 2. 13) in the cavity of 
an ESR spectrometer the spectrum shown in Figure 2. 36a was obtained. The spectrum of 
the major radical was short-lived, and was recorded within a few minutes of initiation of 
the reaction at 298 K. Inspection of Figure 2. 36a indicates the presence of one major 
radical showing a triplet hyperfine splitting by one nitrogen and a doublet splitting by one 
hydrogen atom. In addition, a minor radical is also present which probably has similar 
basic interactions, but slightly different hyperfine splitting. The spectrum was simulated 
using a software package due originally to Heinzer (1972; Figure 2.36b) and the best fit 
hyperfine splitting as given in Table 2. 2. The ESR parameters of the major radical are 
consistent with the thiyl radical spin adduct. The identity of the minor radical is uncertain, 
but might be due to a diastereomer of the thiyl radical spin adduct.
From our results, we suggest that the initial step in 5-nitrosothiol photolytic decomposition 
might be homolytic cleavage of the S-N bond to give NO and an alkyl thiyl radical. In the 
final step the thiyl radical will react by combination with another thiyl radical to give the 
corresponding disulphide. More work should be carried out in this area in order to 
determine the actual mechanism.
104
SNO
0 _
DMPO
thiyl radical spin adduct
Scheme 2. 13: The alkyl thiyl radical produced by the homolytic decomposition of 2 was detected by ESR spin trapping using (DMPO).
Photochemical decomposition may be important due to the fact that, the endogenous S~ 
nitrosothiols decompoosed to the corresponding disulphide and NO by light. Therefore, 
using laser light may be another way of supplying NO to the cells in the human body 
instead of using exogenous drugs.
Recently the photochemistry of GSNO has been examined in more detail and the quantum 
yield and a first-order rate constant have been determined (Sexton et at., 1994). In this 
reaction it is likely that homolysis of the S-N bond is the primary process.
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TABLE 2. 2
Hyperfine interactions in DMPO spin adducts of thiyl radical
Radical T /K
Thiyl radical spin adduct  ^ 1.48
1.40Minor radical ^
Footnotes:
(a) in acetonitrile
(b) obtained by computer simulation of spectra, in mT.
1.76
1.56
298
298
n
Figure 2. 36: Experimental and simulated 9.3 GHz ESR spectra of spin adducts from 
DMPO and S-nitrosothiol 2 in acetonitrile: (a) experimental spectrum at 298 K (b) simulation of spectra using the parameters given in the table. ESR spectra were recorded on a BRUKER ER 200 D spectrometer.
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2. 2. 5. The Thermal Decomposition of S-Nitrosothiols
S-Nitrosothiols have also been shown to decompose thermally to give the corresponding 
disulphide and NO (Josephy et al, 1984):
RSNO A 1/2 RSSR + NO
This is similar to photochemical decomposition and probably occurs by homolytic cleavage 
of the S-N bond to give NO and an alkyl thiyl radical. Then the thiyl radical will react with 
another thiyl radical to give the corresponding disulphide (Scheme 2. 14):
2 RSNO 
2 RS
2 RS + 2 NO 
RSSR
Scheme 2. 14: The proposed mechanism of thermal decomposition of S-nitrosothiols (Mechanism A).
Another mechanism, may be by homolytic cleavage of the S-N bond to give NO and an 
alkyl thiyl radical, followed by reaction of the thiyl radical with another S-nitrosothiol 
molecule to give the corresponding disulphide and NO (Scheme 2. 15):
RSNO - A ^  RR- NO
RS + RSNO - w RQQR 1 NO
Scheme 2. 15: The suggested mechanism of thermal decomposition of S-nitrosothiols (Mechanism B).
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Most S-nitrosothiols are unstable at room temperature although some, such as tertiary S- 
nitrosothiols, are quite stable (e.g. SNAP; 1) (Field et ai, 1978).
Previous work in our laboratories has shown that SNAP (1), and also GSNO (13) 
decompose thermally to the corresponding disulphide and NO. More work should be 
carried out in this area in order to determine the actual mechanism.
2. 2. 6. Which Mechanism is Predominant in vivo?
Interest in S-nitrosothiols was heightened when it was discovered that they occur naturally, 
principally as the S-nitrosothiol of human serum albumin (7 |iM) (Stamler et a i, 
1992a,b,c,d&e), but fairly high levels of GSNO also occur in human blood plasma (2p,M) 
(Leone and Rhodes, 1996) and human bronchial lavage fluid (0.3 jxM) (Gaston et a l, 
1993). It has been generally assumed that naturally occurring S-nitrosothiols act as stores 
of NO which can be released when required (Stamler el al, 1992a,b,c,d&e). However, it 
has not been established how endogenous S-nitrosothiols are formed (reaction of NO with 
a thiol does not produce an S-nitrosothiol) nor how NO is released on demand. With 
GSNO enzymatic cleavage of one of the peptide bonds does result in much more rapid 
decomposition of the S-nitrosothiol moiety (Askew et a l, 1995a&b) but this does not 
address the problem of what causes mpture of the S-NO bond.
As we have seen, S-nitrosothiols are susceptible to decomposition by a number of 
mechanisms. The extent to which each of these different mechanisms causes decomposition 
of S-nitrosothiols in vivo is difficult to ascertain quantitatively.
Copper ions are present in the human body in a suitable concentration, and thiols are 
present in high concentration compared with copper ions:
Cu^+ + RS' ----------------► Cu+ + RS
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Therefore, copper could be present as Cu"*" ions in the body. We proved that Cu"  ^ is the 
true catalyst for the decomposition of ^ -nitrosothiols and it is possible that endogenous S- 
nitrosothiols are decomposed by Cu+ to release NO on demand.
^-Nitrosothiols in vivo probably also undergo transnitrosation with cysteine and S~ 
nitrosocysteine requires Cu"*" for NO release.
GSNO, a naturally occurring S-nitrosothiol, will probably undergo enzymatic metabolism 
to give 5-nitrosocysteinylglycine and this will be decomposed again by copper ion catalysis 
to give the corresponding disulphide and NO. Therefore, all the previous mechanisms need 
copper ions (i.e. Cu+) in order to release NO.
Under other circumstances the photochemical mechanism may be important. The vascular 
smooth muscle cells contain a finite store of a photosensitive molecule(s) which is capable 
of releasing NO when irradiated with UV or visible light. This store can be exhausted 
rapidly by exposing vessels to laser light but subsequently regenerates in the dark with an 
absolute dependence upon endothelium-derived NO (Megson, 1993). Work by Megson et 
al. provides evidence that the photosensitive 'store' is an 5-nitrosothiol or 5-nitrosoprotein, 
since it is known that ethacrynic acid, a thiol alkylating agent, also prevents repriming of 
the 'store'. As, in some cases, it may not be possible to give a patient S-nitrosothiol as an 
NO-donor it might be possible to rely on endogenous iS-nitrosothiol which is decomposed 
by a laser beam to target cancer cells. The laser beam will increase the endogenous 
decomposition of iS-nitrosothiols to give a suitable dose of NO and the dose may be 
regulated by controlling the intensity and the width of the ray. There is no harmful effect 
from the process by using it for short periods to solve limited problems.
In the human body, some decomposition of the endogenous ^'-nitrosothiols (e.g. CysNO) 
may be due to thermal decomposition.
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In our opinion, the predominant mechanism will be Cu+ catalysis for the decomposition of 
5-nitrosothiols in vivo. If, therefore, naturally occurring 5-nitrosothiols are a store of NO 
which can be released on demand at a suitable rate, dose, and time we need Cu+ in the cell. 
Both cysteine and copper are present in the cell at reasonable concentrations and it has been 
proposed that copper is, indeed, present as Cu+. This is a completely new biological role 
for Cu+.
In the next sections we will describe several experiments which prove that Cu+ is required 
for endogenous 5-nitrosothiol decomposition.
2. 3. The Chemical Stability of S-N itrosothiols
The chemical stability of ^ -nitrosothiols in solution depends upon two main factors: a) the 
presence of metal ions in the buffer; b) the presence of the corresponding thiols as an 
impurities. Here we report the chemical stability of ^-nitrosothiols in the presence of 
chelating agent such as EDTA and neocuproine and in the presence of the corresponding 
thiol.
2. 3. 1. The Effect of Metal Ions on Decomposition of the S- 
Nitrosothiols
In this section new ^-nitrosothiols 2-11 will be considered and their decomposition rates 
compared with those of SNAP (1) and GSNO (13). Full details of the way in which 
copper ions bring about NO release from ^-nitrosothiols are given in the previous section 
(Section 2. 2). However, there is spontaneous decomposition, as well as a reaction 
catalysed by Cu "^  ^ions, which leads to the release of NO. In both pathways the reactivities 
of 2-11 are considerably less than that of SNAP and more than that of GSNO.
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2. 3. 1. 1. The Effect of EDTA on the Decomposition of S-
Nitrosothiols
Workers in the past have discussed the stability of 5^-nitrosothiols but have not taken into 
account the crucial role of metal ions, at concentrations to be found even in distilled water, 
in the release of NO. When we say that SNAP is more stable than SNC we mean simply 
that it is possible to prepare and isolate SNAP but SNC has to be prepared and used in situ. 
It appears that the two p-methyl groups in SNAP are responsible for this difference and this 
is why we have made dipeptides where the thiol-containing component is p,p- 
dimethylcysteine rather than cysteine. To give the term stability a more precise meaning we 
must compare the rate of NO-release from 5-nitrosothiols in solution in the absence of light 
and in the presence and absence of metal ions. Askew et al. have done this for a number of 
^-nitrosothiols and their results in are given in previous work (Askew et al., 1995a&b). 
We carried out a similar study with 2-11 and can compare their stabilities with those of 
SNAP (1) and GSNO (13). Unfortunately, 2-11 are not readily soluble in an aqueous 
buffer and addition of 10% DMSG is necessary for solution. To make the comparison 
precise we used the same DMSO-buffer mixture to study NO-release from SNAP (1) and 
GSNO (13).
Addition of EDTA to the buffer effectively removes all metal ions and the disappearance of 
absorbance at 330-340 nm, due to loss of NO, must be a spontaneous, thermal reaction. 
Over a short time there appeared to be no reaction, but monitoring over a 24 h period 
indicated some decomposition which may be due to theimal decomposition. The results are 
displayed in Figure 2. 37 and show that the decomposition of 2 is somewhat slower than 
that of SNAP and faster than that of GSNO but the difference is not great.
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Figure 2. 37: Absorbance-time plots for the decomposition of (a) [SNAP] = 5 x 10“^  
mol dm"3 (square) (b) [2] = 5 x 10"  ^mol dm"^ (half filled square) (c) [GSNO] = 5 x 10"  ^
mol dm‘3 (segmented square), during 24 hours ( at pH = 7.4, 340 nm, and 30 °C).
Addition of copper(II) nitrate to the buffer had a dramatic effect on the decomposition of 
SNAP, 2-11, and GSNO, the data are displayed in Figure 2. 38 and Table 2. 3. 
Inspection of the curves shows that, at identical Cu^+ ion concentrations, 2 decomposes 
less rapidly than SNAP (1) and more rapidly than GSNO. However, we can give a 
somewhat more precise measure of this difference.
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Figure 2. 38: Absorbance-time plots for the decomposition of (a) [SNAP] = 5 xl0“4 mol 
dm-3, [EDTA] = Ix lQ-5 mol dm'3, and [Cu2+] Ix 10-5, 2  xlQ-5, 3 xlQ-5 mol dm"3 
respectively (circle) (b) [2] = 5 xl0"4 mol dm"3, [EDTA] = Ix lQ-5 mol dm“5, and [Cu^+] 
Ix 10"5, 2 xlO"5, 3 xlQ-5 mol dm"5 respectively (square) (c) [GSNO] = 5 xlO"4 mol dm"5, 
[EDTA] = Ix IQ-5 mol dm"5, and [Cu^+] Ix 10"5, 2 xlO"5, 3 xlO"5 mol dm"5 respectively 
(diamond).
As noted from previous work by Askew et al. (1994) Cu^+ catalysed SNAP decomposition 
obeys reasonably good first-order kinetics over a restricted range of Cu^+ concentrations. 
We found this also to be the case using a DMSO-buffer mixture and the data are displayed 
in Table 2. 3.
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Inspection of Table 2. 3 shows that, if we take the value of k for SNAP, and the values of 
k for 2-11, the ratio of the two k values is ~ 10, indicating that the Cu+ catalysed 
decompositions of 2-11 occur less readily than that of SNAP. So, for both the 
spontaneous and the Cu+ catalysed decomposition of 2-11 are less reactive than SNAP. 
For the latter reaction it could be that, because of the additional amino acid moiety, Cu+ 
binds less readily to 2 11 than to SNAP.
Also, if we take the values of k for 2-11, and the value of k for GSNO, the ratio of the two 
k values is -  100, indicating that the Cu+ catalysed decomposition of GSNO occurs less 
readily than that of 2-11. So, for both the spontaneous and the Cu+ catalysed reactions 
GSNO is less reactive than 2-11. For the latter reaction it could be that, because of the 
additional amino acid moiety, Cu"^  binds less readily to GSNO than to 2-11.
Moreover, if we take the value of k for SNAP, and the value of k for GSNO, the ratio of 
the two k values is ~ 1000, indicating that the Cu+ catalysed decomposition of GSNO 
occurs less readily than that of SNAP. So, for both the spontaneous and the Cu+ catalysed 
decomposition, GSNO is less reactive than SNAP. For the latter reaction it could be that, 
because of the additional two amino acid moieties, Cu+ binds less readily to GSNO than to 
SNAP.
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TABLE 2. 3
Values of k for the decomposition of the 6"-nitrosothiols (1-13; 5.0 x 10“^  mol dm"^) in the 
presence of added EOT A (1.0 x 10"  ^mol dm"^) and 
various Cu ions concentrations
Compound Number
Added 
(1.0x10"^ mol dm"^)*
Rate constant (k/s~^)
Added Cu^ '*' 
(2.0x10"5 mol dm"^)**
Added Cu7+ 
(3.0x10-5
SNAP (1) 5.0 X 10-4 11.5 X 10-4 13.7 X 10-4
2 3.3 X 10-5 13.3 X 10-5 18.3 X 10-5
3 1.6 X 10-5 11.6 X 10-5 23.0 X 10-5
4 1.6 X 10-5 8.3 X 10-5 18.3 X 10-5
5 1.6 X 10-5 10.0 X 10-5 15.0 X 10-5
6 1.7 X 10-5 8.3 X 10-5 16.7 X 10-5
7 6.2 X 10-5 7.0 X 10-5 10.8 X 10-5
8 1.7 X 10-5 9.3 X 10-5 9.3 X 10-5
9 insoluble in the buffer insoluble in the buffer insoluble in the buffer
10 2.5 X 10-5 7.8 X 10-5 10.5 X 10-5
11 2.8 X 10-5 8.9 X 10-5 12.5 X 10-5
12 4.3 X 10-5 7.8 X 10-5 12.3 X 10-5
GSNO (13) 2.5 X 10-7 3.7 X 10-7 4.3 X 10-7
6.995, 0.975, 1.000, and 0.998 respectively).
(** r = 0.996, 0.997, 0.999, 1.000, 0.999, 1.000, 0.0937, 1.000, insoluble in the buffer, 6.999, 1.000, 0.999, and 1.Ô00 respectively).
(*** r = 0.995, 0.992, 0.997, 1.000, 1.000, 1.000, 0.980, 1.000, insoluble in the buffer, 1.000, 0.998, 0.997, and 1.0Ô0 respectively).
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2. 3. 1. 2. The Effect of Neocuproine on S - N i t r o s o t h i o l s  
Decomposition
Neocuproine is a complexing agent specific for Cu+ (Smith and McCurdy, 1952). Addition 
of neocuproine to give a 5 x 10“4 M solution in phosphate buffer at pH 7.4 completely 
suppresses the decomposition of S-nitrosothiols (1-13) which normally occurs in about 30 
minutes to 7 days, depending upon the structure of 5'-nitrosothiols, in a clean first-order 
reaction (Figure 2. 39). The effect is less pronounced at lower concentrations of 
neocuproine (Figure2. 22). As has been reported previously (Askew, 1994), EDTA has the 
same effect but it is a non discriminating complexing agent. It is the specificity of 
neocuproine for Cu+ which allows us to propose that it is the interaction of Cu+ with the S- 
nitrosothiol which results in NO release (Section 2. 2). 5-Nitrosothiols other than (1-13) 
have been examined in the same way and the stabilising effect of neocuproine is general.
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Figure 2. 39: Effect of neocuproine on the rate of decomposition of SNAP (5 x 10"4 mol 
dm"5) in the presence of added copper (1.8 x 10“5 mol dm"3); [neocuproine] = 5 x 10“4, 0 
mol dm"5 respectively (circles), 2 (5 x 10“4 mol dm~ )^ in the presence of added copper (1.8 
X 10"5 mol dm~3); [neocuproine] = 5 x 10"4, 0 mol dm“3 respectively (squares), GSNO (5 
X 10-4 mol dm"3) in the presence of added copper (1.8 x lQ-5 mol dm-^); [neocuproine] = 
5 X 10"4, 0 mol dm-3 respectively (diamonds).
Inspection of Table 2. 4 shows that in the case of neocuproine we found similar behaviour 
to that of EDTA. In view of this similarity we can conclude that the only catalytic effect 
occurring in buffered solution is due to the presence of Cu+ ions.
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TABLE 2. 4
Values of k for the decomposition of the 5'-nitrosothiols (1-13; 5.0 x 10"4 mol dm“5) 
in the presence and absence of added neocuproine (5.0 x 10~4 mol dm“5) and in 
the presence of added Cu^+ (i.g x 10"5 mol dm“3)
Compound Number
Rate Constant (/t/s" )^
Added Neocuproine No Added Neocuproine
SNAP (1) no decomposition 4.4 X 10“4
2 no decomposition 1.5 X 10-5
3 no decomposition 1.5 X 10-5
4 no decomposition 1.3 X 10-5
5 no decomposition 0.6 X 10-5
6 no decomposition 1.3 X 10-5
7 no decomposition 1.7 X 10-5
8 no decomposition 8.5 X 10-5
9 insoluble in the buffer insoluble in the buffer
10 no decomposition 2.2 X 10-5
11 no decomposition 0.7 X 10-5
12 no decomposition 8.7 X 10-5
GSNO (13) no decomposition 4.9 X 10-7
(r = 1.000, 0.970, 1.000, 1.000, 1.000, 0.989, 0.999, 0.986, the compound is insoluble in the buffer, 1.000, 0.998, 0.999, and 0.994 respectively).
117
2. 3. 2. The Effect of Thiol on the Decomposition of S-
Nitrosothiols
There is direct evidence for the involvement of Cu+ in nitrosothiol decomposition from a 
study of the effect of added thiol on the decomposition of 5-nitrosothiols. The results of a 
typical experiment are shown in Figure 2. 40. The observation is consistent with the 
catalytic effect of Cu+, rather than Cu^+, as it is known that cysteine (Stricks and Kolthoff, 
1951) and penicillamine (Laurie and Prime, 1979) reduce Cu^+ to Cu+ (Section 2. 2):
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Figure 2, 40: Effect of added thiol on the copper-catalysed decomposition of SNAP (5 x 
10“4 mol dm"3) (a) [added Cu^+] = 1.4 x 10“^  mol dm"^; [NAP] = 0 (diamond)(b) [added 
Cu^+] = 1.4 X 10"5 mol dm”3; [NAP] = 2.5 x 10"  ^mol dm"^ (segmented diamond), 2 (5 x 
10"4 mol dm"3) (a) [added Cu^+] = 1.4 x 10"  ^mol dm"^; [NAP-Gly-OMe] = 0 (square) (b) 
[added Cu^+] = 1.4 x 10“^  mol dm"^; [NAP-Gly-OMe] = 2.5 x 10"4 mol dm'^ (segmented 
square), GSNO (5 x lO'^ mol dm"^) (a) [added Cu^+] = 1.4 x 10~  ^ mol dm"^; [GSH] = 0 
(circle) (b) [added Cu^+] = 1.4 x 10"  ^ mol dm"^; [GSH] = 2.5 x lO"  ^ mol dm"^ 
(segmented circle).
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TABLE 2. 5
Values of k for the decomposition of the 5-nitrosothiols (1-13; 5.0 x 10'^ mol dm'3) in the 
absence and presence of added the corresponding thiol (2.5 x 10"*^  mol dm"^) and in 
the presence of added Cu^+ (1.8 x 10”^  mol dm“3)
Compound Number
Rate Constant {klsr^)
No Added Thiol* Added Thiol**
SNAP (1) 3.6 X 10 -4 18.1 X 10-4
2 8.0 X 10-5 8.0 X 10-5
3 2.0 X 10-5 7.5 X 10-5
4 0.8 X 10-5 6.7 X 10-5
5 2 .2  X 10-5 9.2 X 10-5
6 3.0 X 10-5 10.3 X 10-5
7 3.3 X 10-5 2.5 X 10-5
8 6.3 X 10-5 6.3 X 10-5
9 insoluble in the buffer insoluble in the buffer
10 3.8 xlO-5 4.7 X 10-5
11 0.6 X 10-5 6.2 X 10-5
12 34.2 X 10-5 5.0 X 10-5
GSNO (13) 3.7x 10-7 23.3 X 10-5
(* r = 1.000, 0.995, 0.988, 0.999, 0.999, 0.999, 0.995, 1.000, the compound is insoluble in the buffer, 0.999, 0.999, 0.937, and 0.999 respectively).
(** r = 0.981, 0.995, 0.998, 0.970, 1.000, 0.996, 0.979, 1.000, the compound is insoluble in the buffer, 0.997, 0.999, 0.999, and 0.974 respectively).
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The results in Table 2. 5 show clearly that addition of thiol in the presence of added Cu^+ 
increases the rate of NO release. This result is consistent with the mechanism of reaction set 
out earlier. The effect is greatest with SNAP and GSNO, and least with 2-12. Also, these 
results explain the apparently contradictory ones in the literature (Feelisch et a l, 1994) 
some of which report catalysis of RSNO decomposition by added thiols whilst other find a 
reduction in rate upon thiol addition (Section 2. 2. 1. 1. 3. 1).
The reason for the great catalytic effect of Cu+ ions is not, at the moment, understood. 
Probably Cu+ ions bind to 5-nitrosothiols but, as the latter have at least four binding sites, 
the structure of the complex is far from certain. This matter has been discussed briefly in 
previous work (Askew et a l, 1995a&b). Cu+ ions are rapidly oxidised to Cu^+ by 
dioxygen but we found that for most 5-nitrosothiols purging the solutions with argon had 
little effect on the kinetics. This would be the case if binding of Cu+ to the 5-nitrosothiol is 
faster than oxidation.
It is cleai’ from what has been reported in this thesis that all previous studies of the in vitro 
release of NO from 5"-nitrosothiols which do not take into account the production of Cu+ 
ions from adventitious copper present in the buffer and thiol contaminating the S- 
nitrosothiol need reinterpretation. This need for reinterpretation is true even for S~ 
nitrosocysteine which, until now, has been regarded as thermally very unstable. Its 
formation had been seen as a mechanism whereby more stable 5-nitrosothiols (such as 
GSNO) could release NO in vivo as GSNO readily transfers NO+ to cysteine with 
formation of 5"-nitrosocysteine (Barnett et a l, 1994; Meyer et a l, 1994; Arnelle and 
Stamler, 1995), which could then undergo thermal homolytic fission to release NO. 
Transnitrosation reactions are very fast (Barnett et al, 1994). However, addition of EDTA 
to a buffered solution of 5-nitrosocysteine, prepared in situ, renders the compound 
relatively stable. It is clear that the metal ion catalysed pathway for the decomposition of S- 
nitrosothiols is not a minor one. In the presence of even micromolar quantities of Cu+ it is 
thermal fission which is of little importance.
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2. 4. Study of the Pharmacological and Physiological Properties
of S-Nitrosothiols
In this section, the pharmacological and physiological properties (smooth muscle relaxation 
and inhibition of platelet aggregation) of compounds 2-12 are compared with those of 
SNAP and GSNO in an effort to understand the relationship of structure to chemical 
stability and biological activity. Also, there is a report of an investigation of the effect of 
neocuproine on vasodilator responses to bolus injections of SNAP and GSNO in an ex 
vivo model, using a rat tail artery preparation. As well, there is a report of a direct proof 
from the literature that Cu+ is involved in the biological activity of GSNO on platelet 
aggregation and soluble guanylate cyclase.
2. 4. 1. Smooth Muscle Relaxation
SNAP and GSNO are NO-donor drugs whose biological activities in water are well 
documented (Megson, 1993; Askew, 1994). Here we compare the biological activities of 
SNAP (1) and GSNO (13) with those of 5-nitrosated dipeptides (2-12) in 10% aqueous 
DMSO.
Male Wistar rats (300 - 400 g) were killed by cervical dislocation and their tails removed. 
Lengths of tail artery (8-11 mm) were dissected free, cannulated and perfused internally 
with Krebs solution (37 °C) at a constant flow rate (2 cm^ min"i). Temperature was 
maintained by superfusion with pre-warmed Krebs solution. Vessels were precontracted 
with phenylephrine hydrochloride (PE; 2 - 8  }iM) in the internal perfusate, generating 
perfusion pressures of 100 - 120 mm Hg, measured upstream of the artery by a differential 
pressure transducer (SenSym; SCX15DNC). Microinjections (10 pi) of SNAP or GSNO
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were made through a resealable rubber septum located immediately upstream of the cannula 
(transit time ca. 4 sec). Increasing control doses (10“^  - lO"^  M) of S'-nitrosothiol injected 
into the internal perfusate caused relaxations which were allowed to recover fully before 
subsequent doses were administered. Doses were then repeated in the presence of 
ferrohaemoglobin, a recognised NO 'scavenger' (Hb; 15 jiM; prepared by the method 
described by Martin et a l 1985; Figures 2. 41 - 2. 54 respectively) for comparison with 
controls. Results are expressed as the peak amplitude of relaxation as a % of PE-induced 
pressure. Results are mean + S.E.M. of 5-7 separate experiments. They were compared by 
unpaired students’ f-test and p < 0.05 was considered as statistically significant (details of 
the rat tail artery preparation are reported elsewhere ; Flitney et al, 1992).
For statistical comparison a student's paired/unpaired f-test was carried out individual data points. All the plots obtained by use of a cricket graph program.
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SNAP
SNAP, and vessels were perfused internally with Krebs solution oontaning 15 pM Hb
2, and vessels were perfused Internally with Krebs solution oontaning 15 pM Hb
GSNO
GSNO, and vessels were perfused internally with Krebs solution combing 15 pM Hb
Figure 2. 41: Pressure recordings showing the vasodilator effects of 10 pi microinjections of SNAP, 2, and GSNO in the absence and presence of 15 pM Hb.
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5-Nitrosothiols (1-13) are fast acting and potent vasodilators. As can be seen in Figure 2. 
41, the responses are sharp, appearing soon after injection, and there is full recovery, in a 
matter of minutes, to the original precontracted tone of the artery.
When traces like those in Figure 2. 41 are translated into log dose-response curves like 
those shown in Figures 2. 42 - 2. 54 it is evident that all 5-nitrosothiols (1-13) are 
effective vasodilators, and are excellent NO-donor drugs.
The results show that bolus injections of all compounds into the internal perfusate elicit 
transient responses which recover rapidly. Hb significantly inhibits, but does not abolish, 
the responses to all drugs, with SNAP being less sensitive than the others.
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Figure 2. 42; Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of SNAP; 1. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols shows responses in the presence of oxyhaemoglobin (15 pM).
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Figure 2. 43: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 2. Filled symbols show responses in the absence of oxyhaemoglobin and open symbol shows responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 2 compared to those of SNAP. (*= P<0.05, **= P<0.01, *»*= P<0.001).
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Figure 2. 44: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 3. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t~ tests were carried out to determine the statistical significance of responses to 3 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figure 2. 47: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 6. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 6 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0,001).
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Figure 2, 48: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 7. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 7 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figure 2.49: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 8. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 8 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figure 2. 50: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 9. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine statistical the significance of responses to 9 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
129
I
M 4 0 -
I..
-2-4 -3-  6 -5- 8 -7
LOGio DOSE(M)
Figure 2. 51: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of 10. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 10 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figure 2. 52: Log dose-response curves comparing the vasodilator effects of 10 pi bolus 
injections of 11. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols shows responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- tests were carried out to determine the statistical significance of responses to 11 compared to those of SNAP. (*= P<0.05, **= p<0.01, ***= P<0.001).
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Figure 2. 53; Log dose-response curves comparing the vasodilator effects of 10 jil bolus injections of 12. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired t- 
tests were carried out to determine the statistical significance of responses to 12 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figure 2, 54: Log dose-response curves comparing the vasodilator effects of 10 pi bolus injections of GSNO; 13. Filled symbols show responses in the absence of oxyhaemoglobin and open symbols show responses in the presence of oxyhaemoglobin (15 pM). Unpaired r-tests were carried out to determine the statistical significance of responses to 13 compared to those of SNAP. (*= P<0.05, **= P<0.01, ***= P<0.001).
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Figures 2. 42 - 2. 54 show log dose-response curves (closed circles) derived from 
experiments involving microinjections of (a) SNAP, (b) 2-12 and (c) GSNO. In all cases, 
ED5 0  values have been determined using the response to 10"  ^M injections as the 
maximum. 10~2 M injections could not be carried out since DMSO in concentrations greater 
than 10% produced a significant relaxation response which would preclude the effect of the 
drug alone. 'ED5 0 ' values of 0.8 - 45 p,M have been estimated for SNAP , 2-12 , and 
GSNO respectively. The addition of 15 pM Hb to the internal perfusate caused a significant 
reduction in potency for all compounds (open circles). Hb is a well recognised NO 
scavenger and these results indicate that NO is the effector agent in vasodilation by all 
thirteen compounds. Figures 2. 41 -2. 54 show the effect of Hb on vasodilator responses 
to all compounds. There is no significant difference between the response amplitudes at any 
concentration. Therefore, responses to 2 12 and GSNO were inhibited to a greater extent 
than those to SNAP. (P<0.01 for all doses of compounds 1-13 when compared to control 
values using an unpaired Student’s r-test).
These results show that all 5-nitrosothiols (1-13) were capable of causing vasodilation in 
pre-contracted lengths of isolated rat tail artery. 11 was significantly more effective at 
causing vasodilation (Table 2. 6) than the others. This result was contraiy to that expected 
from the chemical stability (Section 2. 3).
ED5 0  : equivalent dose for 50% response.
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TABLE 2. 6
A comparison of the vasodilator effectiveness of SNAP, 2-12, and GSNO
on rat tail artery
Compound Number ED5 0  (pM) * 10-5 M
SNAP (1) 2 0
2 4 Î
3 3.5 Î*
4 3 Î
5 1.5
6 45 i**
7 1 0 T
8 4.5 Î
9 9.5 T
1 0 5 T**
1 1 0 . 8 ***
1 2 2
GSNO (13) 0.9
i: the drug was significantly less effective at causing vasodilation than SNAP. 
Statistical analysis of data in the table:
statistical analysis on the data was carried out using an unpaired students f-test. 
* indicates data is significantly different at the P = 0.05 confidence level.
** indicates data is significantly different at the P = 0.01 confidence level.
*** indicates data is significantly different at the P = 0.001 confidence level.
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A very close scrutiny of the results leads to the following conclusions:
(a) We have examined the biological activity of these compounds on smooth muscle 
relaxation and compared it with that of SNAP(l) and GSN0(13). We have found that S~ 
nitrosated dipeptides are potent vasodilators but are chemically very stable in the absence of 
copper ions (SNAP<5-nitrosated dipeptides<GSNO).
(b) Differences in spontaneous (thermal) decomposition do not account for differences in 
NO release from these ^-nitrosothiols in vivo.
(c) Since 5-nitrosothiols are thermally unstable there is likely to be release of some NO 
spontaneously in the lumen where it would be susceptible to Hb inactivation. Recent 
experiments (Section 2. 2. 2) have shown that 5-nitrosothiols undergo a process known as 
transnitrosation in the presence of -SH-containing compounds, such as cysteine. It is 
possible, therefore, that NO could be 'stripped' from 5-nitrosothiols to form a compound 
whose action may not be susceptible to Hb inhibition. Potentially, therefore, S~ 
nitrosothiols can release NO by several mechanisms, only some of which are susceptible to 
Hb inhibition.
(d) A number of mechanisms are involved in the decomposition of 5-nitrosothiols in vivo. 
The dominant mechanism in the decomposition of ^ -nitrosated dipeptides may be different 
to that operative with SNAP and/or GSNO.
(e) 2, 3, 4, 5, 7, 8 , 9, 10, I I ,  12, and GSNO (13) are more effective than SNAP (1) . 
Compound (6 ) was found to be less effective than SNAP but that may be because 6  was an 
impure compound. The similarity is surprising as in 1-12 the local chemical environment 
of the -SNO groups are almost identical (i.e. 1-12 (3° carbon) but different in GSNO (1“ 
carbon)). This finding is contrary to what might be expected on the basis of their chemical 
stabilities in vitro and may indicate that the 5-nitrosated dipeptides and GSNO interact with 
tissue components or show greater permeability than SNAP.
(f) In ex vivo and in vivo situations, many factors may influence NO release from S- 
nitrosothiols.
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2. 4. 2. Copper Chelation-Induced Reduction of the Biological 
Activity of S-Nitrosothiols in Smooth Muscle Relaxation
In vitro kinetics studies have shown that 5-nitrosothiols spontaneously decompose in 
solution (pH = 7.4) to release NO, a reaction which is accompanied by formation of the 
corresponding disulphide only. In section 2. 2. 1. 1, we reported that this process is 
dependent upon catalysis by adventitious metal ions (Dicks et a i, 1996; Butler and Al- 
Sa'doni, 1996; Al-Sa'doni e ta l,  1996). The release of NO by 5-nitrosothiols is inhibited 
by the non-specific metal ion chelating agent EDTA and accelerated by addition of Cu^+ 
ions. Most importantly, a selective Cu+-chelating agent (Smith and McCurdy, 1952), 
neocuproine, also prevents their decomposition and is equally as effective as EDTA in this 
regard.
The experiments to be reported here employed an ex vivo model, the isolated, internally 
perfused rat tail artery preparation (Flitney et ai, 1992), to ascertain whether Cu+ catalysis 
plays a role in the vasodilatation actions of SNAP and GSNO.
The experiments were performed in a dark laboratory since SNAP, GSNO, and NP are all 
photosensitive and release NO when exposed to light. The following protocol was used 
throughout. First, phenylephrine (1-7 )liM) was added to the Krebs solution (in PI; Figure
3. 1) to precontract the artery, generating a perfusion pressure of 100-120 mm Hg. Bolus 
microinjections (10 p.M) of SNAP or GSNO (10~^-10"3 M; prepared by serial dilution of 
the stock solutions) were then delivered into the internal perfusate. Stock solutions of 
SNAP and GSNO (10"3 M) were prepared in 10% aqueous dimethyl sulphoxide (DMSO). 
These produced transient vasodilator responses which were allowed to recover fully 
between successive injections. The injection sequence was then repeated with SNAP and 
GSNO after pre-mixing with neocuproine (10"^ M) for 30 min. Finally, vessels were 
perfused internally with Krebs solution containing neocuproine (lO'^M, added to PI; 
Figure 3. 1) and solutions of SNAP or GSNO alone were injected into the artery. Stock 
solution of neocuproine (10"2 M) was prepared in 25% ethanol.
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Control experiments showed that the highest working concentrations of DMSO (1%) and 
ethanol (2.5%) alone did not cause vasodilation of the artery. Control experiments were 
performed with neocuproine previously complexed to Cu+.
Vasodilator responses to standard bolus injections of sodium nitroprusside (NP; 10‘5 M) 
were recorded periodically (Figure 2. 55). Like SNAP and GSNO, NP relaxes vascular 
smooth muscle by increasing cyclic GMP levels, but it does so by reacting with rather than 
by spontaneous release of NO in solution (Flitney et al, 1992).
GSNO
10'®.neocuproine
Figure 2. 55: Pressure recording showing the vasodilator effect of 10 p,l microinjection
of sodium nitroprusside (NP; 10"  ^M), GSNO, and sodium nitroprusside (NP; 10"  ^M) respectively.
The concentration of contaminating copper in Krebs solution {ca. 10"  ^M; in distilled water) 
was determined by atomic absorption spectroscopy.
Figure 2. 56 shows vasodilator responses obtained by injecting drug concentrations of:
(a) SNAP or GSNO alone in pre-contracted arteries.
(b) SNAP or GSNO pre-mixed with neocuproine (10"4 M) in pre-contracted arteries.
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(c) SNAP or GSNO alone, and vessels were perfused internally with Krebs solution 
containing neocuproine (10"  ^M) in pre-contracted arteries.
The vasodilator effect of both compounds was severely attenuated in the presence of 
neocuproine. Log dose-response curves (data from 5-1 experiments) are presented in 
Figures 2. 57 and 2. 58 (solid symbols). Neocuproine caused a marked rightward shift in 
the dose-response curve: the ED5 0  values for both compounds were increased 
approximately 1 0 0  fold.
The addition of neocuproine (10“^ M) alone to reservoir PI, containing the internal 
perfusate (= Krebs + neocuproine), elicited a prompt vasoconstrictor response (mean +/- 
SEM = 17.9 +/- 3.1%; n = 7 vessels) which was fully reversible on washout (Figure 2. 
55). The magnitude of the effect was significantly less than that produced by including 
either haemoglobin (5 pM; 56.5 +/- 4.9%; n =8) or by the nitric oxide synthase inhibitor L- 
monomethyl-L-arginine (100 |iM: 57.1 +/- 6.1%; n = 10) in the internal perfusate. In 
contrast, control experiments showed that the pre-prepared stoichiometric complex of 
neocuproine and Cu+ had no effect on phenylephrine-induced tone.
Vasodilator responses to bolus injections of SNAP or GSNO (empty symbols) 
administered while vessels were being continuously perfused with Krebs and neocuproine 
were also impaired, and under these conditions the maximum vasodilator response was 
depressed too (Figures 2. 57 and 2. 58). The effect was greater for SNAP than GSNO. 
Again, the neocuproine-Cu+ complex had no effect on vasodilator responses to SNAP 
(GSNO was not tested).
Finally, vasodilator responses to NP (10"^ M) were unaffected by the presence of 
neocuproine in the internal perfusate: the amplitudes were 44.3 +/- 3.7% (n = 5-7 separate 
experiments) in normal Krebs solution and 43.2 +/- 5.3% (n = 5-7 separate experiments) in 
Krebs solution containing neocuproine.
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SNAP
SNAP pre-mixed with neocuproine (lO'^^M)
SNAP alone, when vessels were perfused internally with Krebs solution containing 
neocuproine (1 O'® M)
GSNO
GSNO pre-mixed with neocuproine (10""^  M)
GSNO alone, when vessels were perfused internally with Krebs solution containing 
neocuproine (10'® M) ^
Figure 2. 56: Pressure recordings showing the vasodilator effects of 10 jil microinjections of SNAP, and GSNO in the absence and presence neocuproine.
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Neocuproine is a selective chelating agent of Cu+ ions. The results presented here show 
that it strongly inhibits vasodilator responses of isolated rat tail artery to bolus injections of 
SNAP or GSNO, demonstrating that Cu+-catalysed release of NO from S-nitrosothiols is 
important in a functionally-intact ex vivo physiological system.
The nature of the inhibitory effect was found to depend upon the experimental protocol, 
specifically on the manner in which SNAP and GSNO were administered: that is, whether
(a) pre-mixed with neocuproine prior to injection or (b) injected without pre-mixing into 
vessels that were continually perfused with Krebs solution and neocuproine. The dose- 
response curves to bolus injection of SNAP or GSNO pre-mixed with neocuproine 
demonstrate a competitive inhibition: that is, a marked rightward shift of the curve but with 
similar maximum responses at higher doses (Figures 2. 57 and 2. 58). On the other hand, 
the form of the dose-response curves to SNAP or GSNO alone when injected into arteries 
perfused with Krebs solution and neocuproine is suggestive of a non-competitive inhibition 
(Figures 2. 57 and 2. 58). Here, maximum responses to both compounds are significantly 
diminished. Importantly, responses to bolus injections of NP were not impaired under 
these conditions, demonstrating that prolonged exposure of vessels to neocuproine per se 
does not impair vascular smooth muscle relaxation directly.
The period of time that vessels are exposed to neocuproine appears to be the important 
factor which determines the form of the dose-response curve. This was negligible (ca. 300 
ms) in the 'pre-mix’ experiments, but considerable (1-12 s) in those experiments which 
involved continuous infusions of Krebs and neocuproine.
The results of the kinds of the experiment can be interpreted if we postulate a dual 
mechanism of action for SNAP and GSNO. First, a 'direct' relaxant effect, due to Cu+- 
catalysed release of free NO into solution; and second, an 'indirect' relaxant effect, due to a 
process involving Cu+-catalysed release of NO within the tissue.
There can be little doubt that the concentration of neocuproine present (10"'  ^M) in the 'pre­
mixed' solution was sufficient to chelate the trace amounts of Cu+ likely to be present.
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Atomic absorption spectroscopy showed that this was in the region of 10“^  M. The ability 
to give near maximal responses at the highest doses of SNAP or GSNO under these 
conditions (Figures 2. 57 - 2. 58) can therefore be attributed to trace copper ions and 
contaminating thiols present in the internal perfusate, to which each compound was 
momentarily exposed following injection, while en route to, and within, the artery.
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Figure 2. 57: Log dose-response curves comparing the vasodilator effect of 10 |il bolus 
injections of SNAP. Filled circles show responses of SNAP alone, closed triangles show 
SNAP pre-mixed with neocuproine (lO'^M), open triangles show SNAP alone when 
vessels were perfused internally with Krebs solution containing neocuproine (lO"  ^M), and open squares show SNAP alone when vessels were perfused internally with Krebs 
solution containing neocuproine (10“5 M), copper(II) acetate (0.5 x 10"  ^ M), and L- 
glutathione (0.5 x 10“^  M).
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Figure 2. 58: Log dose-response curves comparing the vasodilator effect of 10 p,l bolus 
injections of GSNO. Filled circles show responses of GSNO alone, closed triangles show 
GSNO pre-mixed with neocuproine (10"4 M), and open triangles show GSNO alone when 
vessels were prefused internally with Krebs solution containing neocuproine (10“5 M).
The 'indirect' process would be significantly impaired if there was sufficient time available 
for neocuproine to chelate all contaminating Cu"^  in the Krebs solution and also any cellular 
Cu+, either by entering vascular smooth muscle cells and/or by acting as an external 'sink'. 
The sustained vasoconstrictor response observed when vessels were continuously perfused 
with neocuproine alone (Figure 2. 55) provides some support for this hypothesis and
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raises the possibility that vascular smooth muscle tone may be regulated, at least in part, by 
Cu+-catalysed release of NO from the endogenous 5-nitrosothiols. It will be recalled that 
the magnitude of the effect was considerably less than that produced by continuous 
infusions of either haemoglobin (5 |xM) or LNMMA (100 (xM), so this source of NO may 
be less important than endothelium-derived NO in regulating vessel tone. However, it was 
shown recently (Schrammel et a l, 1996) that copper ions inhibit basal and NO-stimulated 
recombinant soluble guanylate cyclase activity and that Cu+ is more effective than Cu^+ in 
this regard (Section 2. 4. 5). Neocuproine may therefore exert opposing effects on vessel 
tone: inhibition of NO release from endogenous 5-nitrosothiols, causing a vasoconstrictor 
action, and a simultaneous vasodilation, due to removal of the inhibitory effect of Cu+ on 
guanylate cyclase activity. Clearly, the amplitude of the net response will depend upon the 
relative contributions from the two processes, making it difficult at present to decide 
whether endothelial- or 5-nitrosothiols-derived NO plays the more important role in 
controlling smooth muscle contractility.
The amplitude of the vasodilator response to SNAP or GSNO is given as the maximum 
drop in pressure expressed as a percentage of that existing immediately prior to injecting the 
vessel. Results presented are mean (+/- SEMSs) for 5-7 experiments. Statistical 
significances were calculated using a paired Student's r-test, compaiing responses obtained 
at each dose of SNAP/GSNO in the presence of neocuproine (pre-mixed or added to the 
internal perfusate) with control responses recorded in Krebs solution only. A p value of 
0.05 or less was taken to indicate a statistically significant difference between mean values.
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2. 4. 3. Inhibition of Platelet Aggregation
It has recently been shown that 5-nitrosoproteins such as 5-nitroso albumin and 5-nitroso- 
tissue type plasminogen activator, like the low-molecular-weight 5-nitrosothiols such as 
GSNO (Radomski et a l, 1992), have strong anti-platelet effects with ICso's in the range of 
1.5 p,M (Simon et a l, 1993). Furthermore, it has been postulated that these stable adducts 
release and deliver NO by transfer to low-molecular-weight thiols such as cysteine and 
glutathione (Simon et al, 1993).
It is known that NO is generated in platelets and that it acts as a negative feedback system to 
modulate aggregation (Radomski et a l, 1990 a&b). Generation of platelet-derived NO is 
NADPH-dependent, inhibited by LNMMA and dependent on free intracellular Ca^+. 
Addition of L-arginine to the medium does not alter basal NO production, but enhances the 
increase in NO production when aggregation is initiated using collagen, ADP or 
arachidonic acid. The interference from this is that nitric oxide synthase exists in platelets 
and is stimulated to enhance NO synthesis from L-arginine once aggregation is initiated 
(due to an increase in intracellular Ca^+: Ware et a l, 1986). The increase in intracellular 
NO has been shown to be accompanied by an increase in cGMP but not cAMP. The 
mechanism by which cGMP inhibits aggregation is not fully understood, but it may involve 
sequestration of free intraplatelet Ca^+ (Busse et a l, 1987). Nitric oxide, therefore, may 
play an important antithrombotic role in vivo by inhibiting both platelet aggregation and 
adhesion to vessel walls, particularly as its actions are enhanced by the synergistic effect of 
prostacyclin. This evidence suggests that 5-nitrosothiols have a possible role as 
thromboregulators controlling platelet aggregation. Although blood platelets play a central 
role in maintaining haemostasis and in the pathogenesis of thrombosis, the precise 
mechanisms regulating platelet production, release and ageing, are still not fully 
understood.
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In a normal human, it is estimated that approximately 35 x 10  ^platelets are produced per 
litre of blood every day (Marker and Finch, 1969). This production rate is under relatively 
strict control and finely regulated as evidenced by very narrow limits within the blood 
platelet count variations from day to day, or month to month (Brecher and Cronkite, 1950).
In the last decade knowledge of some of the regulating mechanisms of megakaryocyte 
proliferation and maturation has become much more certain, but many unanswered 
questions remain. The final stage of the liberation of platelets from these precursors is also 
poorly understood. Our lack of insight is highlighted by the controversy concerning 
whether platelets are released from the megakaiyocytes in the bone marrow or in the lungs. 
It is also not clear why platelet volume is so heterogeneous and what determines the 
ultimate size of the platelet.
Platelets in the circulation change with ageing (Hirsh et ai, 1968), but little is known of the 
chaiacteristics of newly formed platelets that distinguish them, or could make it possible to 
isolate senescent platelets from those of average age. In respect of human platelets at least, 
the claims that young platelets can be identified by their characteristic buoyant density, 
volume, and biochemical features (Karpatkin, 1969a&b, 1970; Corash etal., 1977, 1978), 
must now be regarded as mistaken (Boneu et a l, 1980; Maitin et al., 1983).
The major cause of the difficulties relating age with features such as size, has been the 
confusion between 'stress platelets' and normal young platelets. Stress platelets are 
produced under conditions of stimulated platelet production (Karpatkin 1984; Penington 
1984), and they differ from normal young platelets in respect of volume and functional 
characteristics (McDonald et al., 1964; Ginsberg and Aster, 1972; Marker and Slichter, 
1972). The presence of megathrombocytes in the blood reflects increased platelet turnover. 
This characteristic has become clinically important with the advent of automated 
measurement of platelet volume (Levin and Bessman, 1983). Although the presence of 
megathrombocytes on the peripheral blood film may be used as an index of megakaryocyte 
number (Garg et a i, 1971), it should be recognised that in a steady state the distribution of
144
platelet volume is log-normal (Paulus, 1975). The peripheral blood will therefore always 
have some large platelets. There is now conclusive evidence that the volume of platelets 
does not decrease with ageing (Thompson et al., 1983). An increase of stimulated platelet 
production and turnover, should therefore be interpreted simply to reflect a shift to the right 
of the log-normal distribution curve describing platelet size (Penington and Streatfield,
1975).
There are many important variables in platelet aggregation:
(a) Type of anticoagulant:
Citrate is satisfactory for most studies. It should be noted that an increase in the 
concentration of citrate results in reduced platelet aggregation.
(b) Methods of preparation of platelet-rich plasma:
This should be carefully standardised. Some platelets will not be recovered in platelet-rich 
plasma prepared by centrifugation and it is possible that, in some circumstances, a 
population of platelets of higher density may exhibit aggregation responses different from 
those of the remainder of the platelet population. Such platelets may not be represented in 
the platelet-rich plasma.
The study of platelet aggregation by light ti'ansmission methods necessitates the separation 
of platelets from other blood cells. This is clearly an entirely artificial situation as platelet 
response in vivo may be influenced by these other cellular elements. Thus, for example, 
red cells are a potent source of ADP.
(c)pH:
Maximum responses occur in a pH range of 7.4 to 8.0 and steps should be taken to ensure 
that the pH is standardised and within this range (Mustard and Packham, 1970; Rogers,
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1972). pH is largely dependent on CO2  content and this should be controlled.
(d) Temperature:
Platelet aggregation tests should be performed at 37 °C (Mustard and Packham, 1970; Han 
and Ardlie, 1974). Aggregation is sensitive to temperature variations and secondary 
responses to ADP are not seen at temperatures below 30 °C (Valdorf-Hansen and Zucker, 
1971).
(e) Stirring :
The number of collisions between platelets is governed by the rate of stirring and the 
physical characteristics of the stirrer bar. These should be standardised (Born, 1962; Coller 
and Gralnick, 1976).
(f) Platelet count in platelet-rich plasma:
For meaningful comparisons of responses between samples, the platelet counts must be 
matched. Responses are difficult to interpret with a platelet count in platelet-rich plasma of 
less than 100 x 10^ /1. A method has been described for the analysis of samples with counts 
as low as 50 x 10^ /1 (Levine, 1976).
(g) Difference in light transmission:
It should be noted that the difference in light transmission between platelet-poor and 
platelet-rich plasma in lipaemic samples is narrowed and analysis of aggregation responses 
may not be possible.
The responses to adrenaline are variable, a proportion of normal subjects failing the 
respond to this agonist at any concentration. This is also a characteristic of neonatal 
platelets (Corby and Schulman, 1971).
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We have examined the pharmacological effects of the previous 5-nitrosothiols (2-12) on 
human platelets ex vivo and compared them with the pharmacological properties of SNAP 
and GSNO.
Human blood was collected from healthy volunteers who had not ingested drugs known to 
affect platelet function for two weeks prior to the study (details of inhibition of platelet 
aggregation procedure are described elsewhere; Experimental Section). Briefly, the light 
beam from the spectrophotometer (Platelet Aggregation Profiler) passed through the sample 
cuvette containing a stirred solution of platelet rich plasma (PRP) at 37 and the 
absorbance noted. Collagen added to PRP was used to aggregate the platelets. This caused 
a dramatic decrease in the absorbance due to reduced light scattering by the aggregating 
platelets. Example traces are shown in Figure 2. 59. Various concentrations of the 5- 
nitrosothiols to be tested were injected into the cuvette prior to the addition of collagen.
Incubation of the drugs with platelet rich plasma (PRP) resulted in a concentration- 
dependent inhibition of the collagen-induced aggregation (Figure 2. 60 and Table 2. 7, 
results are the mean of at least two separate experiments). The inhibitory activity of these 5- 
nitrosothiols was reversed by haemoglobin, indicating the involvement of NO in the 
process.
2, 3, 4, 9, 10, 11, 12, and GSNO were significantly more potent than SNAP as 
inhibitors of platelet aggregation, and, 5, 6, 7, and 8 were significantly less potent than 
SNAP. No significent difference were found in the inhibition of collagen release from 
platelets caused by the drugs (Table 2. 7).
It is clear that 5-nitrosothiols, as a class of NO donor drugs, are very effective at inhibiting 
platelet aggregation. Whether endogenously or exogenously produced, they are far more 
potent than other commercially available NO-donor drugs and, with two exceptions, they 
were found to be more potent than NO itself.
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Figure 2. 59: The effect of SNAP, 2, and GSNO on platelet aggregation by collagen in platelet rich plasma (1. added drug, and 2. no added drug).
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Figure 2. 60: Inhibition of collagen-induced platelet aggregation by 5-nitrosothiols (1- 
13).
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TABLE 2. 7
A comparison of the relative effectiveness at inhibiting platelet aggregation of the 5-nitrosothiols (1-13) by collagen-induced aggregation
Compound Number IC5 0  (|lM)*
SNAP (1) 4.4
2 1.8
3 4.1
4 4.1
5 4.6
6 7.1
1 5.3
8 6 . 2
9 2.7**
1 0 1.9
1 1 2 . 8
1 2 3.2
GSNO (13) 1.3
* IC5 0 : concentration required to inhibit by 50%.
** The stock solution was the dmg dissolved in DMSO, because the drug is insoluble in the buffer.
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2. 4. 4. Copper Chelation-Induced Reduction of the Biological 
Activity of 5-Nitrosothiols in Inhibition of Platelet Aggregation
A particularly interesting finding recently (Gordge et al, 1995) shows that the inhibition of 
platelet aggregation activity by GSNO is much reduced in the presence of neocuproine and 
the closely related bathocuproine, both specific Cu+-chelating agent. In addition, 
bathocuproine sulphonate reduces the stimulation of platelet guanylate cyclase by both S- 
nitroso-L-cysteine and GSNO.
2. 4. 5. The Effect of Copper Ions on Soluble Guanylate Cyclase
Very recently, Schrammel et a l  (1996) found that recombinant bovine lung soluble 
guanylate cyclase (sGC) purified from a baculovirus overexpression system (Weld et a l,
1994) was inhibited by low concentrations of CUSO4 . Their data are shown in Figure 2. 
61. CUSO4 inhibited cGMP formation by the enzyme stimulated with 1 p-M 2,2-diethyl-1- 
nitroso-oxyhydrazine (DEA/NO) with an IC5 0  of -  2 pM; complete inhibition was 
observed with 10 pM CUSO4 . GSH protected sGC from copper-induced inhibition, as 
revealed by a more than 10-fold reduced potency of CUSO4  in the presence of 1 mM of the 
thiol (Figure 2. 61). Haemoglobin exhibits a high-affinity binding site for Cu(I) ions, 
which may be involved in copper-induced, thiol-sensitive methaemoglobin formation 
(Rifkind, 1981; Smith et a l, 1993). Since sGC was reported to contain stoichiometric 
amounts of copper (Gerzer et a l, 1981) it is conceivable that copper-induced enzyme 
inhibition may be due to oxidation of haem-iron, resulting in reduced affinity for NO and 
thus deactivation of the NO-stimulated cyclase. However, their data indicate that the 
inhibitory effect of CUSO4  is not due to interference with stimulation of the enzyme by NO, 
because (a) CUSO4  inhibited basal and NO-stimulated enzyme activities with similar 
potency, (b) higher concentrations of DE A/NO did not prevent inhibition, and (c) reaction 
of CUSO4 with NO was negligible under their experimental conditions.
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Figure 2. 61: Inhibition of sGC by CUSO4 and protection by a) added GSH (filled 
circles) b) no added GSH (empty circles); (adapted from Schrammel et el., 1996).
Inhibition of sGC due to the oxidative properties of copper was further excluded in 
experiments performed with selective Cu+ and Cu^+ chelating agents (Gordge et at.,
1995). Figure 2. 62 shows that the inhibitory effect of 3 |iM CUSO4  was almost completely 
antagonized by the Cu+-specific antagonist neocuproine, whereas cuprizone, a compound 
with Cu^+ selectivity, was much less effective.
Chelating Agents (M)
Figure 2. 62: Effect of the Cu+-specific chelating agents, neocuproine (empty circles) and cuprizone (filled circles) on sGC activity in the presence of 3 pM CUSO4  (adapted from Schrammel et. a l, 1996).
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GSH is known to form highly stable complexes with Cu+ ions (Miller et a l, 1990), but the 
protective role of the thiol was probably not due to chelation of copper, as several other 
thiols were also effective.
The present data show that copper ions induce a pronounced inhibition of cGMP formation 
by sGC. The inhibitory effect of CUSO4  may be due to the binding of Cu+ ions to one or 
more sulphhydryl groups critically involved in the catalytic function of sGC, since the 
enzyme was protected by a Cu+-selective chelating agent and several thiols. Intracellular 
GSH levels are in the millimolar range and copper occurs primarily in chelated, redox- 
inactive forms, suggesting that Cu+-induced inhibition of sGC is insignificant under 
physiological conditions. However, oxidative stress may cause depletion of tissue GSH 
(Bray and Taylor, 1993), and redox-active copper was reported to be mobilized in the 
course of myocardial ischemia (Chevion, 1993) or may be released from caeurloplasmin by 
peroxynitrite (Swain, 1994). Thus, impaired accumulation of cGMP induced by free 
copper may contribute to the pathophysiology of certain diseases.
2, 4. 6. Cu+ Catalysed NO Release from Endogenous S-  
Nitrosothiols
All the previous results are a direct proof that Cu+ causes NO release from endogenous S- 
nitrosothiols. This strongly suggests that nitric oxide is generated from 5"-nitrosothiols by a 
process which involves Cu+. Copper is therefore required for the full activity of these S~ 
nitrosothiol compounds. However, another recent article (Bannenberg et a l, 1995) claims 
that bronchodilation induced by GSNO does not require the formation of NO. The medical 
importance of 5-nitrosothiols has been highlighted recently by two reports (Longford et al, 
1994; de Beider et a l, 1995) which describe the clinical use of GSNO to inhibit platelet 
aggregation during coronary angioplasty and also to treat a form of pre-eclampsia, a high 
blood pressure condition suffered by some pregnant women.
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2. 5. The Correlation between Structure, Chemical Stability, 
and Physiological Activity
As described earlier, the chemical stability of the 5-nitrosothiols was monitored 
spectrophotometrically in the presence of different copper concentrations or in the presence 
of the corresponding thiols. The synthetic 5-nitrosothiols (1-13) were tested for biological 
activity in two assay systems, an isolated smooth muscle preparation and a platelet 
aggregation assay. All the 5-nitrosothiols tested were active in each assay. They relaxed 
smooth muscle preparations (rat tail artery), and inhibited collagen-induced platelet 
aggregation. Although the structures and chemical properties of the synthetic 5- 
nitrosothiols varied considerably, all the compounds were active in both bioassay systems. 
Coupled with the fact that the starting thiols and the product disulphide were inactive, this 
indicates that the -S-N=0 functional group is responsible for the biological activity of these 
compounds. The R- group, however, significantly influences the biological activity. We 
have found that 5-nitrosated dipeptides are potent vasodilators and suitable inhibitors for 
platelet aggregation but are chemically very stable in the absence of copper ions (SNAP < 
5-nitrosated dipeptides < GSNO; Table 2.8). The potency of the 5-nitrosothiols varied as a 
function of the structure by as much as 0.8 - 45 |lM orders of magnitude in the isolated 
smooth muscle preparation, and 1.3 - 7.1 jxM in the platelet aggregation assay. It is clear 
that the platelet aggregation assay is more sensitive to 5-nitrosothiols than the isolated 
smooth muscle preparation. The effect of the R- group on biological activity was different 
in each assay; this is reflected by the different rank orders of activity observed in the 
systems. We found that the solution stability did not correlate with inhibition of platelet 
aggregation or relaxation of vascular smooth muscle. The effect of the structure on activity 
is pronounced; similar structures had different activity profiles (Table 2. 8).
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A close inspection of Table 2.8 indicates that 2-12 (except 6 which was impure) are 
substantially more potent than SNAP in the smooth muscle relaxation bioassay, although 
the chemical environments of the -SNO groups are almost identical. There is an inverse 
correlation between chemical reactivity and biological activity only in the smooth muscle 
relaxation bioassay, a result which provides further evidence that extracellular 
decomposition of 5-nitrosothiols (2-12) to give NO cannot account for all their vasodilator 
effects. It suggests, rather, that the 5-nitrosothiol enters the cell intact, a process controlled 
partly by the lipophilicity of the complete molecule, before decomposition occurs or 5- 
nitrosated dipeptides interact with tissue components. Also the biological activity of the 5- 
nitrosothiols (1-13) in the platelet aggregation assay does not coiTelate with their chemical 
stability.
Unlike acidified nitrite, where biological activity is due to NO (Furchgott, 1988), the 
activity of 5-nitrosothiols is not due to the generation of NO in solution. These results are 
consistent with previous reports suggesting that 5-nitrosothiols do not act by releasing NO 
in solution. For example, the relaxation of smooth muscle by 5-nitrosothiols was shown to 
be enhanced by cysteine (Askew et a l, 1995a&b) and superoxide dismutase and inhibited 
by A-acetyl-D,L-penicillamine, agents that had the opposite effect on 5-nitrosothiol 
degradation (Kowaluk and Fung, 1990a&b), indicating that spontaneous liberation of NO 
was not responsible for the vascular activity of these compounds.
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TABLE 2. 8
The correlation between structure, chemical stability, and physiological activity
Compound Number
Relative Rate of 
Decomposition
(^ 5-Nitrosothio/^ GSNo) *
Smooth Muscle 
Relaxation 
ED5 0  (|X M)
Inhibition of Platelet 
Aggregation 
IC5 0  (p M)
SNAP (1) 2000 2 0 4.4
2 132 4 1.8
3 64 3.5 4.1
4 64 3 4.1
5 64 1.5 4.6
6 68 45 7.1
7 248 10 5.3
8 68 4.5 6.2
9 insoluble in the buffer 9.5 2.7**
1 0 100 5 1.9
1 1 112 0.8 2 . 8
1 2 172 2 3.2
GSNO (13)* roriTAi — To/ 1 0.9 1.3
[Cu] = [added Cu] + [Cu present in the buffer]
** The stock solution was the drug dissolved in DMSO, because the drug is insoluble in the buffer.
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Relaxation of vascular smooth muscle by a variety of agents, including 5-nitrosothiols, is 
believed to be due to stimulation of soluble GC (Ignarro and Kodowitz, 1995). Elevated 
cGMP levels may also regulate tone in nonvascular trached smooth muscle (Katsuki and 
Murad, 1977b) and may be involved in platelet aggregation (Mellion et al., 1981). 
Inhibition of GC using methylene blue (Ignarro et al., 1981 a&b) and N- 
methylhydroxylamine (Gibson et al., 1992) blocks the activity of 5-nitrosothiols. Thus, all 
of the actions of 5-nitrosothiols (1-13) that we have reported here, could be explained by 
stimulation of soluble GC. However, the biological activity of the 5-nitrosothiols in the 
smooth muscle relaxation assays and in the platelet aggregation assay does not correlate 
with the ability to stimulate platelet soluble GC. This suggests that additional factors are 
important in determining activity in these systems.
The stimulation of soluble GC in these systems could occur either directly or indirectly via 
NO release. Direct stimulation would require that the intact 5-nitrosothiols enter the cell and 
activate GC, perhaps by transnitrosation of the active site haem moiety to form catalytically 
active NO haem (Ignarro, 1990). Alternatively, once inside the cell, the 5-nitrosothiols 
could liberate NO to stimulate GC. Although the ability of 5-nitrosothiols to cross 
membranes is not known, some of the 5-nitrosothiols examined here, such as SNAP (1) 
and GSNO (13), would not be expected to be able to enter cells easily. From our results 
we suggest that the ability of 5-nitrosothiols to cross membranes and enter cells is required 
for activity.
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2. 6. The Role of L-Ascorbic Acid (Vitamin C) in the
Breakdown of S-Nitrosothiols in vitro and in vivo
L-Ascorbic acid (vitamin C) is a water-soluble vitamin, although it does not function as a 
coenzyme in the manner of the B vitamins. Like vitamin E, the role of vitamin C in 
nutrition is still a subject of uncertainty. Whereas vitamin E protects the lipid portion of 
cells, vitamin C (a highly polar compound) serves as an antioxidant in the aqueous regions. 
Vitamin C participates in several biological oxidation reactions, such as the hydroxylation 
of proline and lysine moieties in collagen. It reacts with oxygen and/or oxidising agents to 
form dehydroascorbic acid (Scheme 2. 17; Baum, 1987).
In 1747, James Lind discovered that citrus fruit was effective in treating sailors suffering 
from scurvy, a weakening of the collagenous tissues. The symptoms are swollen gums, 
loose teeth, sore joints, bleeding under the skin, and slow healing of wounds. It was not 
until 1932, however, that the vitamin was isolated from citrus fruit. Vitamin C was the first 
dietary component to be recognised as essential for preventing a human disease (Baum, 
1987).
The controversy surrounding vitamin C received extra impetus in 1970, when Linus C. 
Pauling published his best-selling book. Vitamin C and the Common Cold. He stated that 
vitamin C in doses ranging from 1 to 5 g a day could prevent colds and that as much as 15 
g a day could cure a cold. Scientists investigating Pauling's claims have obtained 
conflicting results and the RDA of vitamin C for adults is 60 mg (Baum, 1987).
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Some scientists report that taking 1.5 g of vitamin C every half hour over a period of 2 
hours can cure a cold. Others concede that this may be true for a small group of the 
population. However, as one researcher puts it " For the remainder of the population, 
vitamin C is relatively or completely ineffective in curing the common cold, since large- 
scale controlled studies have been quite unimpressive" (Baum, 1987).
There have also been claims that vitamin C can prevent cancer and that it is useful in the 
therapy and management of cancer patients. Its role in cancer/cold prevention is related to 
its supposed stimulation of the immune system and its activity as an antioxidant in 
suppressing the damage caused by free radicals and in blocking the formation of 
nitrosamines. There is as yet no concrete evidence to substantiate or to invalidate these 
claims (Baum, 1987).
Since vitamin C is water soluble, excess is excreted rather than being stored in the body. 
However, some scientists point to the possible dangers of taking massive doses of this 
vitamin. Such doses, for example, may raise the uric acid level in body fluids and thus 
cause gout in people predisposed to this disease. Also, it is known that the ingestion of 5 g 
of ascorbic acid by the normal adult human will cause dianhoea (Baum, 1987).
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Plants and animals, except guinea pigs and primates (including man), can synthesise 
ascorbic acid from D-glucose. The enzyme which is missing in the species that are unable 
to produce the ascorbic acid is L-gulonoxidase, which converts L-gulonolactone to 3-keto- 
L-gulonolactone (Conn and Stumpf, 1976):
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Scheme 2. 16: Synthesis of ascorbic acid from D-glucose.
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The absence of ascorbic acid in the human diet gives rise to scurvy, a disease characterised 
by oedema, subcutaneous hemorrhages, anemia, and pathological changes in the teeth and 
gums. The disease was known to the ancients, especially among sailors, who often 
travelled for extended periods of time away from sources of fresh fruits and vegetables that 
were known to prevent scurvy (Conn and Stumpf, 1976).
A primary characteristic of scurvy is a change in connective tissue. In ascorbic acid 
deficiency, the mucopolysaccharides of the cell ground substance are abnormal in 
character, and there are significant changes in the nature of the collagen fibrils that are 
formed. The presence of ascorbic acid is required for the formation of normal collagen in 
experimental animals. At the enzyme level, there is an induction that ascorbic acid is 
involved in the conversion of proline to hydroxyproline, an amino acid found in relatively 
high concentrations in collagen (Conn and Stumpf, 1976).
The biochemical role which ascorbic acid plays is undoubtedly related to its being a good 
reducing agent. Its oxidized form, dehydroascorbic acid, is capable of being reduced again 
by various reductants including glutathione (GSH), and the two forms of ascorbate 
constitute a reversible oxidation-reduction system ( Scheme 2. 17; Conn and Stumpf, 
1976).
In the case of collagen formation, ascorbic acid can function as the external reductant that is 
required in the conversion of proline to hydroxyproline. Ascorbic acid can function as an 
external reductant in the hydroxylation of /?-hydroxyphenylpyruvic acid to homogentisic 
acid in the liver and in the conversion of dopamine to norepinephrine that occurs in the 
adrenals. Moreover, guinea pigs that aie maintained on an ascorbic-acid-deficient diet will 
excrete p-hydroxyphenylpymvic acid in their urine.
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Scheme 2.17: The biochemical role of ascorbic acid.
Thus, it appears that the biochemical role of ascorbic acid is related to its involvement in 
hydroxylation reactions in the cell. It is interesting in this connection that the highest 
concentrations of ascorbate in animal tissues are found in the adrenals (Conn and Stumpf,
1976).
The aim of the work described in Section 2.6 (2. 6. 1 & 2. 6. 2) was to elucidate the role of 
L-ascorbic acid (vitamin C) in the breakdown of 5-nitrosothiols in vitro and in vivo.
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2. 6. 1. The Effect of L-Ascorbic Acid on the Decomposition of
S-Nitrosothiols in vitro
Addition of L-ascorbic acid enhanced the decomposition of S-nitrosothiois. Figures 2. 63 
and 2. 64 show the effect on the decomposition rate of adding L-ascorbic acid (Dasgupta et 
a/., 1996).
Figure 2. 63 shows the following behaviour: (a) at low L-ascorbic acid concentrations the 
rate becomes dependent on the L-ascorbic acid concentration, and (b) at high L-ascorbic 
acid concentrations the rate becomes independent of the L-ascorbic acid concentration. 
Therefore, addition of more L-ascorbic acid will not increase the rate of the GSNO 
decomposition. This behaviour is similar to the copper ion catalysed S-nitrosothiol 
decomposition.
0 . 4
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T i m e  /  s
6 0 0 0 8 0 0 0
Figure 2. 63: Absorbance-time plots for the reaction of GSNO (6.0 x 10"  ^mol dm"3) in the presence of added ascorbic acid at pH = 7.4, 340 nm, and 30 °C,
(a) no added ascorbic acid (square), (b) 6.0 x 10“5 mol dm"3 ascorbic acid (diamond), (c) 
3.0 X 10~4 mol dm"3 ascorbic acid (segmented diamond), (d) 6.0 x 10"4 mol dm"3 ascorbic 
acid (triangle), (e) 9.0 x 10"4 mol dm"^ ascorbic acid (circle), (f) 1.5 x 10"3 mol dm"^ ascorbic acid (segmented square).
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Figure 2. 64: Plots of In (AfAoo) versus time for the decomposition of GSNO (6,0 xlO" 
5 mol dm"3) in the presence of added ascorbic acid at pH = 7.4, 340 nm, and 30 °C.
(a) 6.0 X 10"5 mol dm"^ ascorbic acid (square), (b) 3.0 x 10"'^  mol dm'^ ascorbic acid 
(diamond), (c) 6.0 x 10"4 mol dm'3 ascorbic acid (circle), and (d) 9.0 x 10”^  mol dm~3 
ascorbic acid (triangle), (e) 1.5 x 10’  ^ mol dm“3 ascorbic acid (segment square), (r = 
1.000, 0.998, 1.000, 0.999, and 0.999 respectively).
On the other hand, addition of L-ascorbic acid and EDTA reduces the decomposition of 5- 
nitrosothiols compared with that caused by L-ascorbic acid only. Figures 2. 65 and 2. 66 
show the effect on the decomposition of adding L-ascorbic acid and EDTA. The rate of 
GSNO decomposition in the presence of L-ascorbic acid and EDTA decreases by a factor 
of two compared with the GSNO decomposition in the presence of L-ascorbic acid only 
(Figure 2. 67 and Table 2. 9). This means that the EDTA must remove most of the metal 
ions in the buffer. From the previous Figure it is seem that, at low L-ascorbic acid 
concentration the reaction was first order with respect to L-ascorbic acid, at high L-ascorbic 
acid concentration the reaction was zero order with respect to L-ascorbic acid.
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Figure 2. 65: Absorbance-time plots for the reaction of GSNO in the presence of EDTA 
([GSNO] = [EDTA]; 6.0 x lO"  ^mol dm"^) and varying concentrations of added ascorbic 
acid at pH = 7.4, 340 nm, and 30 °C. (a) 6.0 x 10"  ^mol dm"3 ascorbic acid (square), (b) 
3.0 X 10"4 mol dm"3 ascorbic acid (diamond), (c) 6.0 x 10“^  mol dm"^ ascorbic acid 
(circle), (d) 9.0 x 10'^ mol dm"^ ascorbic acid (segmented square), (e) 1.5 x 10“3 mol dm" 
3 ascorbic acid (triangle).
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Figure 2. 66: Plots of In (AfAoo) versus time for the decomposition of GSNO in the 
presence of EDTA ([GSNO] = [EDTA]; 6.0 x 10"  ^mol dm"^) and varying concentrations 
of added ascorbic acid at pH = 7.4, 340 nm, and 30 °C. (a) 6.0 x 10"  ^mol dm"3 ascorbic 
acid (square), (b) 3.0 x 10"  ^mol dm"^ ascorbic acid (diamond), (c) 6.0 x 10"  ^mol dm"^ 
ascorbic acid (circle), (d) 9.0 x 10""^  mol dm"^ ascorbic acid (triangle), and (e) 1.5 x 10"  ^
mol dm"3 ascorbic acid (segment square), (r = 0.997, 1.000, 0.999, 0.999, and 0.999 respectively).
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Figure 2. 67: First order rate constants (k) for the reaction of GSNO (6.0 x 10"  ^ mol 
dm-3) at pH = 7.4, 340 nm, and 30 T  (a) No added EDTA , and (b) Added EDTA (6.0 x 
10-5 mol dm'3) as a function of added ascorbic acid.
From the primary previous results, we suggest two possible mechanisms of 6"-nitrosothiol 
decomposition by L-ascorbic acid. The first one involves the reduction of Cu^+ by L- 
ascorbic acid to Cu'*'. Details are reproduced below (Scheme 2. 18). The second one 
involves electron-transfer from L-ascorbic acid to RSNO to give dehydroascorbic acid and 
5-nitrosothiol radical anion [RSNO]-. Details are also reproduced below (Scheme 2. 19).
At this stage it is difficult to decide if either of these mechanisms functions in vivo. In the 
human body many chemicals and enzymes function and it is very difficult to decide which 
one is favoured.
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TABLE 2. 9
First order rate constants {k) for the decomposition of GSNO (6.0 xlO~5 mol dm“^ ) 
in the absence and in the presence of EDTA (6.0 x 10"5 mol dm"^) and various concentrations of added ascorbic acid at pH = 7.4, 340 nm, and 30
[GSNO] : [ascorbic acid]
Rate Constant x lO"  ^/s'* 
No Added EDTA
Rate Constant x 10 “'^/s'i 
Added EDTA
1: 1 2.0 1.0
1 :5 4.8 2.0
1: 10 4.1 2.3
1: 15 4.7 2.6
1:25 4.7 2.3
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Scheme 2. 18: The proposed mechanism of 5-nitrosothiol decomposition by L-ascorbic acid (vitamin C; mechanism A).
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Scheme 2. 19; The proposed mechanism of S'-nitrosothiol decomposition by L-ascorbic acid (vitamin C; mechanism B).
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According to the first mechanism (mechanism A; Scheme 2. 18) at pH 7.4 L-ascorbic acid 
will be converted into the corresponding ascorbate which will react with (present in 
the buffer) to give the ascorbate diradical (dehydroascorbic acid) and Cu+. Cu+ will then 
react with the 5-nitrosothiols as described previously.
According to the second mechanism (mechanism B; Scheme 2. 19) at pH 7.4 L-ascorbic 
acid will converted into the corresponding ascorbate which will react with 5-nitrosothiol by 
an electron-transfer mechanism to give the ascorbate diradical and 5-nitrosothiol radical 
anion [RSNO]^.The S-nitrosothiol radical anion [RSNO]  ^will be converted directly into the 
corresponding thiolate (RS") and nitric oxide.
Due to the effect of EDTA on the ascorbic acid catalysed reaction, the experimental 
evidence is consistent with the first mechanism. Thus, L-ascorbic acid could play a role in 
the in vivo release of NO from naturally occurring ^'-nitrosothiols and could be 
responsible, in part, for the biological activity of the endogenous 5-nitrosothiols. We 
suggest that the role of L-ascorbic acid in the decomposition of 5-nitrosothiols is as a 
reducing agent for Cu^+ which is present in vivo.
2. 6. 2. The Effect of L-Ascorbic Acid on the Decomposition of 
S-Nitrosothiols ex vivo
Here we will study the effect of L-ascorbic acid on smooth muscle relaxation and platelet 
aggregation.
2. 6. 2. 1. The Effect of L-Ascorbic Acid on Smooth Muscle 
Relaxation
The effect of L-ascorbic acid on the activity o f GSNO (13) ex vivo was investigated using 
L-ascorbic acid and GSNO with rat tail artery as target cells. In vitro, GSNO decomposes 
rapidly to the corresponding disulphide and NO in the presence o f L-ascorbic acid. So, we 
were not able to study the ex vivo action of bolus injections o f the drug and L-ascorbic acid 
premixed before injection.
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Therefore, the ex vivo vasodilation action of bolus injections of GSNO was studied with L- 
ascorbic acid in the internally perfused Krebs buffer supply (Figure 2. 68). The effect of L- 
ascorbic acid on the action of GSNO was not great (Figure 2. 69).
GSNO
GSNO alone and vessels perfused Internally with Krebs solution containing 
vitamin 0  (10'"^  M)
Figure 2. 68: Pressure recordings showing the vasodilator effects of 10 pi
microinjections o f GSNO (10"^ - 10“^  M) in the absence and presence of L-ascorbic acid 
(vitamin C).
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Figure 2. 69; Log dose-response curves comparing the vasodilator effects of 10 pi bolus 
injections of GSNO; 13. Filled symbols show responses in the absence of L-ascorbic acid and open symbols show responses in the presence of L-ascorbic acid (100 pM). Paired t- tests were carried out to determine the statistical significance of responses to 13 in the presence of L-ascorbic acid compared to those of GSNO. (*= P<0.05, **= P<0.01, ***= 
P<0.001).
The ED5 0  value for microinjection of GSNO was found to be approximately the same in the 
absence and in the presence of 10'^ M L-ascorbic acid (Figure 2. 69). As GSNO has 3-5 
seconds to react with L-ascorbic acid before reaching the artery, it is reasonable to suppose 
that it decomposes to the corresponding disulphide and NO.
From our results, we conclude that L-ascorbic acid has no significant role in vasodilation.
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2. 6. 2. 2. The effect of L-ascorbic acid on platelet aggregation
The effect of L-ascorbic acid on the activity of GSNO (13) ex vivo was investigated using 
human platelets as target cells.
We found that L-ascorbic acid had no significant effect or only a very small effect on the 
anti-aggregation action of GSNO. The IC5 0  value for microinjection of GSNO was found 
to be approximately the same in the absence and in the presence of 10"4 M L-ascorbic acid 
(IC5 0  = 2.4 pM (no added vitamin C), and IC5 0  = 2 . 1  pM (added vitamin C); Figure 2 . 
70).
This, may be due to the following reasons:
a) The concentration of L-ascorbic acid in the human platelet is high already. Therefore, 
addition of 2 pi L-ascorbic acid (10"^ M) will not increase the concentration of L-ascorbic 
acid in the human platelet that much.
b) From the kinetics results, we found that at high concentration of L-ascorbic acid the rate 
becomes independent of the L-ascorbic acid concentration, which means addition of more 
L-ascorbic acid will not increase the rate of the decomposition.
From our results, we conclude that L-ascorbic acid has no significant role in inhibition of 
platelet aggregation.
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Figure 2.70: Inhibition of collagen-induced platelet aggregation by GSNO.
(a) added vitamin C (10"'  ^M; half filled square).(b) no added vitamin C (square).
The work in this section is preliminary. Therefore, more experiments in vitro and in vivo 
should be carried out to give a clear picture about the mode of action of L-ascorbic acid in 
vivo.
174
2. 7. Detection of NO to Show that 5-N ltrosothiols are NO- 
Donor Drugs
Here we describe efforts to detect NO by three methods to show that 5-nitrosothiols are 
NO-donor drugs. The first method is the use of an ISO-NO sensor, the second method is 
addition of haemoglobin (Hb) to the internal perfusate of smooth muscle, and the third 
method is addition of Hb to the platelet suspension.
a) Evidence from NO-Probe
We detected nitric oxide from the decomposition of S-nitrosothiols (1-13) using the NO- 
probe electrode system when the reaction was carried out anaerobically. Yields of more 
than 70% have been noted for the more reactive S-nitrosothiols (e.g. SNAP) but the yield 
was always far from quantitative. However, as yet we have not taken steps to minimise the 
loss of NO to the headspace and by oxidation and hydrolysis to nitrite (Wink et a l, 1993), 
so that for the slower reacting compounds (2-13) this loss is a major competitor. Figure 2. 
71 shows the response of an ISO-NO sensor (2 mm) to NO released from GSNO, one of 
the less reactive 5-nitrosothiols in our series (0.5 x 10“^  mol dm"^) catalysed by L-ascorbic 
acid (0.5 x 10“3 mol dm“3) under aerobic conditions at pH = 7.4 and at RT. In the presence 
of oxygen, however, the final product is nitrite ion. Separate experiments using only nitric 
oxide solutions under aerobic conditions have confirmed (Wink et al, 1993) that nitrite ion 
is the only product. The rationalisation of this is given by the following equations:
2 NO + Og  ----------------- ► 2 NO2
NO2 + NO   ^  NgOg
N2O3 + 20H ^  2N0g + HgO
Nitric oxide is oxidised to nitrogen dioxide which, in turn, reacts with more nitric oxide to 
give dinitrogen trioxide. In aqueous solution at pH = 7.4 this is converted into nitrite 
anion.
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Figure 2. 71; The response of an ISO-NO sensor (2 mm) to NO released from GSNO 
(0.5 X 10"3 mol dm"3) by L-ascorbic acid (0.5 x lO"  ^mol dm"^) in aerobic conditions at pH 
= 7.4 and at RT.
b) Evidence from Smooth Muscle Relaxation
The ability of NO to bind to free coordination sites of iron complexes has important 
implications in biology. The formation of such nitrosyl complexes may result to activation / 
inhibition of enzymatic systems containing iron centers.
One well-known example is deoxyhaemoglobin which binds NO with a much greater 
affinity than O2 and CO (Traylor and Sharma, 1992):
HbFe(ll) + NO HbFe(ll) (NO)
HbFe(ll) (NO) + Og HbFe(lll)
Nitrosylhaemoglobin is paramagnetic and can be easily detected by EPR spectroscopy at 77 
K. This offers a very convenient method for the spin trapping of NO (Henry et al., 1991).
176
The iron centre is oxidized in the presence of oxygen. Methaemoglobin is formed together 
with nitrite and nitrate. It should be noted that, unlike O2 , NO binds to both iron(II) and 
iron(III) porphyrin. The great reactivity of NO towards haemoglobin suggests that in red 
blood cells NO will be rapidly converted into NO3" and eliminated.
In this research, the inhibitory effect of Hb, a recognised NO scavenger, was investigated. 
Addition of Hb to the internal perfusate produced a rapid rise in pressure. Injections of 
drugs in the presence of Hb are still capable of producing substantial vasodilator responses. 
Responses to intermediate doses of 5-nitrosothiols were significantly inhibited by Hb, 
though not abolished entirely. It is possible, therefore, that only part of 5-nitrosothiols- 
induced vasodilation is due to NO released in solution in the lumen. The Hb-resistant 
element of vasodilator responses to 5-nitrosothiols may be due either to an NO-independent 
mechanism, or to 'cross-nitrosation' of 5-nitrosothiols with membrane-bound or 
intracellular thiols. In the latter case, free NO would not exist as a single entity outside the 
tissue and would be resistant to Hb inactivation.
Exogenous Hb, which binds NO extracellularly, has been used as a classic probe of NO 
generation in the extracellular space (Martin et a l, 1985; Ignarro, 1989a&b). Typical traces 
showing the effect of perfusing ferro-haemoglobin (Hb, 15 |liM) through the internal 
circuit, on SNAP (1), (2), and GSNO(13) vasodilation responses are shown in Figure 2. 
41. Ferro-haemoglobin reduced the ED5 0  value for SNAP (1) by a factor of 10 only, by 
different factors of 70 to 200 for 2-12 whereas that for GSNO (13) is reduced by a factor 
of 200 (Table 2. 10, and Figures 2. 42 - 2. 54 respectively). These results are consistent 
with the finding that SNAP is less stable than GSNO in solution and suggest that SNAP 
does not require tissue to release NO, decomposing, at least in part, in the lumen. The 
vasodilator actions of SNAP (1), 2-12, and GSNO (13) are only partially inhibited by 15 
pM Hb. This suggests that a significant percentage of each drug reaches the vascular 
smooth muscle cells before releasing NO, probably at the membrane surface (Kowaluk and 
Fung, 1990a&b).
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TABLE 2. 10
A comparison of the vasodilator effectiveness of SNAP, 2 12, and GSNO on rat tail arteryin the absence and presence of 15 pM Hb (the vasodilator actions of 5-nitrosothiols are only partially inhibited by 15 pM Hb)
Compound Number ED5 0  (pM) 
no added Hb
ED5 0  (pM)
15 jxM added Hb
SNAP (1) 2 0 223
2 4 272
3 3.5 223
4 3 223
5 1.5 2 0 2
6 45 332
7 1 0 90
8 4.5 223
9 9.5 165
1 0 5 406
1 1 0 . 8 165
1 2 2 182
GSNO (13) 0.9 182
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c) Evidence from Inhibition of Platelet Aggregation
From our results, we found that the inhibitory activity of these 5-nitrosothiols was reversed 
by haemoglobin, indicating the involvement of NO in the process.
2. 8. Do S-Nitrosothiols Decompose Inside or Outside the Cell?
From our in vitro experiments, we found that the 5-nitrosated amino acid (1) was less 
stable than 5-nitrosated dipeptides (2-12), and the latter were less stable than the 5- 
nitrosated tripeptide (13). This means that, by increasing the molecular size, the chemical 
stability is increased.
From a chemical point of view, SNAP (1), and GSNO (13) were less lipophilic than 5- 
nitrosated dipeptides. On the other hand, GSNO is said to be more lipophilic than SNAP. 
GSNO is more bulky, more polar, and more ionic than SNAP, which suggests that SNAP 
may enter the cell more easily than GSNO. If 5-nitrosothiols decompose before entering 
the cell, we would expect that SNAP will be more effective in biological assays than 5- 
nitrosated dipeptides, and the latter will be more effective than GSNO, but this not 
observed. Moreover, if 5-nitrosothiols decompose after entering the cell we expect that 5- 
nitrosated dipeptides would be more effective than SNAP and the latter more effective or 
similar to GSNO.
From our results, we found that the latter expectation is more likely. Furthermore, the 
polar, and probably the ionised nature of SNAP and GSNO at physiological pH, makes it 
unlikely that they would traverse cell membranes readily, which supports this hypothesis.
So 2-12 are substantially more potent than SNAP although the chemical environment of 
the -SNO groups are almost identical. Thus, there is an inverse correlation between 
chemical reactivity and biological activity, a result which provides further evidence that 
extracellular decomposition of 5-nitrosothiols to give NO cannot account for its vasodilator 
effect. It suggests, rather, that the 5-nitrosothiol enters the cell intact, a process controlled 
partly by the lipophilicity of the complete molecule, before decomposition occurs.
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There are three possibilities for the decomposition of 5-nitrosothiols inside or outside the 
cell:
(a) the differences in effectiveness are possibly due to the rate of NO generation at the cell 
surface, due to differences in the ability of different tissues to catalyse RSNO 
decomposition,
(b) the target cell may have a transport system that could allow entiy of a specific RSNO 
into the cell making it more effective on the tissue than on another tissue in which it is not 
transported, and
(c) 5-nitrosothiols enter the cell first, then 5-nitrosothiols decompose by one of the 
previous mechanisms (Section 2. 2 and 2.6), and this possibility depends upon the 
lipophilicity of the RSNO.
SNAP can spontaneously release NO without the presence of tissue. 5-Nitrosated 
dipeptides (2-12) may release NO in the presence of tissue, because they show that they 
are more effective than SNAP and also they are more stable (Section 2. 4. 1).
The response of 5-nitrosated dipeptides and GSNO is not completely abolished by ferro- 
haemoglobin and a significant percent of the drug, or 'bound NO' from interaction of 
SNAP with tissue such as the endothelium, reaches the vascular smooth muscle cells.
From our results, we suggest that 5-nitrosothiols which are polar, ionic, and can 
spontaneously release NO may decompose before entering the cell or at the cell surface. 5- 
Nitrosothiols which are less polar, not ionic, lipophilic, and cannot spontaneously release 
NO may decompose inside the cell, or may use a transport system that could allow entry of 
a specific RSNO into the cell. GSNO is more lipophilic than SNAP and it is more likely 
that GSNO decomposes inside the cell by one of the previous mechanisms.
We are forced to conclude that 5-nitrosothiols decompose inside and outside the cell, 
depending upon the structure of RSNO.
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2. 9. A Tissue Selective NO-Donor Drug
Smooth muscle and platelet respond differently to different 5-nitrosothiols. These 
differences are not likely to be related to any intrinsic activity of the R- group of the 
RSNOs, because the starting thiols were inactive in each of the assays. The difference 
could be related to factors such as the agent used to contract the tissue (Rapoport et a l, 
1983a,b&c) or the sensitivity of the different soluble GCs to activation by NO. The 
differences could also be due to variations in the rate of NO generation at the cell surface. 
The difference could even be due to variations in the rate of NO generation inside the cell, 
depending upon the structure of the 5-nitrosothiol. In addition to displaying differences in 
overall sensitivity to 5-nitrosothiols, the various tissues revealed different rank orders of 
activity, indicating that these tissues can somehow distinguish among the various 5- 
nitrosothiols. One possibility is that the cell surfaces in the various tissues differ in their 
ability to catalyse 5-nitrosothiol decomposition. Alternatively, NO release at the cell surface 
is not correct in all cases (Section 2. 8). For example, in some cases the target cell might 
have a transport system that could allow entry of a specific 5-nitrosothiol into the cell, and 
this compound could be very potent in the cell. The same 5-nitrosothiol might be much less 
potent at other tai'get cells which do not have this transport system.
The profile of biological activity of the 5-nitrosothiols that is described here is similar to 
that seen with clinically used vasodilators. This is not suiprising, because 5-nitrosothiols 
have been suggested to be the active metabolites of the nitrovasodilators in the development 
of tolerance. Several reports in the literature indicate that 5-nitrosothiols may not develop 
tolerance (Henry et a l, 1989; Shaffer et a l, 1992; Bauer and Fung, 1991; Kowaluk and 
Fung, 1990a&b). Our findings that the activity of 5-nitrosothiols is not related to their 
chemical stability and that the tissue specificity is a function of the R- group suggest that a 
stable, active 5-nitrosothiol targeted to a specific site may be found. Further research in this 
area may yield useful therapeutic agents.
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2. 10. Conclusion
5-Nitrosothiols are an important class of NO-donor drugs. These compounds are of 
interest because of their potent pharmacological properties and possible physiological role 
in smooth muscle relaxation and inhibition of platelet aggregation.
A series of eleven new 5-nitrosothiols (2-12) derived from dipeptides has been prepared, 
and their chemical properties and physiological effects studied and compared with those of 
SNAP (1), derived from an amino acid, and GSNO (13), derived from a tripeptide. In 
order to look for a correlation between structure, chemical stability and physiological 
activity. Among the thirteen 5-nitrosothiols (1-13) whose structure are depicted in the 
previous Section (Section 2. 1) only SNAP (1) and GSNO (13) have been prepared and 
characterised previously.
The situation has been complicated by the recent discovery that the main route for the 
release of NO from 5-nitrosothiols is a copper (I)-catalysed process. Therefore, we 
examined the effect of copper ions on the stability of the compounds we synthesised.
A detailed kinetic study has shown that the dominant pathway for the decomposition of 5- 
nitrosothiols in most circumstances is one catalysed by Cu+ ions. We suggest that the 
thiolate ion necessary to bring about Cu^+ reduction is either present as a thiol impurity or 
is generated in small quantities by partial hydrolysis of 5-nitrosothiols, which results in an 
induction period. The implications of this discovery for an understanding of the biological 
action of 5-nitrosothiols are discussed.
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In the absence of Cu(I) the 5-nitrosothiols are much more stable. All the new compounds 
examined show less susceptibility to copper (I)-catalysed release of NO than SNAP but are 
more reactive than GSNO. We have found that 5-nitrosated dipeptides are potent 
vasodilators and suitable inhibitor for platelet aggregation but are chemically very stable in 
the absence of copper ions.
All thirteen compounds (1-13) combine the favoured property of chemical stability with a 
high level of biological activity.
However, no correlation was found between the solution stability of the compounds and 
their biological activity, suggesting that other factors may be important. For example, due 
to their thermal instability the compounds are likely to release some NO spontaneously in 
the lumen where it would be susceptible to Hb inactivation. On the other hand, 5- 
nitrosothiols undergoes a process known as 'cross nitrosation' or transnitrosation in the 
presence of -SH-containing compounds, such as cysteine. It is possible, therefore, that NO 
could be 'stripped' from 5-nitrosothiols and then transported into a cell where it may not be 
susceptible to Hb inhibition. Potentially, therefore, 5-nitrosothiols can release NO by 
several mechanisms, only some of which is susceptible to Hb inhibition.
The effect of L-ascorbic acid (vitamin C) on the activity of the 5-nitrosothiols was also 
examined, but was found to be negligible. This may be due to the two factors. Firstly, the 
concentration of L-ascorbic acid in human platelet is already high, and so may not be 
changed very much by the addition of a small amount, and, secondly, the chemical studies 
showed that at high concentrations the effect of the decomposition of the 5-nitrosothiols 
become independent of the L-ascorbic acid concentration, so that an increase in 
concentration will have no effect on the rate.
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All thirteen compounds examined show ability to release NO in vitro. The inhibitory effect 
of Hb, a recognised NO scavenger, was investigated. Responses to intermediate doses of 
5-nitrosothiols were significantly inhibited by Hb, though not abolished entirely. We found 
that the inhibitory activity of these 5-nitrosothiols was reversed by haemoglobin, indicating 
the involvement of NO in the process.
The potency of the compounds studied was found to be very markedly as a function of 
structure, by up to 5 order of magnitude in the platelet aggregation studies, and up to 55 
order of magnitude in the smooth muscle relaxation studies, even though the difference in 
the group R- were relatively small. This suggests that it may be possible to produce a 
stable, active 5-nitrosothiols targeted to a specific site by a suitable choice of the group R.
Overall, then, we conclude that the biological activity of 5-nitrosothiols depends upon the 
release of NO in a process catalysed by Cu(I), and that the decomposition may occur inside 
or outside the cell, depending upon the structure of RSNO.
We found that copper(I) chelation induced reduction of the biological activity of 5- 
nitrosothiols in smooth muscle relaxation. The results show that responses to both SNAP 
and GSNO are reversibly inhibited by neocuproine. We conclude that relaxation of 
vasodilator smooth muscle by SNAP and GSNO is caused in part by NO released into 
solution via a Cu+-dependent catalytic reaction. One may speculate that a similar process is 
involved in the maintenance of a vasodilator 'store' in vivo, in which endogenous Cu(I) 
ions catalyse the decomposition of naturally occurring 5-nitrosothiols.
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It is interesting to compare the results given here with those recently reported by Gordge et 
al (1996), who showed that the inhibition of platelet aggregation activity shown by GSNO 
is much reduced in the presence of neocuproine and the closely related bathocuproine, both 
specific Cu(I) chelating agents, and those of Schrammel et a l  (1996), who showed that 
copper ions inhibit basal and NO-stimulated recombinant soluble guanylate cyclase activity, 
and that Cu(I) is more effective than Cu(II) in this regard.
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2. 11. Scope of Future Work
Due to the importance of NO-donor drugs there are many areas of work which can be 
further researched:
1. The design and synthesis of a new generation of 5-nitrosothiols with the following 
properties:
(a) Stable drugs.
(b) Solid drugs.
(c) Lipophilic drugs.
(d) They can release NO in vivo.
(e) They do not release NO during storage.
(f) With high purity.
2. Initial results in this thesis show that vitamin C has a dramatic effect on the stability of 
GSNO and presumably other 5-nitrosothiols. As vitamin C is present in larger 
concentrations than copper in vivo, a full study of the effect of vitamin C on 5-nitrosothiols 
is needed, in order to understand the role of vitamin C in vitro and in vivo, and to suggest 
the mechanism of action.
3. More work should be carried out using the NO electrode in order to gain more 
quantitative results.
4. Synthesis of 5-nitrosothiols which have alternative metal ion binding sites away from 
the -SNO moiety.
186
5. More studies should be carried out on human blood plasma. This would give a better 
insight into how robust this class of drugs are likely to be in the in vivo situation, and 
whether they are still susceptible to copper catalysis in this more complex media.
6. Initial results presented in this thesis show that the photochemical decomposition of S~ 
nitrosothiols occurs. As laser light could be used to accelerate the endogenous 
decomposition of 5-nitrosothiols.
7. More research into the synthesis of tissue selective drugs to release NO in specific 
tissues.
8. Despite the fact that 5-nitrosothiols are potent mediators of NO signalling, the 
mechanism(s) by which they donate NO and alter cellular function are poorly understood. 
More experiments in vivo should be carried out in order to increase our knowledge of these 
exogenous 5-nitrosothiols.
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In tHis chapter, loe descriSe in detail the various methods employed in our zi>orl<i, These iîu^ lude 
instrumental, synthetic, pharmacological and physiological procedures.
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3. 1. Chemicals
The following is a list of chemicals and materials used throughout this work: A-cyclohexyl- 
A'-2-[A-morpholino]ethylcarbodiimide metho-p-toluenesulphonate (Aldrich), r-butyl nitrite 
(Aldrich), A-acetyl-D,L-p,p-dimethylcysteine (Sigma), glycine methyl ester hydrochloride 
(Sigma), L-alanine methyl ester hydrochloride (Sigma), L-valine methyl ester hydrochloride 
(Sigma), L-leucine methyl ester hydrochloride (Sigma), L-phenylalanine methyl ester 
hydrochloride (Sigma), L-isoleucine methyl ester hydrochloride (Sigma), L-methionine 
methyl ester hydrochloride (Sigma), Ag-CBZ-L-lysine methyl ester hydrochloride (Sigma), 
L-proline methyl ester hydrochloride (Sigma), L-aspartic acid dimethyl ester (Sigma), L- 
glutamic acid dimethyl ester (Sigma), and L-glutathione (Sigma). They were used without 
purification. Dichloromethane was distilled from CaH2  prior to use (Vogel, 1989). Dry 
diethyl ether was distilled before use (Vogel, 1989). Dimethyl sulfoxide (DMSO; Sigma- 
Aldrich Chemicals) was HPLC grade (99.9%). Neocuproine, sodium nitroprusside, 
phenylephrine and haemoglobin were obtained from Sigma Ltd. Krebs and Henks solution 
components were obtained from BDH and were Aristar grade. LNMMA was a gift from Dr 
Harold Hodson of the Wellcome Research Laboratories, Beckenham, Kent. Compounds 
were dried in vacuo over self-indicating silica gel. All the buffer components for the 
kinetics and chemical stability studies were Aristar grade.
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3. 2. Instrumentation
Melting points were determined on a capillary apparatus (Gallenkamb). Elemental analyses 
were carried out using an Elemental Analyzer Mod. 1106 (CARLO ERBA 
STRUMENTAZIONE). IR spectra were recorded on a Perkin-Elmer 1710 (Infrared 
Fourier Transform Spectrometer). UV-Visible spectra were recorded on a Phillips PU8700 
UV-Visible scanning spectrophotometer. IH-NMR spectra were recorded at 300 MHz on a 
Bmker AM300. 1%-, DEPT 90°-, and DEPT 135°-NMR spectra were recorded at 75 MHz 
on a Bruker AM300. All chemical shifts (Ô) are reported in parts per million (ppm) 
reference to TMS and coupling constants (7) are quoted in Hz. FAB-Mass spectra were 
recorded on a VG Auto Spec. (FISONS Instruments) run in 3-nitrobenzyl alcohol. The a 
apparatus used for perfusing isolated segments of rat tail artery is described in Section 3.3.
4. 1. All platelet aggregation studies were performed in a Platelet Aggregation Profiler, 
Blood Platelet Counter (COULTER T-540), and lEC Centra-3C Centrifuge. The NO- 
sensitive electrode was obtained from World Precision Instruments. Measurements of pH 
were measured using a Digital pH Meter (Griffin).
3. 3. Experimental Procedures
In this section, we will describe the following procedures: synthesis of the dipeptides, 
synthesis of the 5-nitrosothiols, chemical stability of the 5-nitrosothiols, pharmacological 
and physiological activity, the effect of L-ascorbic acid, trapping the thiyl radical and 
detection of NO from 5-nitrosothiols.
3. 3. I. Synthesis of the Dipeptides
(i). Procedure A (Bodanszky and Bodanszky, 1984):
A solution of the amino acid methyl ester hydrochloride (50 mmol) in water (40 cm^) was 
treated with a solution of potassium carbonate (72 mmol) in water (20 cm^) and the mixture 
was extracted with methylene chloride (3x50 cm^). The methylene chloride extracts were 
combined, dried over magnesium sulphate and the solvent removed under moderately
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reduced pressure. The residue (about 40 mmol) was added to a suspension of V-acetyl- 
D,L-p,p-dimethylcysteine (20 mmol) in purified dichloromethane (100 cm^) followed by the 
addition of iV-cyclohexyl-V '-2-[iV-morpholino]ethylcarbodiimide metho-/?- 
toluenesulphonate (20 mmol). A precipitate of the urea derivative started to separate almost 
immediately and its amount gradually increased. After one day at room temperature the urea 
derivative was removed by filtration and washed with dichloromethane (40 cm^). The 
combined filtrate and washing were extracted with a saturated solution of citric acid (60 
cm^), a saturated solution of potassium hydrogen carbonate (60 cm^), and water (60 cm^), 
dried over magnesium sulphate and evaporated to dryness in vacuo. The residue was 
dissolved in dry diethyl ether; scratching of the walls with a glass rod induced 
crystallization of the dipeptide. The crystalline solid was collected by filtration, washed 
with cold dry diethyl ether and dried. The desired dipeptides were formed in moderate 
yields (~ 25%; data are shown in Table 3.1). The dipeptide was used for the next step 
without hirther purification.
(ii). Procedure B (Bodanszky and Bodanszky, 1984):
A solution suspension of A-acetyl-D,L-p,p-dimethylcysteine (20 mmol) in purified 
dichloromethane (50 cm^) was cooled in an ice-water bath and treated with A-cyclohexyl- 
A^-2-[iV-morpholino]ethylcarbodiimide metho-p-toluenesulphonate (20 mmol) and then 
with a solution of the amino acid ester hydrochloride ( 2 1  mmol) and triethylamine ( 2 0  
mmol) in purified dichloromethane (50 cm^). StiiTing was continued at 0“C for about an 
hour and then at room temperature for one day. A precipitate of the urea derivative started 
to separate almost immediately and its amount gradually increased. After one day at room 
temperature the urea derivative was removed by filtration and washed with dichloromethane 
(40 cm^). The combined filtrate and washing were washed with a saturated solution of 
citric acid (60 cm^), a saturated solution of potassium hydrogen carbonate (60 cm^), and 
water (60 cm^), dried over magnesium sulphate and evaporated to dryness in vacuo. The 
residue was dissolved in dry diethyl ether; scratching of the walls with a glass rod induced 
crystallization of the dipeptide. The crystalline solid was collected by filtration, washed
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with cold solvent and dried. The desired dipeptides were formed in moderate yields (~ 
25%; data are shown in Table 3.1). The dipeptide was used for the next step without 
further purification.
The dipeptides were characterised by IR, and DEPT 90“ and DEPT 135“-NMR 
spectroscopy. Accurate mass determinations of the molecular ion peaks were obtained only 
by the use of high resolution FAB-MS but not by other techniques. Melting points, 
elemental analyses, and other data are shown in Table 3.1.
Notes:
(i) Preferably freshly distilled solvents were used.
(ii) The free amino acid ester was not stored: it is gradually transformed into the 
diketopiperazine.
(iii) Use of a water soluble carbodiimide ensures that the product is not contaminated with 
urea.
3. 3. 2. Synthesis of the S-Nitrosothiols (Nitrosation Reaction)
In this work, 5-nitrosothiols were prepared by three different methods depending upon the 
structure of the thiol.
(a) S-nitrosated amino-acid
5-Nitroso-iV-acetyl-D,L-p,p-dimethylcysteine (SNAP; 1) was prepared as a pure solid by a 
modified literature procedure (Royle et a i, 1983) in high yield (81%). A solution of N- 
acetyl-D,L-|3,p-dimethylcysteine (383 mg, 2.00 mmol) in 15 cm^ of acetone and 1 cm^ of 
water was treated with 2.0 cm^ of r-butyl nitrite. After 30 min., the red solution was 
evaporated to remove the 15 cm^ acetone, then additon of water, and the green solid was 
separated off, filtered, washed well with water and then dried under vacuum (355 mg ,
1.61 mmol, 81%).
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(b) S-nitrosated dipeptides
S-Nitrosothiols were synthesised by treatment of the corresponding dipeptide (0.125 
mmol) in methylene chloride (2 cm^) with r-butyl nitrite (1 cm^) at -78 “C. After 30 min., a 
green solution was obtained and evaporated to dryness in vacuo. The residue was 
suspended in diy diethyl ether a suitable and the green solid 5"-nitrosothiol filtered off and 
then dried in vacuo. In case where the product was green sticky solid, the residue was 
suspended in a dry diethyl ether (Table 3. 2), then decanted and the rest of the solvent 
removed by evaporation to dryness in vacuo. The 5-nitrosothiols (2-12) were obtained in 
high yields (greater than 80%) and data are shown in Table 3.2.
(c) S-nitrosated tripeptides
5'-Nitroso-L-glutathione(GSNO) was synthesised according to Hart's procedure (1985). 
To a stirred ice-cold solution of L-glutathione (1.53 g, 5 mmol) in water ( 8  cm^) containing 
2n HCl (2.5 cm^) was added in one portion sodium nitrite (0.345 g, 5 mmol). After 40 
minutes at 5“C the red solution was treated with acetone (10 cm^) and stirred for a further 
10 minutes. The resulting fine pale red precipitate was filtered off and then washed 
successively with ice-cold water (5x1 cm^), acetone (3 x 10 cm^) and ether (3x10 cm^) 
to afford 5-nitroso-L~glutathione (1.29 g, 3.8 mmol, 76%).
Samples of S-nitrosothiols were chaiacterised by IR (e.g. Figure 2. 2), UV-Visible (e.g. 
Figure 2. 3), ^H (e.g. Figure 2. 4), and (e.g. Figure 2. 5), DEPT 90“ (e.g. Figure 2. 
6 ), DEPT 135“-NMR spectroscopy (e.g. Figure 2. 7). Accurate mass measurements on the 
molecular ion peaks were obtained using high resolution FAB-MS.
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TABLE 3. 1
Characterisation of the dipeptides by m.p., NMR, FAB-MS, and elemental analysis
Depeptides are sometimes difficult to characterise by elemental analyses as small amounts of the disulphide are present which are difficult to remove. Similar compounds were authenticated by Moynihan and Roberts (1994) without elemental analyses.
I. A-acetyl-D,L-p,p-dimethylcysteinylglycme methyl ester*^
m.p. 142 “C (dec.). 6 c (300 MHz; CDCI3 ) 23.24, 28.64, 30.74, 52.31 (CH3 ), 41.12 
(CH2 ), 60.23 (CH), 45.99 (C), 169.87, 170.23, and 170.39 (CO). (Found: m/z (FAB) 
263.1061 (MH+) C10H 19N2 O4 S requires 263.1066 (MH+)). [Found: C, 44.9; H, 6.9; N,
10.6 Calc, for C10H 18N2 O4 S: C, 45.8; H, 6.9; N, 10.7%].
II. A-acetyl-D,L-p,p-dimethylcysteinyI-L-alanine methyl ester*^t$
m.p. 150 “C (dec.). 6 c  (300 MHz; CDCI3 ) 17.58, 17.97, 23.22, 23.27, 28.58, 28.63,
30.50, 31.07, 52.36, and 52.44 (CH3 ), 48.20, 48.23, 60.01, and 60.27 (CH), 46.03, 
and 46.28 (C), 169.38, 169.45, 170.20, 170.32, 172.76, and 172.91 (CO). (Found: m/z 
(FAB) 277.1229 (MH+) C 11H2 1N2 O4 S requires 277.1222 (MH+)). [Found: C, 48.7; H, 
6.7; N, 10.2 Calc, for C11H2 0 N2 O4 S: C, 47.8; H, 7.3; N, 10.1%].
III. A-acetyl-D,L-p,p-dimethylcysteinyl-L-valine methyl ester#
m.p. 174 “C (dec.). 6 c (300 MHz; CDCI3 ) 17.76, 18.08, 19.00, 19.10, 23.22, 23.22, 
28.47, 28.57, 31.27, 31.27, 52.07, and 52.11 (CH3 ), 30.64, 30.93, 57.61, 57.64,
60.18, and 60.18 (CH), 45.88, 46.15 (C), 169.93, 170.03, 170.21, 170.28, 171.68, and 
171.89 (CO). (Found: m/z (FAB) 305.1565 (MH+) C13H2 5 N2 O4 S requires 305.1535 
(MH+)). [Found: C, 51.6; H, 8.0; N, 9.2 Calc, for C13H2 4 N2 O4 S: C, 51.3; H, 7.9; N, 
9.2%].
continued
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rV. iV-acetyl-D,L-p,p-dimcthylcystelnyl-L-leucine methyl ester**tt
m.p. 124 “C (dec.). 8 c (300 MHz; CDCI3 ) 21.61, 21.79, 22.74, 22.81, 23.21, 23.26,
28.50, 28.64, 30.41, 31.06, 52.19, and 52.22 (CH3 ), 40.75, and 41.02 (CH2 ), 24.80, 
24.86, 50.98, 51.09, 60.02, and 60.11 (CH), 46.02, and 46.35 (C), 169.81, 169.85,
170.16, 170.30, 172.80, and 172.93 (CO). (Found: m/z (FAB) 319.1705 (MH+) 
C 1 4H2 7 N2 O4 S requires 319.1691 (MH+)). [Found: C, 53.5; H, 8 .8 ; N, 8 . 8  Calc, for 
C 14H2 6 N2 O4 S: C, 52.8; H, 8.2; N, 8 .8 %].
V. Al-acetyl-D,L-|3,|3-dimethylcysteinyI-L-phenylalanine methyl ester**ft
m.p. 116 "C (dec.). 8 c (300 MHz; CDCI3 ) 23.19, 13.19, 28.42, 28.49, 30.64, 30.81,
52.34, and 52.40 (CH3 ), 37.71, and 37.86 (CH2 ), 53.33, 53.43, 60.30, and 60.30 (CH), 
45.73, and 45.89 (C), 126.99, 127.21, 128.43, 128.54, 128.66, 128.93, 129.20, 
129.32, 135.60, and 135.99 (aromatic carbons), 169.47, 169.53, 170.07, 170.18, 
171.55, and 171.62 (CO). (Found: m/z (FAB) 353.1545 (MH+) C1 7H2 5 N2 O4 S requires 
353.1535 (MH+)). [Found: C, 59.5; H, 7.3; N, 8.1 Calc, for C 17H2 4 N2 O4 S: C, 57.9; H, 
6.9; N, 7.9%].
VI. V-acetyl-D,L-p,p-dimethylcysteinyl-L-lsoleucine methyl ester**tf
m.p. 136 ”C (dec.). 8 c (300 MHz; CDCI3 ) 11.50, 11.59, 15.60, 15.63, 23.23, 23.23, 
28.45, 28.52, 30.62, 31.23, 52.03, and 52.07 (CH3 ), 25.14, and 25.35 (CH2 ), 37.31, 
37.54, 56.79, 56.88, 60.14, and 60.24 (CH), 45.90, and 46.16 (C), 169.78, 169.88, 
170.21, 170.30, 171.69, and 171.84 (CO). (Found: m/z (FAB) 319.1690 (MH+) 
C 1 4H2 7 N2 O4 S requires 319.1691 (MH+)). [Found: C, 52.0; H, 7.5; N, 8.7 Calc, for 
C 14H2 6 N2 O4 S: C, 52.8; H, 8.2; N, 8 .8 %].
continued
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VII. V-acetyl-D,L-p,p-dimethylcysteinyI-L-methionine methyl ester*#t$
m.p. 128 “C (dec.). 6 c  (300 MHz; CDCI3 ) 15.40, 15.40, 23.24, 23.29, 28.44, 28.65,
31.12, 31.20, 52.46, and 52.48 (CH3 ), 30.00, 30.09, 30.59, and 31.04 (CH2 ), 51.64, 
51.64, 60.17, and 60.32 (CH), 45.92, and 46.15 (C), 169.79, 169.79, 170.27, 170.37, 
171.78, and 171.92 (CO). (Found: m/z (FAB) 337.1250 (MH+) C13H2 5N2 O4 S2  requires 
337.1255 (MH+)). [Found: C, 47.7; H, 7.5; N, 8 . 6  Calc, for C1 3H2 4 N2 O4 S2 : C, 46.4; 
H, 7.2; N, 8.3%].
VIII. V -acety l-D ,L -p ,p -d im ethylcysteinyl-L -V e-C B Z -L -lysine methyl
ester*®#tt
m.p. 96 “C (dec.). 6 c (300 MHz; CDCI3 ) 23.12, 23.16, 28.52, 28.73, 30.59, 30.95,
52.34, and 52.38 (CH3 ), 22.40, 22.48, 29.26, 29.33, 31.19, 31.38, 40.30, 40.48, 
66.67, and 66.67 (CH2 ), 52.05, 52.21, 60.28, 60.44 (CH), 45.89, and 46.01 (C), 
128.08, 128.08, 128.08, 128.08, 128.50, 128.50, 128.50, 128.50, 136.64, and 136.64 
(aromatic carbons), and 156.59, 156.76, 169.76, 169.92, 170.40, 170.52, 172.20, 
172.30 (CO). (Found: m/z (FAB) 468.2153 (MH+) C2 2 H3 4 N3 O6 S requires 468.2168 
(MH+)). [Found: C, 57.7; H, 7.7; N, 9.3 Calc, for C2 2 H3 3 N3 O6 S: C, 56.5; H, 7.1 N, 
9.0%].
IX. V-acetyI-D,L-p,p-dlmethylcysteinyl-L-proline methyl ester
m.p. syrup. 8 c  (300 MHz; CDCI3 ) 23.05, 23.16, 28.34, 28.84, 30.52, 30.63, 52.06, and 
52.22 (CH3 ), 24.63, 24.93, 29.17, 29.20, 48.06, and 48.16 (CH2 ), 56.79, 56.90, 
58.84, 59.04 (CH), 46.45, and 46.59 (C), 169.41, 169.79, 170.03, 172.04, 172.30, and
172.73 (CO). (Found: m/z (FAB) 303.1371 (MH+) C13H2 3 N2 O4 S requires 303.1378 
(MH+)). [Found: C, 52.0; H, 7.7; N, 9.2 Calc, for C13H2 2 N2 O4 S: C, 51.6; H, 7.3; N, 
9.3%].
continued
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X. V-acetyl-D,L-p,p-dimethylcysteinyl-L-aspartic acid dimethyl ester#
m.p. 120 “C (dec.), ôc (300 MHz; CDCI3 ) 23.20, 23.26, 28.49, 28.49, 30.63, 31.09,
52.16, 52.24, 52.86, and 52.92 (CH3 ), 35.76, and 35.91 (CH2 ), 48.41, 48.77, 60.47, 
and 60.70 (CH), 45.79, 46.08 (C), 169.40, 169.50, 170.20, 170.31, 170.55, 170.64,
171.12, and 171.28 (CO). (Found: m/z (FAB) 335.1273 (MH+) C13H2 3 N2 O6 S requires 
335.1277 (MH+)). [Found: C, 46.8; H, 6.4; N, 8.3 Calc, for C 13H2 2 N2 O6 S: C, 46.7; H, 
6 .6 ; N, 8.4%].
XI. A-acetyl-D,L-p,p-dimethylcysteinyl-L-glutamic acid dimethyl ester*^#t$
m.p.l34 “C (dec.). Ôc (300 MHz; CDCI3 ) 23.23, 23.29, 28.54, 28.54, 30.72, 31.31, 
51.96, 51.96, 52.54, and 52.54 (CH3 ), 26.61, 26.74, 29.99, and 30.12 (CH2 ), 51.93, 
51.93, 60.32, and 60.42 (CH), 45.74, and 46.02 (C), 169.80, 169.80, 170.22, 170.37, 
171.63, 171.73, 173.21, and 173.21 (CO). (Found: m/z (FAB) 349.1450 (MH+) 
C 1 4H2 5 N 2 O6 S requires 349.1433 (MH+)). [Found: C, 48.7; H,7.1; N, 8.1 Calc, for 
C 14H2 4 N2 O6 S: C, 48.3 H, 6.9; N, 8.0%].
* In this instance the results of the elemental analysis differ slightly from the values required to confirm the identity of the compound. However, the molecular ion peak in the FAB-MS spectrum has the required agreement and the identity of the compound is 
confirmed by the l^C-NMR spectrum which contains no additional peaks.
^  In procedure A and/or B (Section 3. 3. 1) the residue was washed with cold dry ether to give solid product.
# Vmax. (nujol)/cm“l ~ 2500w (SH), -1600 (CONH), -  1700 (CONH; peptide bond), and 
-  1750 (CO; aliphatic ester).
t  As the A/-acetyl-D,L-p,p-dimethylcysteine used was a racemic mixture the products (the 
dipeptides) were two diastereomers. Due to this the compound has a complicated ^H-NMR spectrum, but we were able to identify the -SH, CH3 CONH, and the proton of the peptide 
bond (-CONH- ) which indicate that we have the correct dipeptide.
$ In the l^C-NMR spectrum there are two lines for each carbon due to the presence of the 
two diastereomers and usually DEPT 90“ and DEPT 135“ enabled CH3 -, -ÇH2 -, and -ÇH- 
to be distinguished. In the case of V-acetyl-D,L-p,|I-dimethylcysteinylglycine methyl ester the two isomers formed are enantiomers rather than diastereomers. Accordingly only one
set of lines is seen in the l^C-NMR and the proton spectrum is also simpler {Ôh (300 MHz; 
CDCI3 ) 1.34 (s, 3H, CH3 ) 1.53 (s, 3H, CH3 ) 2.07 (s, 3H, CH3 ) 2.63 (s, IH, SH) 3.75 (s, 3H, CH3 ) 4.02 (dd, 2H, 7 18, 6 , CH2 ) 4.64 (d, IH, J 9, CH) 6.77 (d, IH, J 9, NH), and 7.42 (br s, IH, NH)}.
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TABLE 3. 2
Characterisation of S-nitrosothiols by NMR, UV-visible, FAB-MS, and elemental analysis
Satisfactory elemental analyses for compounds 3, 5 ,6 , 8 , 9 and 12 could not be obtained since the samples are contaminated with unreacted thiol (and possibly disulphide) and we were unable to find any satisfactory purification procedure. Other workers (Moynihan and Roberts, 1994) must have had similar difficulties as their compounds are authenticated 
without elemental analyses.
I. S-nitroso-A-acetyl-D,L-|3,p-dimethylcysteme (SNAP; 1)
SNAP was prepared as a pure solid by a modified literature procedure (Royle et a l, 1983). 
^max. = 340 nm in 10 % DMSO. (Found: m/z (FAB) 221.0582 (MH+) C7 H 1 3N2 O4 S 
requires 221.0596 (MH+)). [Found: C, 38.5; H, 5.7; N, 12.9 Calc, for C7H 12N2 O4 S: C, 
38.2; H, 5.5; N, 12.2%].
II. S-nitroso-A-acetyl-D,L-p,jI-dimethylcysteinylglycme methyl ester (2)#§t
ÔC (300 MHz; CDCI3 ) 23.31, 24.94, 26.77, 52.62 (CH3 ), 41.02 (CH2 ), 58.54 (CH),
59.11 (C), 169.13, 169.90 and 170.40 (CO). X,max. = 336 nm. (Found: m/z (FAB) 
292.0976 (MH+) C10H 18N3O5S requires 292.0967 (MH+)). [Found: C, 41.0; H, 6.2; N, 
14.2 Calc, for C 10H 17N3 O5S: C, 41.2; H, 5.9; N, 14.4%].
III. S-nitroso-A-acetyl-D,L-p,3-dim ethyIcysteinyl-L-alanine methyl ester
(3)*a#§t$
ÔC (300 MHz; CDCI3 ) 17.16, 17.75, 23.16, 23.16, 24.90, 25.54, 26.60, 26.82, 52.57,
52.73 (CH3 ), 48.11, 48.18, 58.65, 58.87 (CH), 59.09, 59.09 (C), 168.27, 168.48, 
170.39, 170.52, 172.78, and 172.91 (CO), l^ax . = 339 nm. (Found: m/z (FAB) 
306.1133 (MH+) C11H2 0N3 O5 S requires 306.1124 (MH+)). [Found: C, 42.6; H, 5.9; N,
12.7 Calc, for C11H 19N3O5 S: C, 43.3 ; H, 6.3; N, 13.8%].
continued
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IV. S-nitroso-V -acetyl-D ,L-3,3-dim ethylcysteinyl-L-valine methyl ester
(4 )#§t$
ÔC (300 MHz; CDCI3) 17.55, 17.95, 18.96, 19.09, 23.23, 23.23, 25.25, 25.78, 26.64, 
26.83, 52.34, 52.41 (CH3 ), 30.36, 30.74, 57.56, 57.56, 58.58, 58.89 (CH), 58.97,
59.12 (C), 168.98, 169.12, 170.26, 170.31, 171.68, and 171.85 (CO). X^ax. = 340 nm. 
(Found: m/z (FAB) 334.1090 (MH+) C13H2 4N3O5S requires 334.1436 (MH+)). [Found: 
C, 46.4; H, 6 .6 ; N, 12.0 Calc, for C13H2 3N3O5 S: C, 46.8; H, 7.0; N, 12.6%].
V. S-nitroso-/V-acetyl-D,L-p,3-dim ethylcystelnyl-L-leucine methyl ester
(5)*a#§t$
ÔC (300 MHz; CDCI3 ) 21.11, 21.28, 21.42, 21.52, 22.76, 22.87, 24.54, 24.95, 25.49, 
26.60, 52.48, 52.91 (CH3 ), 40.04, 40.21 (CH2 ), 23.16, 24.47, 50.86, 50.97, 58.60, 
58.88 (CH), 59.08, 59.08 (C), 168.88, 168.93, 170.27, 170.54, 172.85, and 172.90 
(CO). X,niax. = 336 nm. (Found: m/z (FAB) 348.1587 (MH+) C1 4H2 6 N3 O5 S requires
348.1593 (MH+)). [Found: C, 47.9; H, 6.3; N, 11.5 Calc, for C 14H2 5 N3 O5 S: C, 48.4; 
H, 7.2; N, 12.1%].
VI. S-nitroso-V-acetyl-D,L-p,|î-dimethylcysteinyl-L-phenylalanme methyl 
ester (6)*«#§t$ ,
ÔC (300 MHz; CDCI3 ) 22.98, 22.98, 25.12, 26.55, 28.90, 30.97, 52.42, 52.60 (CH3 )
37.37, 37.37 (CH2 ), 53.67, 53.67, 58.71, 58.79 (CH), 59.10, 59.10 (C), 168.72, 
168.85, 170.50, 170.50, 171.54, 171.72 (CO), 127.08, 127.08, 128.41, 128.56, 
128.71, 129.03, 129.08, 129.08, 129.22, 129.22 (CH; aromatic carbons), 135.57, and 
136.01 (C; ai'omatic carbons). A-max. = 339 nm. (Found: m/z (FAB) 382.1326 (MH+) 
C 17H2 4 N3 O5 S requires 382.1437 (MH+)). [Found: C, 55.1; H, 6.3; N, 11.7 Calc, for 
C 17H2 3 N3O5S: C, 53.5; H, 6.1; N, 11.0%].
continued
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VIL S-nitroso-V-acetyl-D,L-p,p-dimethylcysteinyl-L-isoleucine methyl ester
(7)#§t$
ôc (300 MHz; CDCI3) 11.48, 11.71, 15.40, 15.40, 23.20, 23.20, 25.18, 25.73, 26.62, 
26.80, 52.27, 52.36 (CH3 ), 24.77, 24.98 (CH2 ), 36.98, 37.22, 56.76, 56.89, 58.65, 
58.65 (CH), 58.95, 58.95 (C), 168.81, 168.97, 170.18, 170.28, 171.57, and 171.73 
(CO). Xmax. = 339 nm. (Found: m/z (FAB) 348.1596 (MH+) C 14H2 6 N3 O5 S requires
348.1593 (MH+)). [Found: C, 48.9; H, 7.4; N, 11.7 Cale, for C1 4H2 5N3 O5 S: C, 48.4; 
H, 7.3; N, 12.1%].
VIII. S-iiitroso-iV-acetyl-D,L-|3,p-dimethylcysteinyI"L-methionine methyl 
ester (8)*®#§t$
ôc (300 MHz; CDCI3 ) 15.07, 15.14, 23.01, 23.43, 26.58, 26.58, 30.93, 31.26, 52.66, 
52.76 (CH3 ), 28.92, 29.65, 30.07, 30.68 (CH2 ), 52.39, 52.58, 58.67, 58.82 (CH), 
58.99, 59.10 (C), 169.04, 169.87, 170.58, 170.79, 171.89, 171.97 (CO). %max. = 339 
nm. (Found: m/z (FAB) 366.1146 (MH+) C13H2 4 N3O5 S2 requires 366.1157 (MH+)). 
[Found: C, 41.7; H, 6 .2 ; N, 9.6 Cale, for C13H2 3 N3O5S2 : C, 42.7; H, 6.3; N, 11.5%].
IX. S-nîtroso- N  -acetyl- D,L -(3,p-dimethylcysteinyl- L -Ae-CBZ- L -lysine 
methyl ester (9)*^#§t$
ôc (300 MHz; CDCI3 ) 22.98, 23.05, 25.37, 25.39, 26.51, 26.90, 52.46, 52.76 (CH3 ),
22.18, 22.47, 28.53, 28.91, 30.80, 30.97, 40.16, 40.38, 66.39, 66.56 (CH2 ) 52.25,
52.50, 58.86, 58.93 (CH), 59.05, 59.05 (C), 156.56, 156.81, 168.93, 169.16, 170.60, 
170.68, 172.10, 172.26 (CO), 127.65, 128.13, 128.13, 128.33, 128.44, 128.44, 
128.49, 128.73, 128.73, 128.94 (CH; aromatic carbons), 135.97, 136.09 (C; aromatic 
carbon), l^iax. = 340 nm in DMSO (insoluble in the buffer). (Found: m/z (FAB) 497.1342 
(MH+) C2 2 H3 3 N4 O7 S requires 497.2070 (MH+)). [Found: C, 53.4; H, 6 .8 ; N, 10.3 
Calc, for C2 2H32N4 O7 S: C, 53.2 H, 6.5; N, 11.3%]. continued
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X. 5-nitroso-V -acetyl-D ,L-p,p-dim ethylcysteinyl-L-proline methyl ester
(1 0 )#§t$
ÔC (300 MHz; CDCI3 ) 22.58, 22.62, 25.82, 26.51, 30.88, 31.08, 52.43, 52.50 (CH3 ),
24.38, 24.46, 28.90, 29.01, 48.07, 48.26 (CH2 ), 56.24, 56.87, 58.65, 58.72 (CH),
59.10, 59.27 (C), 168.29, 168.41, 170.60, 170.97, 172.00, and 172.16 (CO). X^ax. =
338 nm. (Found: m/z (FAB) 332.1268 (MH+) C13H2 2N3O5 S requires 332.1280 (MH'*’)). 
[Found: C, 43.4; H, 5.8; N, 11.3 Calc, for C13H2 1N3O5S: C, 43.0; H, 5.8; N, 11.7%].
XI. S-nitroso-/V-acetyl-D,L-[i,p-dimethyicysteinyl-L-aspartic acid dimethyl 
ester ( ll):# § t4
6 c (300 MHz; CDCI3 ) 23.17, 23.17, 25.16, 25.87, 26.00, 26.80, 52.38, 52.43, 53.02, 
53.09 (CH3 ), 35.40, 35.48 (CH2 ), 47.97, 48.50, 58.29, 58.74 (CH), 59.01, 59.21 (C), 
168.35, 168.54, 170.50, 170.56, 170.65, 170.65, 171.26, and 171.55 (CO). Xmax. =
339 nm. (Found: m/z (FAB) 364.1119 (MH+) C13H22N3O7 S requires 364.1178 (MH+)). 
[Found: C, 44.8; H, 6.0; N, 11.3 Calc, for C13H2 1 N3O7 S: C, 44.6; H, 6.1; N, 11.1%].
X II. S-nitroso-A-acetyl-D,L-p,|3-dimethylcysteinyl-L-glutamic acid dimethyl 
ester (12)*®#§tt
6 c (300 MHz; CDCI3 ) 23.21, 23.24, 25.04, 25.54, 26.07, 26.33, 51.16, 51.16, 52.66, 
52.70 (CH3 ), 26.59, 26.78, 29.76, 29.84 (CH2 ), 52.72, 52.72, 58.56, 58.95 (CH),
59.11, 59.11 (C), 168.80, 168.88, 170.25, 170.45, 171.49, 171.70, 173.19, and 173.27 
(CO). Xmax. = 339 nm. (Found: m/z (FAB) 378.1185 (MH+) C1 4H2 4 N3 O7 S requires 
378.1335 (MH+)). [Found: C, 44.0; H, 5.6; N, 10.7 Calc, for C 14H2 3 N3 O7 S: C, 44.6; 
H, 6.1; N, 11.1%].
continued
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XIII. 5-nitroso-L-glutathione (GSNO; 13)
A-max. = 336 nm. (Found: m/z (FAB) 337.0856 (MH"^) C10H 17N4 O7 S requires 337.0818 
(MH+)). [Found: C, 35.2; H, 4.9; N, 16.4 Calc, for C10H 16N4 O7 S: C, 35.2; H, 4.7; N, 
16.3%].
* In this instance the results of the elemental analysis differ slightly from the values required to confirm the identity of the compound. However, the molecular ion peak in the FAB-MS spectrum has the required agreement and the identity of the compound is 
confirmed by the 13C-NMR spectrum which contains no additional peaks.
^  The drug was contaminated by small amounts of the unreacted thiol and/or by small 
amounts of the disulphide formed dur ing nitrosation.
# In the nitrosation of the dipeptide (Section 2. 3. 2.b ) the residue was washed with cold 
dry ether to give green solid product (except in the case of compounds 9 and 10 which 
were green sticky solids).
§ Vmax. (nujol)/cm-l ~ 1900w (SNO), -  600 (SN), -1500 (NO), -  1600 (CONH), -1700 
(CONH; peptide bond), and ~ 1750 (CO; alipatic ester).
t  It was possible to identify the CH3 CONH- and -CONH- signals and the disappearance of
-SH which indicates that the nitrosation has occurred. Moreover, the resonances of the a
carbon atoms were shifted downfield (-1 5  ppm), and resonance of P-carbon atoms were 
shifted upfield which also indicates that the nitrosation has occurred. Some decomposition occurred while the spectra were being run.
$ In the i^C-NMR spectrum there are two lines for each carbon due to the presence of the 
two diastereomers and usually DEPT 90“ and DEPT 135“ enabled ÇH3 -, -CH2 -, and -ÇH- 
to be distinguished. In the case of compound 2 the two isomers formed are enantiomers 
rather than diastereomers. Accordingly only one set of lines is seen in the l^C-NMR and 
the proton spectrum is also simpler [Ôh (300 MHz; CDCI3) 2.00 (s, 6 H, 2 x CH3 ) 2.10 (s, 
3H, CH3 ) 3.78 (s, 3H, CH3 ) 4.06 (dd, 2H, J  18, 6 , CH2 ) 5.52 (d, IH, J  10, CH) 6.99 (d, IH, J  11, NH), and 8.04 (br s, IH, NH).
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3, 3. 3. Chemical Stability of the 5-Nitrosothiols
In this section, we will report the effect of EDTA, the effect of copper ions, the effect of 
thiol, the effect of neocuproine, and the effect of L-cysteine on the decomposition of S- 
nitrosothiols. All S-nitrosothiols gave a characteristic broad absorption band centred around 
340 nm. Aliquots of these drugs were used after pH adjustment, taking care to minimise 
exposure to light.
3. 3. 3. 1. The Effect of EDTA on the Decomposition of S - 
Nitrosothiols
The decomposition of each of the test drugs was followed spectrophotometrically by 
determining the absorbance of test drug as a function of time.
A stock solution (2.5 mM) of copper(II) nitrate trihydrate was made up (0.302 g in 500 
cm^ water), and diluted by a factor of 10 to form a 2.5 x 10"1 mM solution. 0.1 cm^ Of 
this solution was added to phosphate buffer (0.1 M KH2PO4 /O.I M NaOH; 1.90 cm^) at 
pH = 7.4. 0.15 cm3 Of DMSO and 0.25 cm^ of EDTA [1.0 x 10"  ^M] were added to the 
resulting solution. The solution in the cell was left for one hour at 30 "C to equilibrate in the 
spectrophotometer. When 0.1 cm^ of the drug solution (12.5 mM; 12.5 x 10"  ^mol in 1.0 
cm3 DMSO) was added to this solution in the spectrophotometer cuvette at 30°C, the final 
concentrations of the drug and copper(II) ions in the cuvette were 5 x 10"! mM and 10 p,M 
respectively. The other concentrations of copper(II) ions were made up in a similar way 
from further dilution of the copper/distilled water stock solutions, always adding a final 
volume of 2.5 cm^ to the cuvette and 0.1 cm^ of the dmg stock solution. Immediately after 
addition of the 0 .1  cm^ of the drug (which had been kept in ice and in the absence of light 
prior to addition), the experiment was started and readings taken at timed intervals against a 
reference cell containing phosphate buffer. For the experiment run in the presence of 
EDTA, the EDTA (100 jiM) was made up in water (250 cm^) from a stock solution 
(0.9306 g in 250 cm^ buffer) which, after addition of the stock drug solution (0.1 cm^), 
resulted in a final concentration of EDTA of 10 pM.
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3. 3. 3. 2. The Effect of Copper Ions on the Decomposition of
S-Nitrosothiols
A stock solution (2.5 x 10"! mM) of copper(II) nitrate trihydrate was made up (0.0060 g in 
100 cm^ buffer). An aliquot of this solution (0.12 cm^, 0.24 cm^, 0.36 cm^, 0.48 cm^ and 
0.60 cm^) was diluted to 10 cm^ with phosphate buffer (0.1 M KH2PO4 /O.I M NaOH) to 
form 0.3 x 1 0 " ,^ 0.6 x 1 0 " ,^ 0.9 x 10'5, 1.2 x 10“^  and 1.5 x 1 0 "  ^ mM solutions. 0.15 
cm3 Of DMSO was added to phosphate buffer containing copper ions pH = 7.4 at (2.25 
cm3) and 30 °C in the spectrophotometer cuvette. The solution in the cell was left for one 
hour at 30 “C to equilibrate in the spectrophotometer. 0.1 cm^ Of the drug solution (12.5 x 
10“^  mol in 1 cm^ DMSO, 12.5 mM) was added to the cuvette. Immediately after addition 
of 0 .1  cm3 of drug (which had kept in ice and in the absence of light prior to addition), the 
experiment was started and readings taken at timed intervals against a reference cell 
containing phosphate buffer and DMSO.
3. 3. 3. 3. The Effect of Thiol on the Decomposition of S -  
N itrosothiols
0.1 cm3 Of 6.25 mM thiol (6.25 pmol in 1 cm^ DMSO) was added to phosphate buffer 
containing copper ions (1.5 x 1 0 "  ^ mM) at pH = 7.4 (2.25 cm^) and 30 °C in a 
spectrophotometer cuvette. 0.05 cm^ Of DMSO was added to the previous solution. The 
solution in the cell was left for one hour at 30 “C to equilibrate in the spectrophotometer. 
0.1 cm^ Of the drug (12.5 pmol in 1 cm^ DMSO) was added to the first cuvette and the 
absorbance decrease at Xmax. was measured as a function of time for the 2.5 x 10“l mM 
thiol / 5.0 X lO'l mM drug solution.
0.15 cm^ Of DMSO was added to phosphate buffer (2.25 cm3) containing copper ions (1.5 
X 10"  ^mM) at pH = 7.4 and 30 °C was placed in a spectrophotometer cuvette. The solution 
in the cell was left for one hour at 30 “C to equilibrate in the spectrophotometer. 0.1 cm^ Of 
the drug (12.5 mM in 1 cm^ DMSO) was added to the second cuvette and the absorbance 
decrease at Xmax. was measured as a function of time.
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The absorbance decrease at Xmax. was measured as a function of time for the first and 
second cuvettes versus a standard cuvette containing all but the S-nitrosothiol at the same 
concentrations.
3, 3. 3. 4. The Effect of Neocuproine on the Decomposition of 
S-N itrosothiols
0.1 cm3 Of 12.5 mM neocuproine (0.0026 g in 1 cm^ DMSO) was added to phosphate 
buffer containing copper ions (2.0 x lO'^ mM; 2.25 cm^) at pH = 7.4 and 30 °C in a 
spectrophotometer cuvette. 0.05 cm^ Of DMSO was added to the resulting solution. The 
solution in the cell was left for one hour at 30 °C to equilibrate in the spectrophotometer. 
0.1 cm^ Of the drug (12.5 mM in 1 cm^ DMSO) was added to the first cuvette.
The solution in the cell was left for one hour at 30 °C to equilibrate in the 
spectrophotometer. 0.1 cm^ Of the drug (12.5 mM in 1 cm^ DMSO) was added to 
phosphate buffer containing copper ions (2.0 x 10"  ^mM; 2.25 cm^) at pH = 7.4 and 0.15 
cvo? DMSO at 30°C in a second spectrophotometer cuvette.
The absorbance decrease at X^ax. was measured as a function of time for the 5.0 x 10“  ^
mM drug solution, versus a standard cuvette containing all but the S-nitrosothiol at the 
same concentrations.
3. 3. 3. 5. The Effect of L-Cysteine on the Decomposition of S- 
Nitrosothiols
0.1 cm3 Of 31.25 mM L-cysteine (0.0378 g in 10 cm^ buffer) was added to phosphate 
buffer at pH = 7.4 (2.15 cm^) and 30 “C in a spectrophotometer cuvette. 0.15 cm^ Of 
DMSO was added to the resulting solution. The solution in the cell was left for one hour at 
30 “C to equilibrate in the spectrophotometer. 0.1 cm^ Of the drug (12.5 [imol in 1 cm^ 
DMSO; 12.5 mM) was added to the first cuvette and the absorbance decrease at X^ax- was 
measured as a function of time for the 12.5 mM L-cysteine / 5xlO"l mM drug solution.
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0.15 ciïi3 DMSO was added to phosphate buffer (2.25 cm^) at pH = 7.4 and 30“C in a 
spectrophotometer cuvette. The solution in the cell was left for one hour at 30 C to 
equilibrate in the spectrophotometer. 0.1 cm^ Of the drug (12.5 mM in 1 cm^ DMSO) was 
added to the second cuvette and the absorbance decrease at Xmax. was measured as a 
function of time for the 5 x 10"! mM dmg solution.
3. 3. 4. Pharmacological and Physiological Activity of the S- 
Nitrosothiols
In this section, we will report the effect of S-nitrosothiols on smooth muscle relaxation, 
and inhibition of platelet aggregation.
3. 3. 4. 1. Smooth Muscle
Methods used to study the effect of S-nitrosothiols, ferro-haemoglobin, and neocuproine 
on smooth muscle relaxation are reported.
3. 3. 4. 1. 1. Materials and Methods 
(1). Preparation
Experiments were performed on 8  -12 mm segments of tail artery taken from normotensive 
adult Wistar rats (270 - 538 g). Animals were killed by cervical dislocation and the tail 
removed. The artery was exposed following removal of the overlying skin and connective 
tissue. Once exposed, the artery was cannulated (Portex cannula), dissected free and 
transferred to a perspex bath. Care was taken to identify and tie-off all side-branches.
(ii). Apparatus
The apparatus is shown in Figure 3.1. The vessel (V) was perfused internally at a constant 
flow rate of 2 cm^ min"^ driven by a peristaltic pump (PI: Gilson minipuls 2). The 
perfusate was pre-warmed to 37 °C by passage through the heat exchanger (HE). Drugs 
were introduced into the lumen of the vessel by bolus injection ( 1 0  pi) through a resealable
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rubber septum (RS). A differential pressure transducer (P: Sensym type SCX 150NC; 
Parnell Electronic Components, Leeds) detected changes in back pressure determined by 
arterial tone.
The outer surface of the vessel was superfused continuously (ca. 8  cm^ m in 'l) with 
solution driven by a second peristaltic pump (P2: BDH minipump). The solution was pre­
warmed to 3 7  °C by passage through a heat exchanger similar to that used in the internal 
circuit.
95% O2
5% CO2
Figure 3.1: Apparatus used for perfusing isolated segments of rat tail artery. See text for 
full description and explanation of lettering.
(iii). Experimental Protocol
Arteries were perfused internally and externally with oxygenated Krebs solution 
(composition (mM): NaCl 118, KCl 4.7, NaHCOg 25, NaH2 P0 4  1.15, CaCl2  2.5, 
MgCl2  1.1, glucose 5.6, gassed with 95% O2 / 5% CO2  to maintain pH 7.4). Internal 
perfusion of the cannulated vessel was initially slow (flow rate ca. 0.2 cm^ min"l). The 
working flow rate of 2  cm^ min"l was attained by gradually increasing the pump speed 
over a period of 10-20 mins. The preparation was then allowed to stabilise for a further 20- 
BO mins, at which time a 'passive' pressure of 5 - 24 mm Hg was recorded. Precontraction 
was induced by addition of phenylephrine hydrochloride (PE) to both internal and external 
perfusates (Figure 3.2).
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■ACTIVE'
PRESSURE
20 mmHg
4 mins
■PASSIVE'
PRESSURE
Figure 3. 2: Pressure recording showing precontraction with PE. 5 |iM PE was added to both internal and external perfusate reservoirs at the time indicated, reaching the vessel through the external perfusate at A and the internal at B. The pressure maintained by the vessel before PE addition is termed ‘passive’, whilst agonist-induced pressure is ‘active’. 
Expt. NÛ 920304.
The PE concentration was adjusted to maintain a pressure of 90 - 138 mm Hg above the 
passive pressure.
At this point in the experimental procedure, the laboratory lights were switched off, leaving 
a red safelight (60 W) as the only means of illumination. This precaution served to prevent 
photorelaxation of the vessel and to protect any NO donor drugs in use from photolytic 
decomposition.
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(iv). Drugs
L-phenylephrine hydrochloride :
Appropriate volumes of a 10"  ^M stock solution were added to both the internal and 
external perfusates to produce concentrations ranging from 1-12 jj.M.
S-Nitroso-N~acetyl-D,L-p,l3-dimethylcysteine:
5-Nitroso-iV-acetyl-D,L-p,p-dimethylcysteine ( SNAP; 1 ) was prepared as a pure solid by 
a modified procedure (Section 3. 3, 2. a). The solid was first dissolved in dimethyl 
sulphoxide (Sigma-Aldrich Chemicals; HPLC grade; 99.9%) to produce a 10"  ^M stock 
solution which was then serially diluted with Krebs solution to produce the desired range 
of concentrations immediately prior to use. Solutions were kept in ice during experiments.
S-Nitroso-N-acetyl-D,L-p,p-dimethylcysteinyl-L-amino-acid methyl esters:
S-Nitroso-N-acetyl-D,L-p,p-dimethylcysteinyl-L-amino-acid methyl esters (2-12) are not 
soluble in water and cannot be dissolved in Krebs solution. The solid was first dissolved in 
dimethyl sulphoxide (Sigma-Aldrich Chemicals; HPLC grade; 99.9%) to produce a 10“^  M 
stock solution which was then serially diluted with Krebs solution to produce the desired 
range of concentrations immediately prior to use. Solutions were kept in ice during 
experiments.
S-Nitroso-L-glutathione:
The solid was first dissolved in Krebs solution (9 cm^) followed by addition of 1 cm^ of 
dimethyl sulphoxide (Sigma-Aldrich Chemicals; HPLC grade; 99.9%) to produce a 10"  ^M
210
stock solution which was then serially diluted with Krebs solution to produce the desired 
range of concentrations immediately prior to use. Solutions were kept in ice during 
experiments.
Preparation of Ferro-haemoglobin:
Ferro-haemoglobin (Mr 64500) was prepared by reduction of 100 cm^ of I mM bovine 
haemoglobin using 10 mM sodium dithionite. The dithionite was dialysed out of solution 
against 3 x 2  litre volumes of deaereated distilled water at 0 - 5 °C. The stock ferro- 
haemoglobin was then split into 3 cm^ aliquots and frozen (-10 °C). Aliquots were added to 
200 cm3 of Krebs buffer used for the internal perfusate of the artery, immediately prior to 
perfusion, to make up the 15 mM concentration required. Samples were used within 2 
weeks.
3. 3. 4. 1. 2. The Effect of Ferro-haemoglobin
The same procedure was carried out as described in Section 3. 3. 4. 1. 1. Bolus injections 
of ^ -nitrosothiols (1 mM - 10 |iM) were administered to the artery via the injection port 
(see Figure 3. 1) to obtain a control dose response curve. Ferro-haemoglobin (15 jiM) and 
superoxide dismutase (150 units (cm^)-!; Sigma Chemical) were then perfused through the 
artery in the internal Krebs buffer supply and the ^-nitrosothiol injections were repeated. 
The mean response amplitudes of experiments were obtained for each concentration and 
statistical analysis of the results was carried out.
Statistical analysis of data in figures (Section 2. 4. 1):
statistical analysis on the data was carried out using an unpaired students t-test. 
* indicates data is significantly different at the P = 0.05 confidence level.
** indicates data is significantly different at the P = 0.01 confidence level.
*** indicates data is significantly different at the P = 0.001 confidence level.
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3. 3. 4, 1. 3. The Effect of Neocuproine on Smooth Muscle 
Relaxation
(a) Pre-mixed
The same procedure was carried out as described in the experimental section (Section 3,3.
4. 1. 1). Bolus injections of SNAP and/or GSNO (1 mM - 10 pM) were administered to 
the artery via the injection Port (Figure 3. 1) to obtain a control dose response curve.
A stock solution (10 cm^) of neocuproine (10'^ M) in 2.5 cm^ ethanol and 7.5 cm^ Krebs 
solution was prepared. The drug was dissolved in Krebs buffer containing dimethyl 
sulfoxide (10% DMSO; Sigma-Aldrich chemicals; HPLC grade; 99.9%) to produce a 10"  ^
M stock solution which was then serially diluted with Krebs solution containing 
neocuproine (10"4 M; 0.1 cm^ of neocuproine (10"^M) and 0.8 cm^ Krebs solution) to 
produce the desired range of concentrations immediately prior to use. Bolus injections of 
SNAP and/or GSNO (1 mM - 10 pM) were administered to the artery via the injection port 
(Figure 3. 1) to obtain a dose response curve and the SNAP and/or GSNO injections were 
repeated. The mean response amplitudes of 6 to 8 experiments were obtained for each 
concentration and statistical analysis of the results was caiTied out.
(b) Perfused
The same procedure was carried out as described in the experimental section (Section 3.3. 
4. 1. 1). Bolus injections of SNAP and/or GSNO (1 mM - 10 pM) were administered to 
the artery via the injection port (see Figure 3. 1) to obtain a control dose response curve. A 
stock solution (10 cm^) of neocuproine (10~  ^M) in 2.5 cm^ ethanol and 7.5 cm^ Krebs 
solution was prepared. Neocuproine solution (lO""^  M; 1 cm^ from the neocuproine stock 
and 99 cm^ Krebs solution) was then perfused through the artery in the internal Kerbs 
buffer supply and the SNAP and/or GSNO injections were repeated. The mean response 
amplitudes of 6 to 8 experiments were obtained for each concentration and statistical 
analysis of the results was carried out.
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3. 3. 4. 2. Platelet Aggregation
Human whole blood was collected over 3.2% trisodium citrate at a ratio of 9 to 1 (blood to 
citrate). Platelet-rich plasma (PRP) was prepared from human whole blood by 
centrifugation at 900 rpm for 20 min. at 25 °C, a platelet account performed(~ 300 + 50 x 
lO^L) and stored in plastic tubes closed to air. Platelet-poor plasma (PPP) was used as a 
blank (200 pL) in the aggregometer and was prepared by centrifugation of PRP for 10 min. 
at 3500 rpm. All platelet aggregations were performed in 196 pi aliquots of PRP in a 
Platelet Aggregation Profiler at 37 °C with a stirring rate of 900 rpm. The test drug (2 pi) 
was added to PRP 5 min. before the addition of 2 pi collagen to stimulate aggregation (run 
for 5 min.).
The percent inhibition of aggregation was determined by dividing (the percent aggregation 
in the control minus the percent aggregation in the test sample which contains the drug) by 
that observed in the control, then multiplying by 100%.
3. 3. 5. The Effect of L-Ascorbic Acid
In this section, we will study the effect o f L-ascorbic acid on the decomposition o f 5- 
nitrosothiols, the effect o f L-ascorbic acid and EDTA on the decomposition of S- 
nitrosothiols, the effect o f L-ascorbic acid on smooth muscle relaxation, and the effect o f L- 
ascorbic acid on platelet aggregation.
3. 3. 5. 1. The Effect of L-Ascorbic Acid on the Decomposition 
of 5-N itrosoth iols
The solutions in all the cells were left for one hour at 30 °C to equilibrate in the 
spectrophotometer before the addition of the drug.
0.1 cm3 Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer (2.4 cm^) at pH = 7.4 and 30 °C in a spectrophotometer cuvette (first 
cell).
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0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing L-ascorbic acid (15 mM; 2.4 cm^) at pH = 7.4 and 30 “C in a 
spectrophotometer cuvette (second cell).
0.1 cm3 of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing L-ascorbic acid (75 mM; 2.4 cm^) at pH = 7.4 and 30 “C in a 
spectrophotometer cuvette (thired cell).
0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing L-ascorbic acid (150 mM; 2.4 cm^) at pH = 7.4 and 30 “C in a 
spectrophotometer cuvette (fourth cell).
0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing L-ascorbic acid (225 mM; 2.4 cm^) at pH = 7.4 and 30 °C in a 
spectrophotometer cuvette (fifth cell).
The bsorbance decrease at Xmax. was measured as a function of time for the 15 mM 
GSNO, versus a standard cuvette containing all but the 5-nitrosothiol at the same 
concentration.
3. 3. 5. 2. The Effect of L-Ascorbic Acid and EDTA on the 
Decomposition of 5-N itrosothiols
The solutions in all the cells were left for one hour at 30 °C to equilibrate in the 
spectrophotometer before the addition of the drug.
0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing EDTA (15 mM; 2.4 cm^) at pH = 7.4 and 30 °C in a 
spectrophotometer cuvette (fir st cell).
0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing EDTA and L-ascorbic acid ([EDTA] = 15 mM; [L-ascorbic
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acid] = 15 mM; 2.4 cm^) at pH = 7.4 and 30 “C in a spectrophotometer cuvette (second 
cell).
0.1 cm3 Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing EDTA and L-ascorbic acid ([EDTA] = 15 mM; [L-ascorbic 
acid] = 75 mM; 2.4 cm^) at pH = 7.4 and 30 “C in spectrophotometer cuvette (third cell).
0.1 cm^ Of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer containing EDTA and L-ascorbic acid ([EDTA] = 15 mM; [L-ascorbic 
acid] = 150 mM; 2.4 cm^) at pH = 7.4 and 30 °C in a spectrophotometer cuvette (fourth 
cell).
0.1 cm^ of 15 mM GSNO (0.0050 g in 1 cm^ phosphate buffer; pH = 7.4) was added to 
phosphate buffer contains EDTA and L-ascorbic acid ([EDTA] = 15 mM; [L-ascorbic acid] 
= 225 mM; 2.4 cm^) pH = 7.4 at 30 °C in spectrophotometer cuvette (fifth cell).
The absorbance decrease at Xmax. was measured as a function of time for the 15 mM 
GSNO, versus a standard cuvette containing all but the 5-nitrosothiol at the same 
concentration.
3. 3. 5. 3. The Effect of L-Ascorbic Acid on Smooth Muscle 
Relaxation
The same procedure was carried out as described in the experimental section (Section 3.3.
4. 1. 1). Bolus injections of SNAP and/or GSNO £1 mM-10 fxM) were administered to the 
artery via the injection port (Figure 3. 1) to obtain a control dose response curve. L- 
Ascorbic acid solution (10"^ M) was then perfused through the artery in the internal Kerbs 
buffer supply and the SNAP and/or GSNO injections were repeated. The mean response 
amplitudes of 6 to 8 experiments were obtained for each concentration and statistical 
analysis of the results was carried out.
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3. 3. 5. 4. The Effect of L -A scorb ic A cid on P la te le t  
Aggregation
The same procedure was carried out as described in the experimental section (Section 3.3. 
4 .2). All platelet aggregations were preformed in 194 \i\ aliquots of PRP in a Platelet 
Aggregation Profiler at 37 °C with a stirring rate of 900 rpm. L-Ascorbic acid (2 pi; 10'^ M) 
were added to PRP. The test drug (2 pi) was added to the previous mixture 5 min. before 
the addition of 2 pi collagen to stimulate aggregation (run for 5 min.). The final 
concentiation of L-ascorbic acid was lO"'^  M.
The percent inhibition of aggregation was determined by dividing (the percent aggregation 
in the control minus the percent aggregation in the test sample which contains the drug) by 
that observed in the control, then multiplying by 100%.
3. 3. 6. Trapping Thiyl Radical
5,5-Dimethyl-3,4-dihydropyrrole-A-oxide (DMPO) was used as a spin trap agent. S- 
Nitroso-A-acetyl-D,L-p,p-dimethylcysteinylglycine methyl ester (2) (0.0029 g, 1 mmol) 
was added to a solution of 5,5-dimethyl-3,4-dihydropyrrole-A-oxide (0.05 cm^ of DMPO 
in 0.95 cm3 of acetonitrite) in an ESR tube. The solution was degassed with nitrogen. 
Before addition no ESR signal (response) was observed. Upon addition of 5-nitroso-A- 
acetyl-D,L-3,p-dimethylcysteinylglycine methyl ester (2) a spectrum was obtained directly 
after the photolysis .
3. 3. 7. NO Assay
A World Precision ISO-NO sensor was used and standardised with a solution of NO 
prepaied from sodium nitrite and L-ascorbic acid.
Statistical analysis of data in figures (Sections 2. 4, 2 & 2. 6. 2. 1): 
statistical analysis on the data was carried out using a paired students f-test.
* indicates data is significantly different at the P = 0.05 confidence level.
** indicates data is significantly different at the P = 0.01 confidence level. 
*** indicates data is significantly different at the P = 0.001 confidence level.
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Introduction.S-Nitrosothiols (RS-NO) arc relatively unstable compounds and break down thermally, photochemically [1] and in a metal ion catalysed process [2] to give a disulphide and nitric oxide (NO):
2 RSNO ------- ► RSSR +2 NO
These compounds are of interest because of their potent pharmacological properties and possible physiologic^ role in smooth muscle relaxation and inhibition of platelet aggregation[3], Endothelium-derived relaxing factor, or EDRF, has pharmacological properties identical to NO or a closely related compound, such as an S-nitrosothiol [4]. We have synthesised 5-nitroso-iV-acetyl-D,L-^p-dimethylcysteine (1; SNAP) and three novel 5-nitrosated dipeptides, S-nitroso- -^acetyl-D,L-p,p- dimethylcysteinylglycine methyl ester (2), S-nitroso-W-acetyl- D.L-p.p-dimethylcysteinyl-L-alanine methyl ester (3) and S- nitroso-Af-acetyl-D,L-p,p-dimethylcysteinyl-L-valine methyl ester(4). The vasodilator properties of compounds 2-4 were compared with that of SNAP to investigate the relationship of structure te chemical stability and Mological activity.
Materiabi and Methods.S-Nitrosothiols: SNAP was prepared according to the method of Field et al [5]. The synthesis of the 5-nitrosated dipeptides (2-4) is described by Butler & Al-Sa’doni [6]:
■NO
o(1: SNAP) om
« & I(3) o À  (*)Figure 1: Chemical structures of SNAP and three novel S- nitrosated dipeptides
Rat Tail Artery Bioassays: Male Wistar rats (300-400g) were killed by cervical dislocation and tlteir tails removed. The tail artery was dissected free, cannulated, and perfused internally with Krebs solution (37‘*C) at a constant flow rate (2ml min-'). Vessels were precontracted with phenylephrine hydrochloride (PE; l-7|iM), generating perfusion pressures of 100-120mmHg.
Results and Discussion.The biological activity of S-nitrosothiols depends upon the structure of R [7]. Thus, changing R results in a new compound with different chemical and physiological properties.The chemical stability of the 5-nitrosated dipeptides was monitored spectrophotometrically (at for -SNO group; 30®C and pH 7.4). All four compounds decomposed to the corresponding disulphide and NO. but the 5-nitrosated dipeptides were found to be more stable than SNAP. The addition of cysteine, a transnitrosating agent, accelerzUed the rate of decomposition of all compounds.
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Figure 2: Log dose-response curves comparing the vasodilator effects of SNAP (filled circles), 2 (filled squares), 3 (filled triangles), and 4 (filled diamonds). Open symbols shows responses in presence of oxyhaemoglobin (lS|iM).
Figiue 2 shows log-dose resptmse curves resulting from bolus injections of compoimds 1-4 into pre-contracted tail arteries. Oxyhaemoglobin (Hb; lS|iM) significantly attenuated responses to all four conqxmnds (P<0.01 for all doses of compounds 1-4 when ctrnqnued to control values using an unpaired Student’s t- test). Hb is a well recognised NO scavenger and these results indicate that NO is the effector agent in vasodilation to all four compounds.5-Nitrosated dipeptides are more effective vasodilators than SNAP (EDsos of 4.1, 2.8, 3.7(JiM, respectively compared with 
1 7 .811M for SNAP). SNAP responses were statistically 
significantly different for KF^ M (3) and KF^ M (2,4) dosc  ^even though the local chemical envircmment of the -SNO grotq» arc almost identical. This finding is contrary to what might be expected on the basis of their chemical stabilities in vitro and may indicate that the 5-nitrosated dipeptides interact with tissue components or show greater penneability than SNAP.
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Synthesis of a novel series of biologically active $• nitrosothiols
ANTHONY R. BUTLER and HAITHAM H. AL-SA’DONI
School of Chemistry, University of St. Andrews, St. Andrews, Fife KYI6  9ST, Scotland, UK
Introduction.S-Nitrosothiols (RSNO) are an important class of NO-donor drugs. They decompose giving NO and a disulfide:
2 RSNO --------- ► RSSR + 2 NO
They have been used clinically and occur naturally where they may have a role in smooth muscle relaxation and in the prevention of platelet aggregation. The most extensively examined nitrosothiols arc S-nitroso-/V-acetyl-D,L-p,p- dimethylcysteine(SNAP) and S-nitroso-L-glutathione(GSNO). We set out to extend the range of compounds of this type and to look for a correlation between chemical structure and biological activity. The situation has been complicated by the recent discovery that the main route for the release of NO from a nitrosothiol is a coppei(I)-catalysed process(A. R. Butler, D. L. H. Williams, H. H. Al-Sa'doni, S. C. Askew, A. P. Dick and H, R. Swift; unpublished results). Therefore we examined the effect of copper ions on the stability of the compounds we synthesised.
Materials and Methods.SNAP(1) and GSN0(13) were prepared by literature raethods[l, 2]. The dipeptides were prepared by coupling N- acetyl-D,L-p,p-dimethylcysteine with tlw methyl esters of a number of amino acids. The coupling agent was jV-cyclohexyl- /V'-2-[A^-morpholino]ethylcarbodiimide metho-p- toluenesulphonate and we found that using a Ar-acetyl-D,L-p,p- dimethylcysteine derivative, it was unnecessary to protect the thiol group during the reaction. The thiol group was nitrosated 
by the use of r-butyl nitrite. For the kinetic studies NO release was monitmed by observing the decrease in absorbance at the Xmax (normally 339 run). The vasodilator effect of nitrosothiols was examined using a length of pre-contracted isolated rat tail artery. The drug was delivered either by bolus injection or as an internal prefusate. The prevention of platelet aggregation was studied using a Platelet Aggregation lYofiler. For the detection of NO a WP NO sensor was used.
Results and Discussion.The 5-nitrosothiols were prepared according to the following scheme:
• !  , ■ >j Coupling HMg«nt 
SH
r "«U-NO,
The new compounds (2-12) prepared are shown in the figure below:
«vau
0
(1; MAI*) (*) (»)
(«)
SNO mo
»no moX w x  &4 =x
(10) !^^ X(11)
(1$; OSNO)
Hie copper catalysed release of NO from nitrosothiols is known( (A. R. Butler, D. L. H. Williams, H. H. Al-Sa'doni, S. C. Askew, A. P. Dick and H. R. Swift; unpublished results) to occur by the following mechanism:
RS + cu*^+
RS- + Cir
RS- + Cui+
RS
1/2 RSSR 
^  RS +
RS
Cu*
Cu+
(i)
(ill)
1/2 RSSR
All the new compound examined show less susceptibility to copper(I)~catalysed release of NO than SNAP but are more reactive than GSNO. However, they are all active as vasodilator[3] and in the prevention of platelet aggregation(A. R. Butler, H. H. Al-Sa'doni, A. J. Bancroft and M. McLaren ; unpublished results).As a class they combine the favoured property of chemical stability with a high level of biological activity.
References1. Field, L., Dilts, R. V., Ravichandran, R. , Lenhert, P. G. and Carnahan, G. E. (1978) J. C. S. Chem. Comm., 6 , 249-250.2. Hart, T. W. (1985) Tetrahedron letters, 26, 2023-2016.3. Butler, A. R., Al-Sa'doni, H. H., Megson, I. L. and Flitney, F. W.(this volume).
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D e c o m p o s i t i o n  o f  5 ^ - n i t r o s o t h i o l s  ( R S N O )  i n  a q u e o u s  s o l u t i o n  a t  p H  7 . 4  i s  b r o u g h t  a b o u t  b y  c o p p e r  
i o n s ,  e i t h e r  p r e s e n t  a s  a n  i m p u r i t y  o r  s p e c i f i c a l l y  a d d e d .  T h e  p r i m a r y  p r o d u c t s  a r e  n i t r i c  o x i d e  a n d  t h e  
d i s u l f i d e .  I n  t h e  p r e s e n c e  o f  t h e  s p e c i f i c  C u *  c h e l a t o r ,  n e o c u p r o i n e ,  r e a c t i o n  i s  p r o g r e s s i v e l y  i n h i b i t e d  a s  
t h e  [ n e o c u p r o i n e ]  i s  i n c r e a s e d ,  t h e  r e a c t i o n  e v e n t u a l l y  s t o p p i n g  c o m p l e t e l y .  T h e  c h a r a c t e r i s t i c  U V - V I S  
s p e c t r u m  o f  t h e  C u ^  a d d u c t  c a n  b e  o b t a i n e d  f r o m  t h e  r e a c t i o n  s o l u t i o n s .  T h i s  s h o w s  c l e a r l y  t h a t  C u ^  
a n d  n o t  C u ^ ^  i s  t h e  e f f e c t i v e  c a t a l y s t .  T w o  l i m i t i n g  k i n e t i c  c o n d i t i o n s  c a n  b e  i d e n t i f i e d  f o r  a  r a n g e  o f  
S - n i t r o s o t h i o l s  a t  s p e c i f i c  c o p p e r  i o n  c o n c e n t r a t i o n s  ( a )  a  f i r s t - o r d e r  d e p e n d e n c e  a n d  ( 6 )  a  z e r o - o r d e r  
d e p e n d e n c e  u p o n  [ R S N O ] .  N o r m a l l y  b o t h  s i t u a t i o n s  a l s o  h a v e  a  s h o r t  i n d u c t i o n  p e r i o d .  T h i s  i n d u c t i o n  
p e r i o d  c a n  b e  r e m o v e d  b y  t h e  a d d i t i o n  o f  t h e  c o r r e s p o n d i n g  t h i o l  R S H .  A  m e c h a n i s m  i s  p r o p o s e d  i n  
w h i c h  C u ^  i s  f o r m e d  b y  r e d u c t i o n  o f  C u ^ ^  b y  t h i o l a t e  a n i o n  via a n  i n t e r m e d i a t e ,  p o s s i b l y  R S C u  \ L o s s  
o f  n i t r i c  o x i d e  f r o m  R S N O  i s  t h e n  b r o u g h t  a b o u t  b y  C u  %  p r o b a b l y  via a n o t h e r  i n t e r m e d i a t e  i n  w h i c h  
C u ^  i s  b o u n d  t o  t h e  n i t r o g e n  a t o m  o f  t h e  N O  g r o u p  a n d  a n o t h e r  e l e c t r o n - r i c h  a t o m  ( s u c h  a s  n i t r o g e n  
f r o m  a n  a m i n o  g r o u p ,  o r  o x y g e n  f r o m  a  c a r b o x y l a t e  g r o u p )  i n v o l v i n g  a  s i x - m e m b e r e d  r i n g .  A s  w e l l  a s  
N O  t h i s  p r o d u c e s  b o t h  R S  a n d  C u ' ^  w h i c h  t h e n  a r e  p a r t  o f  t h e  c y c l e  r e g e n e r a t i n g  C u ^ .  T h i o l a t e  i o n  i s  
o x i d i s e d  t o  R S ’ w h i c h  d h n e r i z e s  t o  g i v e  t h e  d i s u l f i d e .  D e p e n d i n g  o n  t h e  s t r u c t u r e  ( a n d  h e n c e  r e a c t i v i t y )  
o f  R S N O  e i t h e r  C u ^  f o r m a t i o n  o r  i t s  r e a c t i o n  w i t h  R S N O  c a n  b e  r a t e - l i m i t i n g .  C o m p u t e r  m o d e l l i n g  o f  
t h e  r e a c t i o n  s c h e m e  a l l o w s  t h e  g e n e r a t i o n  o f  a b s o r b a n c e  t i m e  p l o t s  o f  t h e  s a m e  f o r m s  a s  t h o s e  g e n e r a t e d  
e x p e r i m e n t a l l y .  Le. f i r s t -  o r  z e r o - o r d e r ,  b o t h  w i t h  o r  w i t h o u t  i n d u c t i o n  p e r i o d s .  W e  s u g g e s t  t h a t  t h e  
t h i o l a t e  i o n  n e c e s s a r y  t o  b r i i ^  a b o u t  C u ^ ^  r e d u c t i o n  i s  e i t h e r  p r e s e n t  a s  a  t h i o l  i m p u r i t y  o r  i s  g e n e r a t e d  
i n  s m a l l  q u a n t i t i e s  b y  p a r t i a l  h y d r o l y s i s  o f  t h e  n i t r o s o t h i o l ,  w h i c h  r e s u l t s  i n  a n  i n d u c t i o n  p e r i o d .  
A d d i t i o n  o f  s m a l l  q u a n t i t i e s  o f  t h i o l  r e m o v e s  t h e  i n d u c t i o n  p e r i o d  a n d  l e a d s  t o  c a t a l y s i s  b u t  l a r g e r  
q u a n t i t i e s  b r i n g  a b o u t  a  r a t e  r e d u c t i o n  b y ,  i t  i s  s u g g e s t e d ,  c o m p l e x a t i o n  o f  t h e  C u '  \  F o r  t w o  v e r y  
u n r e a c t i v e  s u b s t r a t e s ,  5 - n i t r o s o g l u t a t h i o n e  a n d  S - n i t r o s o - i V - a c e t y l c y s t e i n e  v e r y  l a r g e  i n d u c t i o n  p e r i o d s  
w e r e  o b s e r v e d ,  t y p i c a l l y  t h r e e  h o u r s .  T h i s  r e s u l t s ,  w e  s u g g e s t ,  f r o m  c o m p e t i t i v e  r e - o x i d a t i o n  o f  C u ^  t o  
C u ^ ^  b y  t h e  d i s s o l v e d  o x y g e n .  E x p e r i m e n t s  c a r r i e d  o u t  a n a e r o b i c a l l y  c o n f i r m  t h i s ,  s i n c e  t h e r e  i s  t h e n  n o  
i n d u c t i o n  p e r i o d .  A d d i t i o n  o f  h y d r o g e n  p e r o x i d e  e x t e n d s  t h e  i n d u c t i o n  p e r i o d  e v e r  f u r t h e r .  T h e  r e s u l t s  
a r e  d i s c u s s e d  i n  t e r m s  o f  t h e  b i o l o g i c a l  p r o p e r t i e s  o f  S ' - n i t r o s o t h i o l s  w h i c h  a r e  r e l a t e d  t o  n i t r i c  o x i d e  
r e l e a s e .
There is currently much interest in the chemistry of nitric oxide 
following the discoveries that it is involved in a range of human 
physiological processes. Within the area some attention has 
been focussed on the release of nitric oxide from S-nitrosothiols 
(or thionitrites) RSNO, not only from the point of view of their 
potential use therapeutically as alternative NO-releasing drugs, 
but also with regard to their possible involvement in vivo as 
potential NO-storage and transport vehicles. There is a very 
real case for the generation of alternative drugs given the 
tolerance problem associated in many cases with the widespread 
use of glyceryl trinitrate for the treatment of angina and other 
circulatory problems.
5-Nitrosothiols are very easily generated in solution from 
thiols by electrophilic nitrosation,  ^ e.g. in aqueous solution 
using acidified sodium nitrite. These reactions have been 
examined mechanistically and show all the characteristics of 
electrophilic nitrosation reactions. Many 5-nitrosothiols are 
too unstable in their pure form to be isolated (contrasting with 
their oxygen counterparts the alkyl nitrites) and this has 
contributed to the lack of knowledge of their chemistry relative 
to that of the alkyl nitrites, until comparatively recently. A 
number of 5-nitrosothiols however are sufficiently stable to 
allow a full structural characterization. In particular A^ -acetyl-
iS'-nitrosopenicillamine (SNAP) I  and 5-nitrosoglutathione 
(GSNO) 2 appear to be indefinitely stable as solids at room 
temperature. It has been known for some time -^’ that RSNO
HN'^COjH
Ac
SNO
HOjC COiH
species decompose photochemically and thermally to give nitric 
oxide and the corresponding disulfide [eqn, (1)]. R^ently the
2RSNO RSSR + 2NO (1)
photochemical reaction of GSNO has been examined in more 
detail and the quantum yield and a first-order rate constant 1
have been determined.® In both reactions it is likely that |
homolysis of the S-N bond is the primary process. |
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In solution, particularly aqueous solution, and in the absence 
of heat and tight many investigations have reported that the 
same overall reaction occurs. In the presence of oxygen the final 
product is nitrite anion, as expected from the known reaction ^  
of nitric oxide [«jn. (2)], but in the absence of oxygen, nitric
4NO + O2 + 40H = 4 NO2 " + 2H2O (2)
oxide has b%n detected using an electrode syston.^*’ At first 
quantitative rate measurements of RSNO decomposition 
reactions in aqueous solution have yielded erratic results, with 
reported half-lives of reaction varying considerably in different 
reports using the same substrate, usually SNAP. Further, the 
rate-form reported varied widely, zero-, first-, second- and 
various intermediate orders having been reported at some stage. 
This picture was resolved recently when it was realized that 
reaction occurred by a Cu^^-catalysed reaction pathway, and 
that for some reactants there can be enough Cu^  ^ in the 
distilled water/buffer components used, to bring about 
reaction. The [Cu^t] varied from source to source and often 
daily within the same source, which, goes some way to 
explaining the erratic nature of the reported results. When 
Cu^  ^  is removed by complexation with EDTA, virtually no 
reaction takes place. There was no catalysis for a range of other, 
metal ions investigated, including Zn^*, Ca'^, Mg^^, Ni^^, 
C o * M n * C r ’  ^and Fe^^.
In the earlier paper*® we reported that for many RSNO 
compounds over a given [Cu* range (which varied with the 
substrate) the second-order rate equation, eqn, (3), applied,
Rate = k[RSNO][Cu*+] (3)
often with a small autocatalytic component, which we ignored. 
The copper is fully regenerated and so is truly catalytic. That 
work concentrated on the structure-reactivity dependence 
using nitrosothiol species which were of biological interest, 
mainly derivatives of cysteine and glutathione. Values of k 
[eqn. (3)] varied considerably with structure and clearly led to 
the conclusion that high reactivity was associated with RSNO 
structures in which the copper could bind with two sites within 
the molecule via six-membered ring intermediates such as those 
shown in structures 3 and 4. These two binding sites we wrote as
the nitroso-nitrogen atom in each case and either an amine or 
carboxylate group. In the absence of either of these features 
reaction was very slow indeed.
Although we did establish a qualitative structure-reactivity 
pattern it was clear that a full mechanistic picture of this 
reaction had not been described, since outside a given [Cu**] 
(which differed for different substrates) other kinetic patterns 
emerged, in particular at low [Cu*^] there was an increasing 
tendency for autocatalysis to be observed and at high [Cu**] 
there was a move towards a zero-order dependence upon 
[RSNO] and also upon [Cu* ^  ]. These rate forms together with 
a whole range of intermediate situations clearly led to quite a 
complex set of data. A further unusual feature occurred in the 
reaction of V-acetyl-S-nitrosocysteine in that there was a very 
long induction period (many hours) before reaction set in, with 
approximately a first-order dependence. This paper describes in 
more detail the more unusual kinetics and proposes a 
mechanism which is consistent with all of the experimental results.
Results and discussion
The unusual kinetic forms found for a number of RSNO species 
under different conditions of [Cu* +], pwticularly the tendency 
in some cases towards zero-order behaviour, led us to consider 
the possibility that the effective reagent in these reactions is in 
fact Cu+ and not Cu* +. Zero-order dependence upon [RSNO] 
might then be interpreted in terms of a rate-limiting Cu* *
Cu'*' reduction. Earlier*® we had considered this possibility 
and had rejected it on the basis that we had failed to find 
evidence for it from preliminary EPR experiments with SNAP. 
In an alternative approach, we have now made use of the 
specific Cu'*'-chelator neocuproine * * shown in the complexed 
form in 5. In aqueous solution the stability constant of 5 is
Cu
s
about 1 X 10*® dm® mol *. When a Cu*  ^ solution (2 x 10 ® 
mol dm"*) was added to one of neocuproine hydrochloride 
(4 X 10"* mol dm"*) there was no detectable change in the UV- 
VIS spectrum. However upon addition of sodium dithionite (a
well-known reducing agent for Cu*'*'-----»• Cu. )^ an immediate
yellow colour was. noted and an absorbance maximum at 453 
nm was found, as reported in the literature ** for the spectrum 
of 5. We then examined the decomposition of SNAP (1 x 10"* 
mol dm"*) at pH 7.4 containing added Cu*  ^ (2 x 10 * mol 
dm"*) in the presence of increasing concentrations of 
neocuproine in the range 4 x 10"*-l x 10 * mol dm *. The 
resulting absorbance-time plots taken at 340 nm (the 
absorbance maximum for SNAP) are shown in Fig. 1. It is 
immediately clear that the presence of neocuproine reduces the 
reaction rate progressively and at 1 x 10 * neocuproine the 
reaction is completely suppressed. The full spectra showed the 
increasing absorbance at 453 nm as expected for the formation 
of 5. Similar experiments over a slightly smaller range of [added 
neocuproine] yielded reasonably good first-order plots and the 
data are given in Table 1 and Fig. 2 showing clearly the 
inhibiting effect of neocuproine.
Clearly Cu^ is being generated and the question arises as to 
the nature of the reducing agent. Previously we have suggested 
that the reduction could be achieved by thiolate ion present 
from a small quantity of thiol impurity in the 5-nitrosothiol 
sample. However we have been careful to avoid any thiol 
impurity by carrying out reactions on solution samples of 
RSNO generated from thiols and nitrous acid with the nitrous 
acid present in a slight excess, and reaction still occurs. An 
alternative suggestion is that thiolate is generated by hydrolysis 
of the 5-nitrosothiol [eqn. (4)]. This is not expected to be a
RSNO + 20H RS" + NO2 " + H2O (4)
rapid process given our earlier studies of the hydrolysis in acid 
solution,** but even a few percent reaction could be enough to 
initiate the reduction. When the corresponding thiol is added 
to the reaction mixtures initially a rapid increase in the rate 
constant is found. We worked with SNAP with the addition of 
the corresponding thiol V-acetylpenicillamine NAP. Use of a 
different thiol would complicate the situation by rapid NO
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Reaction of SNAP (1 x 10"^  mol dm"^ ) in the presence of Cu^
(2 X 10~* mol dm‘ )^ and varying concentrations of neocuproine; (a) no added neocuproine; {b) 4 x 10”* mol dm * neocuproine; (c) 5 x 10 * mol dm”* neocuproine; (d) 6  x 10 * mol dm * neocuproine; (e) 
8 X 10 * mol dm”* neocuproine; (/) 1 x 10”* mol dm * neocuproine; (g) 2 X 10“* mol dm * neocuproine; {h) 1 x 10 * mol dm * neocuproine
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Fig. 2 First-order rate constants (&,) for the reaction of SNAP 
(I  X 10 * mol dm:*) in the presence of Cu*^  (2 x 10”* mol dm”*) as a  function of [neocuproine]
Table 1 Values of for the decomposition of SNAP in the presence of added Cu** (2 x 10”* mol dm”*) and increasing amounts of neocuproine
Ncocuprome/10”* mol dm * *o/10”* s”‘
1.0 2.14
2.0 0.832.5 0.433.0 0.263.5 0.164.0 0.12
6.0 0.06
8.0 0.04
10.0 0.003
group transfer from RSNO to R'SH leading to R SNO 
formation.With [SNAP] of 1 x 10”* mol dm'*, added 
[Cu**] of I X 10”* mol dm * and [NAP] in the range of 
1 X 10"®-1 X 10 * mol dm”*, reactions are kinetically first- 
order. The results are given in Table 2 and are also shown more 
dramatically in Fig. 3. As expected at low added NAP there is a 
very sharp linear increase in the rate constant until 
[NAP] w 1 X 10”* mol dm”*. The reduction of Cu** by 
thiolate is a well-known process‘* ** and has been studied 
mechanistically as the Cu* * catalysed oxidation of thiols to give 
disulfides [eqn. (5)].
2Cu** 4- 2RSH = 2Cu* 4- 2H* + RSSR (5) 
At higher [NAP] there is initially a sharp drop in k„ followed
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0.00 1  2 3 4 5 6 7 8 9  10
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Fig. 3 First-order rate constants (k„) for the reaction of SNAP (1 X 10 * mol dm”*) as a function of added V-acetylpenicillamine (NAP)
Table 2 Values of k„ for the decomposition of SNAP in the presence of added Cu** (1 x 10”* mol dm”*) and increasing amounts of NAP
[NAP]/10-® mol dm * kJlOr^ s”'
0 4.97
1.0 5.63
2.0 6.253.0 8.354.0 10.45.0 11.9
6.0 12.87.0 14.0
8.0 15.39.0 16.6
10 17.4
20 21.730 18.740 14.550 10.990 6.79
200 4.14300 3.37500 2.67
1000 2.12
by a gradual decrease towards zero. We can explain this pattern 
in terms of the complexing of Cu** fcy NAP, thus effectively 
removing it from solution. These results explain the apparently 
contradictory reports in the literature,** some of which report 
catalysis of RSNO decomposition by added thiols whilst others 
find a reduction in rate upon thiol addition. It is now clear that 
at low added [RSH] there will be catalysis, as this favours the 
reduction of Cu**, whereas complexation of Cu**, probably 
by thé carboxylate group, takes over at higher added [RSH] 
resulting in inhibition of nitric oxide formation. Such copper- 
carboxylates are well-known (see structure 6 ) and some have
■c. -
been isolated and examined structurally.We have previously 
noted'® a reduction in reactivity with increasing buffer 
concentration when the buffer contains a carboxylic acid, an 
effect we attributed to competitive complexation with the 
carboxylic acid.
Earlier we concentrated our kinetic analysis on rate forms 
which gave first-order dependencies upon both RSNO and 
Cu* * in order to establish structure-reactivity factors. We now
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Fig. 6  Absorbance-time plots for the reaction of 5-nitroso-2- diethylaminoethanethiol (1 x 10“^  mol dm“^ ) in the presence of added Cu^  + :(n)5 x 10  ^mol dm'^  Cu^ +; (6 ) 7.5 x 10 ®moldm-*Cu^ ;^(c) I X 10“* mol dm“* Cu*^ ; (d) 3 x 10 * mol dm“* Cu**; (e) 6 x 10 * mol dm * Cu**
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Fig. 5 Absorbance-time plots for the reaction of SNAP ( 1 x 10“* mo! dm“*) in the presence of Cu** (1 x 10 * mol dm *) and varying concentrations of added Af-acetylpenicillamine (NAP); (a) 4 x 10“® mol dm"* NAP; (6) 6 x 10“® mol dm * NAP; (c) 8 x 10“® mol dm * NAP; ( d )  1 X 10 * mol dm * NAP
report the results of a more systematic kinetic study in which 
other rate forms appeared. In all cases we have been following 
the decreasing absorbance at ca. 340 nm due to the RSNO 
reactant, usually at an initial concentration of around 5 x 10"^  
mol dm“*. We have been able to isolate four limiting 
absorbance-time patterns: (u) first-order reaction with an 
induction period, (6 ) first-order reaction with no induction 
period, (c) zero-order reaction with an induction period and (d) 
zero-order reaction with no induction period. In addition we 
observed many forms which could be regarded as intermediate 
between any two of the four limiting forms. Examples of each 
are given in Figs. 4, 5, 6 , 7 and 8 . Fig. 4 is the reaction of 
5-nitroso-2-dimethylaminoethanethiol (SNDMA) 8, at low 
[Cu**] with no added thiol. Fig. 5 is the reaction of SNAP at 
1 X 10"* mol dm“* Cu** in the presence of varying [NAP], 
Fig. 6  is the reaction of 5-nitroso-2-diethylaminoethanethiol 
with various concentrations of added Cu**, Fig. 7 is a similar 
pattern for the reaction of A/'-acetyl-D,L-2,2-dimethylcysteinyl- 
glycine methyl ester 7 with different [Cu**] and Fig. 8 is 
SNDMA 8  at low [Cu**] varying the concentration of added 
thiol. The induction period is quite clear in Figs. 4, 6  and 7 and 
is completely absent in Figs. 5 and 8 at high [RSH]. Equally 
clear is the first-order pattern in Figs. 4 and 5 and zero-order 
dependence in Figs. 6 , 7 and 8 .
On the basis of these and earlier results we propose the 
following outline mechanism: Cu** is reduced by RS~ 
(generated from RSNO or added as RSH) via intermediate X
0.6
0.5
0.4
II 02
0.1
0.0 24
Fig. 7 Absorbance-time plots for the reaction of SNAP-Gly (I X 10* mol dm*) in the presence of added Cu* * : (a) 2.7 x 10 ® mol dm * Cu**; (6) 5.4 x 10 ® mol dm * Cu**; (c) 8.1 x 10“® mol dm * Cu**;(</) 1.1 X 10 * mol dm * Cu**; (e) 1.4 x 10“* mol dm * Cu**
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Fig. 8 Absorbance-time plots for the reaction of S-nitroso-2- dimethylaminoethanethiol (2 x !0“* mol dm'*) in the presence of added Cu** (1 x 10 ® mol dm'*) as a function of added 2-N.N- dimethylaminoethanethiol: (a) No added thiol; (b) Added thiol (I X 10 ® mol dm *) (c) Added thiol (3 x I0“® mol dm *)
to give Cu* and RS'. Intermediate X is probably RSCu*. 
Reaction then occurs between Cu* and RSNO via intermediate 
Y releasing Cu**, RS~ and NO. This is essentially the
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Fig. 9 Computed absorbance-time plot with no added RSH for rate-limiting RSNO reaction with Cu*
Cu^ * + RS~ 7=^X »Cu* + RS"
Cu* + RSNO?=r±Y »Cu^ * + RS + NO
2RS* ►RSSR
Scheme 1
^\ ,SNO
HN^ '^ C^ONHCHjCOiMe
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c SN ON M c j
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mechanism we suggested earlier as a possibility, but without 
at that time sufficient evidence to support it. Intermediates Y we 
believe are akin to structures 3 and 4, now with Cu  ^ and not 
Cu^*, probably also co-ordinated to two water molecules.
Qualitatively we can account for the induction period as the 
time required for the generation of RS' and Cu*. A first-order 
dependence occurs if the reaction of RSNO with Cu* is rate- 
limiting and a zero-order dependence occurs (for the more 
reactive RSNO specie^ s) when Cu* formation is rate limiting. 
The length of the induction period can be reduced by the 
addition of either RSH or Cu^  * which will increase the rate of 
formation of Cu*.
We have attempted to explain the various rate patterns 
encountered experimentally more quantitatively by use of a 
computer model of Scheme 1, and to extract the limiting forms 
which this model predicts. We have not aimed at a full 
treatment optimizing all of the parameters because of the 
uncertainties of the values of the initial [Cu^*] and [RS ] 
particularly when an induction period occurs. Our hope was 
that we would be able to reproduce qualitatively the 
absorbance-time experimental data with those predicted from 
Scheme 1, particularly under four limiting conditions.
(1) Rapid formation and regeneration of Cu*
Scheme I reduces (for kinetic purposes) to eqns. (6 ) and (7). If 
RSNO, Cu^* and RS“ are present at the start then the result
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Fig. 10 Computed absorbance-time plot with added RSH for rate- limiting RSNO reaction with Cu*
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Fig. 11 Computed absorbance-time plot with no added RSH for rate-limiting Cu* formation
RSNO + Cu* 
RS- + Cu'
slow RS + NO -i- Cu'*
- ^ iR S S R  + Cu*
(6)
(7)
will be a simple first order rate equation [eqn. (8)] where the
-d[RSNO]/dt = d[NO]/dt = fc„[RSNO] (8)
observed rate constant k„ will be given by /c[Cu'*] when 
[Cu'*] 4  [ R S ]  (the normal state of affairs with added R S )  
and by &[RS'] when [Cu'*] >  [RS ]. The computer simu­
lation is given in Fig. 10. We have observed many examples 
of such behaviour experimentally (as in Fig. 5 as [NAP] 
is increased). In effect we now have rapid formation and 
regeneration of Cu*, the concentration of which remains 
constant in any one experiment.
Alternatively, if only RSNO and Cu' * are initially present 
the step for the generation of Cu* [eqn. (4)] must be included in 
the simulation. This results in an absorbance-time profile given 
in Fig. 9, with an autocatalytic feature which reproduces that 
observed experimentally in Fig. 4.
(2) Rate-limiting Cu* formation
Under these circumstances Scheme 1 effectively reduces to 
eqns. (9) and (10). If RSNO, Cu'* and RS" are all present
RS + Cu'* 
Cu* + RSNO-
IRSSR + Cu (9)
RS-+ NO + Cu'* (10)
initially then we get a truly zero-order reaction (simulation in 
Fig. 12) with RSNO scavenging Cu* as it is formed 
immediately regenerating RS' and Cu'*. However if only 
RSNO and Cu'* are present initially, then RS has to be 
generated as before and this results in an induction period
J. Chem. Soc., Perkin Trans. 2, J996 485
ï 0.8 5
f  0.6
0.2
0.0
Time (a*, units)
1^  12 Computed absorbance-time plot with added RSH for rate- limiting Cu"^  formation
followed by a zero-order reaction (Fig. 11). Experimental 
examples of both types of behaviour have been observed as in 
Fig. 8 , as [RS ] is increased. Figs. 6  and 7. Figs. 6  and 7 clearly 
show a saturation effect in Cu* ^  at high [Cu* which requires 
that in Cu  ^ formation we have an equilibrium involving 
intermediate X.
All of these experiments were conducted at pH 7.4 in normal 
aerated solvent. When oxygen was rigorously excluded then we 
found no significant difference in behaviour for any of the 
limiting rate forms. This implies that any oxidation reaction, 
such as of Cu  ^by dissolved oxygen, is not a significant reaction 
under these conditions. However for very slow reacting RSNO 
compounds, such as W-acetyl-iS-nitrosocysteine (SNAC) we 
found a very long induction period typically 3 hours'as shown in 
Fig. 13, This result was obtained using a rather impure solid 
sample of SNAC which was known to contain some of the thiol 
and was very difficult to purify. Repetition of this experiment 
with SNAC generated in situ in solution gave no reaction 
whatsoever over a 16 hour period (Fig. 14), so it is likely that 
the thiol is playing a part here in Cu+ generation as ex­
pected. However when the same reaction was carried out in the 
absence of oxygen, reaction occurred immediately, with no 
induction period. Exactly the same pattern was found 
with jf-nitrosoglutathione (GSNO), although in both cases 
it is not clear why complete reaction does not occur. There 
is however a very dramatic effect due to the presence of 
oxygen here, which implies that oxidation of Cu^ by oxygen 
[eqn. (11)] is a competing reaction with the Cu^ reaction
Cu+ + O, = Cu*+ + O, ( 1 1 )
with RSNO.
When the oxygen is removed decomposition can occur. For 
both of these substrates reaction can be induced by the addition 
of the corresponding thiol. An induction period occurs which is 
reduced as the concentration of added thiol is increased until we 
get a good first-order plot at very high [thiol] »  0.15 mol dm *. 
In the presence of thiol, the effect of increasing the [Cu*^] is 
also to reduce the induction period, and as before the removal 
of oxygen also removes the induction period completely. For 
these slower reacting substrates it does seem that re-oxidation 
of Cu  ^ by dissolved oxygen is an important pathway in their 
decomposition reactions.
We believe that we have shown that Cu^ is the effective 
reagent in bringing about decomposition of 5 -nitrosothiols to 
yield nitric oxide. Both the experiments with neocuproine 
and all the kinetic evidence support the outline mechanism 
given in Scheme I. Some details remain as yet unresolved, e.g. the detailed mechanism for the breakdown of inter­
mediate Y, for which at present we have no experimental evidence.
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Fig. 13 Absorbance-time plot for the reaction of Y-acetyl-5 nitrosocysteine SNAC (crude sample)
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F^. 14 Absorbance-time plots for the reactions of GSNO and N- acetyl-S-nitrosocysteine (SNAC) showing the effect of the presence of oxygen: (a) GSNO under aerobic conditions; (b) SNAC under aerobic conditions; (c) GSNO under anaerobic conditions; (d) SNAC under anaerobic conditions
These findings could well have implications for the reactions 
of S-nitrosothiols in vivo. It is known that they have specific 
biological activity notably, vasodilation,*’ the inhibition of 
platelet aggregation*® and the inhibition of neutrophil 
functions.** In the body copper is present not as free Cu*  ^but 
in a bound form with amino acids and proteins. Possibly this is 
reducible to Cu^ by thiolate. Experiments to test this possibility 
are in hand. A recent particularly interesting finding** shows 
that the inhibition of platelet aggregation activity shown by 
GSNO is much reduced in the presence of neocuproine and the 
closely related bathocuproine, both specific Cu^-chelators. 
This strongly suggests (a) that nitric oxide is required to effect 
the activity and (b) that it is generated from 5-nitrosothiols by a 
process which involves Cu^. However another recent article** 
claims that bronchodilation induced by GSNO does not require 
the formation of NO. The medical importance of S~ 
nitrosothiols has been highlighted recently by two reports,** ** 
which describe the clinical use of GSNO to inhibit platelet 
aggregation during coronary angioplasty and also to treat a 
form of pre-eclampsia, a high blood pressure condition suffered 
by some pregnant women.
The reactivity pattern of GSNO is particularly interesting. In 
aerobic solution it is particularly stable, with only a negligibly 
small amount of decomposition occuring over many hours. 
However, in the presence of glutathione GSH decomposition 
occurs much more rapidly but possibly with an induction 
period, the length of which is dependent on [GSH] and [Cu* ^ ]. 
Further, in the absence of oxygen and without added GSH, 
reaction occurs quite readily without an induction period. 
Finally, the presence of another oxidizing agent {e.g. 
hydrogen peroxide) has the effect of stabilizing GSNO, again 
over a period of many hours, in our experiments no 
perceptible decomposition occurred overnight. Again the re­
oxidation of Cu^ ► Cu* ^  does not allow the Cu ^  + RSNO
to occur.
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Experim^tal
All thiols, buffer components, etc. were commercial samples of 
the highest purity grade available. The 5-nitrosothiols were 
mostly synthesized in solution, and not isolated, by nitrosation 
of the thiols with an equivalent of nitrous acid under mildly acid 
conditions. All gave the characteristic broad absorption band 
centred around 340 nm. Aliquots of these freshly prepared 
solutions were used after pH adjustment, taking care to 
minimize exposure to light. In the case of SNAP 1 and GSNO 
2, the solid derivatives were prepared as describwl in the 
literature.**'*’ An impure sample of fV-acetyl-5-nitrosocysteine 
was prepared by a modification of the method used for GSNO. 
The 5-nitroso dipeptide 7 was a new compound and was 
prepared as follows.
A solution of glycine methyl ester hydrochloride (6.28 g, 50 
mmol) in water (40 cm*) was treated with a solution of 
potassium carbonate (72 mmol) in water (20 cm*) and the 
mixture extracted with dichloromethane. After drying (MgSOJ, 
the solvent was removed by evaporation. The residue was added 
to a suspension of iV-acetyl-D, L-penicillamine (3.28 g, 20 mmol) 
in purified dichloromethane (1 0 0  cm*) followed by 1-cyclo- 
hexyl-3-(2-morphoIinoethyl)carbodiimide metho-p-toluene 
sulfonate (8.47 g, 20 mmol). The urea derivative started to 
precipitate immediately and after 2  days was removed by 
filtration and washed with dichloromethane. The combined 
filtrate and washings were extracted with a saturated solution of 
citric acid (60 cm*), a saturated solution of potassium hydrogen 
carbonate (60 cm*) and water (60 cm*), dried (M^SO*) and the 
solvent removed by evaporation. The residue was washed with 
cold ether to give white, flaky crystals of product, mp 142 **C 
(decomp.). It was used without purification for the next stage 
[Found: m/z (FAB) 263.1061 (MH+). CioH^O^N^S requires 
263.1066 (MH^)]. The 5-nitroso derivative was prepared by 
dissolving the dipeptide (0.26 g, 1 mmol) in dichloromethane (8  
cm*) and adding /ert-butyl nitrite (1 cm*). After 1 h the solvent 
from the green solution was removed by evaporation to give 
a green solid. After washing with water the solid was dried in vacuo (0.24 g, 82%), mjz (FAB) 292.0967 (M+, 292.0976) 
[Found: C, 41.0; H, 6.2; N, 14.2. C10H17O5N3S requires C, 
41.2; H, 5.9; N, 14.4%].
Products
The disulfide products, nitrite anion and nitric oxide (in the 
absence of oxygen) were determined as reported earlier.*®
Kinetics
These were carried out also as reported earlier *® by monitoring 
the decreasing absorbance at ca. 340 nm.
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